[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 234
1. McCarthy BA, Boyle E, Wang XP, Guzowski D, Paul S, Catera R, Trott J, Yan XJ, Croce CM, Damle R, Yancopoulos S, Messmer BT, Lesser M, Allen SL, Rai KR, Chiorazzi N: Surface expression of Bcl-2 in chronic lymphocytic leukemia and other B-cell leukemias and lymphomas without a breakpoint t(14;18). Mol Med; 2008 Sep-Oct;14(9-10):618-27
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surface expression of Bcl-2 in chronic lymphocytic leukemia and other B-cell leukemias and lymphomas without a breakpoint t(14;18).
  • Here we show that Bcl-2 also can position on the outer cell surface membrane of B cells from patients with chronic lymphocytic leukemia (B-CLL) and certain other leukemias that do not classically possess the chromosomal breakpoint t(14;18).

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • Genetic Alliance. consumer health - Leukemia, B-cell, chronic.
  • Genetic Alliance. consumer health - B-Cell Lymphomas.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Oncol. 2002 Apr;13(4):501-2 [12056698.001]
  • [Cites] Blood. 2008 Apr 1;111(7):3322-30 [18362212.001]
  • [Cites] Nat Cell Biol. 2003 Jan;5(1):28-37 [12510191.001]
  • [Cites] Nature. 2003 Aug 21;424(6951):952-6 [12931191.001]
  • [Cites] Rev Physiol Biochem Pharmacol. 2003;148:105-50 [12698322.001]
  • [Cites] Cell. 2004 Jan 23;116(2):205-19 [14744432.001]
  • [Cites] Lancet. 2004 Jun 5;363(9424):1869-70 [15183626.001]
  • [Cites] Science. 1985 Sep 27;229(4720):1390-3 [3929382.001]
  • [Cites] Mol Cell Biol. 1989 Feb;9(2):701-10 [2651903.001]
  • [Cites] Adv Immunol. 1989;47:117-85 [2479233.001]
  • [Cites] J Immunol Methods. 1991 Jun 3;139(2):271-9 [1710634.001]
  • [Cites] Annu Rev Cell Biol. 1991;7:663-98 [1809356.001]
  • [Cites] Int Immunol. 1992 Feb;4(2):243-52 [1377947.001]
  • [Cites] Cancer Res. 1993 Oct 1;53(19):4701-14 [8402648.001]
  • [Cites] Cell. 1993 Oct 22;75(2):241-51 [7503812.001]
  • [Cites] J Biol Chem. 1993 Dec 5;268(34):25265-8 [8244956.001]
  • [Cites] Clin Immunol Immunopathol. 1994 Apr;71(1):14-8 [8137555.001]
  • [Cites] J Biol Chem. 1994 Jun 17;269(24):16521-4 [8206964.001]
  • [Cites] Blood. 1994 Nov 15;84(10):3440-6 [7949099.001]
  • [Cites] Science. 1995 Mar 10;267(5203):1445-9 [7878463.001]
  • [Cites] Br J Haematol. 1996 Sep;94(4):612-8 [8826882.001]
  • [Cites] Science. 1997 Feb 21;275(5303):1129-32 [9027314.001]
  • [Cites] J Neurochem. 1998 Jan;70(1):31-9 [9422344.001]
  • [Cites] Annu Rev Immunol. 1998;16:395-419 [9597135.001]
  • [Cites] Science. 1998 Aug 28;281(5381):1309-12 [9721092.001]
  • [Cites] J Cell Sci. 1998 Oct;111 ( Pt 19):2911-22 [9730983.001]
  • [Cites] Leuk Res. 1999 Feb;23(2):127-36 [10071128.001]
  • [Cites] Annu Rev Biochem. 2005;74:739-89 [15952902.001]
  • [Cites] Cell. 2005 Aug 26;122(4):593-603 [16122426.001]
  • [Cites] Cell Death Differ. 2006 Aug;13(8):1351-9 [16763616.001]
  • [Cites] J Biol Chem. 2006 Dec 29;281(52):40493-502 [17090549.001]
  • [Cites] J Clin Invest. 2007 Jan;117(1):112-21 [17200714.001]
  • [Cites] Cell. 2007 Jun 1;129(5):879-90 [17540169.001]
  • [Cites] Nat Rev Mol Cell Biol. 2007 Sep;8(9):741-52 [17717517.001]
  • [Cites] FEBS Lett. 2007 Sep 18;581(23):4479-84 [17765227.001]
  • [Cites] Neoplasia. 2007 Oct;9(10):871-81 [17971907.001]
  • [Cites] Clin Cancer Res. 2007 Dec 15;13(24):7254-63 [18094405.001]
  • [Cites] Cell Prolif. 2002 Aug;35(4):193-206 [12153612.001]
  • (PMID = 18633450.001).
  • [ISSN] 1528-3658
  • [Journal-full-title] Molecular medicine (Cambridge, Mass.)
  • [ISO-abbreviation] Mol. Med.
  • [Language] ENG
  • [Grant] United States / NCRR NIH HHS / RR / M01 RR018535; United States / NCI NIH HHS / CA / R01 CA087956; United States / NCI NIH HHS / CA / R01 CA87956
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Proto-Oncogene Proteins c-bcl-2; 0 / RNA, Messenger
  • [Other-IDs] NLM/ PMC2464573
  •  go-up   go-down


2. Parcells BW, Ikeda AK, Simms-Waldrip T, Moore TB, Sakamoto KM: FMS-like tyrosine kinase 3 in normal hematopoiesis and acute myeloid leukemia. Stem Cells; 2006 May;24(5):1174-84
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] FMS-like tyrosine kinase 3 in normal hematopoiesis and acute myeloid leukemia.
  • FLT3 mutations are identified as the most frequent genetic abnormality in acute myeloid leukemia and are also observed in other leukemias.
  • [MeSH-major] Hematopoiesis. Leukemia, Myelomonocytic, Acute / enzymology. Leukemia, Myelomonocytic, Acute / genetics. fms-Like Tyrosine Kinase 3 / genetics

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16410383.001).
  • [ISSN] 1066-5099
  • [Journal-full-title] Stem cells (Dayton, Ohio)
  • [ISO-abbreviation] Stem Cells
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA108545; United States / NHLBI NIH HHS / HL / HL75826; United States / PHS HHS / / RHL083077A
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Protein Kinase Inhibitors; EC 2.7.10.1 / fms-Like Tyrosine Kinase 3
  • [Number-of-references] 145
  •  go-up   go-down


3. Awan H, Jønsson V, Johannesen TB, Ly B, Tjønnfjord GE: Anticipation in families with chronic lymphocytic leukemia and other lymphoproliferative disorders. Transl Oncogenomics; 2010 Mar 30;4:1-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anticipation in families with chronic lymphocytic leukemia and other lymphoproliferative disorders.
  • Fifty-one parent-offspring pairs with chronic lymphocytic leukemia (CLL) or other lymphoproliferative disorders (nonCLL) such as malignant lymphoma, multiple myeloma, or other types of lymphocytic leukemia than CLL were ascertained independently in 38 families.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Haematol. 2000 Jun;109(4):794-9 [10929032.001]
  • [Cites] Hum Genet. 2000 May;106(5):553-6 [10914686.001]
  • [Cites] N Engl J Med. 2000 Dec 28;343(26):1910-6 [11136261.001]
  • [Cites] Br J Haematol. 2001 May;113(2):407-14 [11380406.001]
  • [Cites] Leukemia. 2002 Jun;16(6):1008-14 [12040432.001]
  • [Cites] Am J Med Genet. 2002 Oct 30;115(3):113-7 [12407690.001]
  • [Cites] Cancer Res. 2004 Apr 1;64(7):2424-33 [15059895.001]
  • [Cites] Cancer. 2004 May 1;100(9):1902-8 [15112271.001]
  • [Cites] Blood. 2004 Sep 15;104(6):1850-4 [15161669.001]
  • [Cites] N Engl J Med. 2005 Feb 24;352(8):804-15 [15728813.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 May;14(5):1245-50 [15894680.001]
  • [Cites] J Clin Invest. 2005 Jun;115(6):1636-43 [15902303.001]
  • [Cites] Br J Haematol. 2005 Aug;130(4):648-9 [16098083.001]
  • [Cites] Nat Rev Genet. 2005 Oct;6(10):729-42 [16205713.001]
  • [Cites] Nat Rev Genet. 2005 Oct;6(10):743-55 [16205714.001]
  • [Cites] Blood. 2007 Apr 15;109(8):3479-88 [17185468.001]
  • [Cites] Leuk Lymphoma. 2006 Oct;47(10):2115-27 [17071485.001]
  • [Cites] Semin Oncol. 2006 Apr;33(2):157-66 [16616062.001]
  • [Cites] Trends Genet. 2007 Apr;23(4):192-9 [17316885.001]
  • [Cites] Science. 2007 Mar 30;315(5820):1800-1 [17395816.001]
  • [Cites] Science. 2007 Apr 20;316(5823):398-9 [17446388.001]
  • [Cites] Br J Haematol. 2007 Dec;139(5):630-4 [18021078.001]
  • [Cites] Br J Haematol. 2007 Dec;139(5):717-23 [18021086.001]
  • [Cites] Blood. 2008 Jun 15;111(12):5446-56 [18216293.001]
  • [Cites] N Engl J Med. 2008 Aug 7;359(6):575-83 [18687638.001]
  • [Cites] Blood. 2008 Oct 15;112(8):3052-6 [18703425.001]
  • [Cites] N Engl J Med. 2009 Feb 12;360(7):659-67 [19213679.001]
  • [Cites] Am J Hum Genet. 1996 Jul;59(1):264-8 [8659536.001]
  • [Cites] Am J Hum Genet. 1996 Nov;59(5):973-9 [8900222.001]
  • [Cites] Am J Hum Genet. 1998 Jul;63(1):270-2 [9634521.001]
  • [Cites] Leukemia. 1998 Nov;12(11):1696-8 [9823943.001]
  • [Cites] Med Oncol. 2007;24(1):55-62 [17673812.001]
  • [Cites] Leuk Lymphoma. 2002 Oct;43(10):1987-90 [12481897.001]
  • [Cites] Cytometry B Clin Cytom. 2003 Mar;52(1):1-12 [12599176.001]
  • [Cites] Br J Haematol. 2007 Jan;136(1):73-9 [17116127.001]
  • [Cites] Br J Haematol. 2000 Jan;108(1):72-9 [10651726.001]
  • [Cites] Hum Genet. 2000 Sep;107(3):290-3 [11071392.001]
  • (PMID = 21566766.001).
  • [ISSN] 1177-2727
  • [Journal-full-title] Translational oncogenomics
  • [ISO-abbreviation] Transl Oncogenomics
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC3072649
  • [Keywords] NOTNLM ; chronic lymphocytic leukemia / epigenetic inheritance / familial clustering / malignant lymphomas / multiple myeloma
  •  go-up   go-down


Advertisement
4. Forconi F, Raspadori D, Lenoci M, Lauria F: Absence of surface CD27 distinguishes hairy cell leukemia from other leukemic B-cell malignancies. Haematologica; 2005 Feb;90(2):266-8
Genetic Alliance. consumer health - Hairy Cell Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Absence of surface CD27 distinguishes hairy cell leukemia from other leukemic B-cell malignancies.
  • All cases other than hairy cell leukemia (HCL) expressed CD27.
  • Intensity was significantly higher in chronic lymphocytic leukemia.
  • [MeSH-major] Antigens, CD27 / biosynthesis. Gene Expression Regulation, Neoplastic. Leukemia, Hairy Cell / metabolism. Lymphoma, B-Cell / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15710587.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Letter; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antigens, CD27; 0 / Biomarkers, Tumor
  •  go-up   go-down


5. Burger JA, Peled A: CXCR4 antagonists: targeting the microenvironment in leukemia and other cancers. Leukemia; 2009 Jan;23(1):43-52
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CXCR4 antagonists: targeting the microenvironment in leukemia and other cancers.
  • Activation of CXCR4 induces leukemia cell trafficking and homing to the marrow microenvironment, where CXCL12 retains leukemia cells in close contact with marrow stromal cells that provide growth and drug resistance signals.
  • CXCR4 antagonists, such as Plerixafor (AMD3100) and T140 analogs, can disrupt adhesive tumor-stroma interactions and mobilize leukemia cells from their protective stromal microenvironment, making them more accessible to conventional drugs.
  • Therefore, targeting the CXCR4-CXCL12 axis is a novel, attractive therapeutic approach that is explored in ongoing clinical trials in leukemia patients.
  • However, because CXCR4 plays a key role in cross-talk between leukemia cells (and a variety of other tumor cells) and their microenvironment, cancer treatment may become the ultimate application of CXCR4 antagonists.
  • Here, we summarize the development of CXCR4 antagonists and their preclinical and clinical activities, focusing on leukemia and other cancers.
  • [MeSH-major] Drug Delivery Systems / methods. Leukemia / drug therapy. Receptors, CXCR4 / antagonists & inhibitors

  • MedlinePlus Health Information. consumer health - Leukemia.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18987663.001).
  • [ISSN] 1476-5551
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016672
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Receptors, CXCR4
  • [Number-of-references] 145
  •  go-up   go-down


6. Goldin LR, Björkholm M, Kristinsson SY, Turesson I, Landgren O: Elevated risk of chronic lymphocytic leukemia and other indolent non-Hodgkin's lymphomas among relatives of patients with chronic lymphocytic leukemia. Haematologica; 2009 May;94(5):647-53
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Elevated risk of chronic lymphocytic leukemia and other indolent non-Hodgkin's lymphomas among relatives of patients with chronic lymphocytic leukemia.
  • BACKGROUND: Previous studies have shown increased familial risk for chronic lymphocytic leukemia.
  • In the most comprehensive study to date, we evaluated risk of chronic lymphocytic leukemia and lymphoproliferative disorders among first-degree relatives of chronic lymphocytic leukemia cases compared to first-degree relatives of controls.
  • DESIGN AND METHODS: Population-based registry data from Sweden were used to evaluate outcomes in 26,947 first-degree relatives of 9,717 chronic lymphocytic leukemia patients (diagnosed 1958-2004) compared with 107,223 first-degree relatives of 38,159 matched controls.
  • RESULTS: Compared to relatives of controls, relatives of chronic lymphocytic leukemia patients had an increased risk for chronic lymphocytic leukemia (RR=8.5, 6.1-11.7) and other non-Hodgkin's lymphomas (NHLs) (RR=1.9, 1.5-2.3).
  • Evaluating NHL subtypes, we found a striking excess of indolent B-cell NHL, specifically lymphoplasmacytic lymphoma/Waldenström macroglobulinemia and hairy cell leukemia.
  • There was no statistical excess of Hodgkin's lymphoma, multiple myeloma, or the precursor condition, monoclonal gammopathy of undetermined significance, among chronic lymphocytic leukemia relatives.
  • CONCLUSIONS: These familial aggregations are striking and provide novel clues to research designed to uncover early pathogenetic mechanisms in chronic lymphocytic leukemia including studies to identify germ line susceptibility genes.
  • However, clinicians should counsel their chronic lymphocytic leukemia patients emphasizing that because the baseline population risks are low, the absolute risk for a first-degree relative to develop chronic lymphocytic leukemia or another indolent lymphoma is low.
  • At this time, an increased medical surveillance of first-degree relatives of chronic lymphocytic leukemia patients has no role outside research studies.

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • MedlinePlus Health Information. consumer health - Family Issues.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Haematol. 2007 Dec;139(5):672-86 [18021081.001]
  • [Cites] Br J Haematol. 2007 Dec;139(5):663-71 [18021080.001]
  • [Cites] Br J Haematol. 2007 Dec;139(5):824-31 [18021093.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2007;:339-45 [18024649.001]
  • [Cites] Gastroenterol Clin North Am. 2008 Mar;37(1):191-213, viii [18313546.001]
  • [Cites] N Engl J Med. 2008 Aug 7;359(6):575-83 [18687638.001]
  • [Cites] Blood. 2008 Sep 15;112(6):2199-204 [18451307.001]
  • [Cites] Nat Genet. 2008 Oct;40(10):1204-10 [18758461.001]
  • [Cites] Blood. 2008 Oct 15;112(8):3052-6 [18703425.001]
  • [Cites] Blood. 2009 Apr 30;113(18):4188-96 [19015397.001]
  • [Cites] Br J Haematol. 2008 Jun;142(2):238-45 [18503587.001]
  • [Cites] Br J Haematol. 2007 Dec;139(5):762-71 [18021089.001]
  • [Cites] Semin Neurol. 1999;19(3):289-99 [12194385.001]
  • [Cites] Blood. 2002 Oct 1;100(7):2289-90 [12239136.001]
  • [Cites] Cytometry B Clin Cytom. 2003 Mar;52(1):1-12 [12599176.001]
  • [Cites] Cancer. 2004 May 1;100(9):1902-8 [15112271.001]
  • [Cites] Nat Genet. 2004 May;36(5):447-9 [15098033.001]
  • [Cites] Blood. 2004 Sep 15;104(6):1850-4 [15161669.001]
  • [Cites] Ann Hum Genet. 2004 Sep;68(Pt 5):498-508 [15469426.001]
  • [Cites] Lancet. 1988 Feb 6;1(8580):292-3 [2893097.001]
  • [Cites] Cancer Res. 1994 May 1;54(9):2378-85 [8162584.001]
  • [Cites] Lancet. 1997 Aug 16;350(9076):459-60 [9274580.001]
  • [Cites] Am J Hum Genet. 1998 May;62(5):1212-27 [9545393.001]
  • [Cites] Cancer. 2005 May 1;103(9):1906-15 [15779016.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 May;14(5):1245-50 [15894680.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Oct;14(10):2402-6 [16214923.001]
  • [Cites] Blood. 2006 Oct 15;108(8):2755-63 [16804116.001]
  • [Cites] Blood. 2007 Mar 1;109(5):2198-201 [17082317.001]
  • [Cites] Leuk Lymphoma. 2007 Jun;48(6):1087-91 [17577771.001]
  • [Cites] Blood. 2007 Jul 15;110(2):695-708 [17389762.001]
  • [Cites] Int J Cancer. 2007 Nov 15;121(10):2260-6 [17583571.001]
  • [Cites] Leuk Lymphoma. 2001 Jun;42(1-2):99-108 [11699227.001]
  • [Cites] Blood. 2007 Nov 1;110(9):3326-33 [17687107.001]
  • [CommentIn] Haematologica. 2009 May;94(5):606-9 [19407315.001]
  • (PMID = 19286886.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] ENG
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Other-IDs] NLM/ PMC2675676
  •  go-up   go-down


7. zur Hausen H: Childhood leukemias and other hematopoietic malignancies: interdependence between an infectious event and chromosomal modifications. Int J Cancer; 2009 Oct 15;125(8):1764-70
MedlinePlus Health Information. consumer health - Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Childhood leukemias and other hematopoietic malignancies: interdependence between an infectious event and chromosomal modifications.
  • A large number of epidemiological observations suggest an infectious origin of hematopoietic malignancies, including various forms of leukemia, nonHodgkin's lymphomas, Hodgkin's lymphomas and multiple myelomas.
  • Incidence of nonHodgkin's lymphomas and Hodgkin's lymphomas, although not of leukemias, is substantially increased under immunosuppression.
  • Presently less than 10% of the global incidence of leukemias and lymphomas can be linked to infections (Epstein-Barr virus, human T-lymphotropic retrovirus, human herpesvirus type 8 and Helicobacter pylori).
  • In childhood leukemias, a protective effect was noted for multiple infections during the first year of life and for at least 6 months of breastfeeding.
  • [MeSH-major] Chromosome Aberrations. Genome, Viral / physiology. Leukemia / etiology. Lymphoma / etiology. Polyomavirus Infections / complications

  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19330827.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 94
  •  go-up   go-down


8. Olavarria E, Siddique S, Griffiths MJ, Avery S, Byrne JL, Piper KP, Lennard AL, Pallan L, Arrazi JM, Perz JB, O'Shea D, Goldman JM, Apperley JF, Craddock CF: Posttransplantation imatinib as a strategy to postpone the requirement for immunotherapy in patients undergoing reduced-intensity allografts for chronic myeloid leukemia. Blood; 2007 Dec 15;110(13):4614-7
Hazardous Substances Data Bank. IMATINIB MESYLATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Posttransplantation imatinib as a strategy to postpone the requirement for immunotherapy in patients undergoing reduced-intensity allografts for chronic myeloid leukemia.
  • We have therefore examined whether imatinib mesylate can delay relapse and postpone the requirement for DLI in 22 patients with chronic myeloid leukemia (CML) allografted using a reduced-intensity regimen.
  • Adjunctive targeted therapy allows the kinetics of disease relapse after a reduced-intensity allograft to be manipulated and represents a novel strategy by which outcome may be improved in patients who undergo transplantation for CML and other leukemias.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation / methods. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / therapy. Piperazines / administration & dosage. Pyrimidines / administration & dosage. Secondary Prevention


9. Kisor DF: Nelarabine: a nucleoside analog with efficacy in T-cell and other leukemias. Ann Pharmacother; 2005 Jun;39(6):1056-63
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nelarabine: a nucleoside analog with efficacy in T-cell and other leukemias.
  • STUDY SELECTION AND DATA EXTRACTION: Clinical studies evaluating the pharmacokinetics of nelarabine, ara-G, and cellular ara-GTP and use of nelarabine, alone or in combination with other agents for the treatment of hematologic malignancies, were included in this review.
  • Nelarabine has significant activity against malignant T-cells and appears to be an important addition to treatments of various leukemias.
  • [MeSH-major] Arabinonucleosides / therapeutic use. Leukemia / drug therapy
  • [MeSH-minor] Area Under Curve. Clinical Trials as Topic. Fatigue / chemically induced. Humans. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / metabolism. Leukemia, T-Cell / drug therapy. Leukemia, T-Cell / metabolism. Meta-Analysis as Topic

  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15870141.001).
  • [ISSN] 1060-0280
  • [Journal-full-title] The Annals of pharmacotherapy
  • [ISO-abbreviation] Ann Pharmacother
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Arabinonucleosides; 60158CV180 / nelarabine
  • [Number-of-references] 34
  •  go-up   go-down


10. Erickson-Miller CL, Kirchner J, Aivado M, May R, Payne P, Chadderton A: Reduced proliferation of non-megakaryocytic acute myelogenous leukemia and other leukemia and lymphoma cell lines in response to eltrombopag. Leuk Res; 2010 Sep;34(9):1224-31
MedlinePlus Health Information. consumer health - Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reduced proliferation of non-megakaryocytic acute myelogenous leukemia and other leukemia and lymphoma cell lines in response to eltrombopag.
  • Leukemia cell lines were treated with eltrombopag or thrombopoietin and their proliferative response was determined.
  • The addition of other cytokines, such as G-CSF, Epo or Tpo, did not affect the decrease in proliferation.
  • These findings suggest that eltrombopag does not enhance, but rather inhibits, proliferation of leukemia cell lines in vitro.
  • [MeSH-major] Benzoates / pharmacology. Hydrazines / pharmacology. Leukemia / pathology. Leukemia, Myeloid, Acute / pathology. Lymphoma / pathology. Pyrazoles / pharmacology

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20202683.001).
  • [ISSN] 1873-5835
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Benzoates; 0 / DNA Primers; 0 / Hydrazines; 0 / Pyrazoles; 0 / eltrombopag
  •  go-up   go-down


11. Fuchs O: [EVI1 and its role in myelodysplastic syndrome, myeloid leukemia and other malignant diseases]. Cas Lek Cesk; 2006;145(8):619-24
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [EVI1 and its role in myelodysplastic syndrome, myeloid leukemia and other malignant diseases].
  • EVI1 was detected in hematopoietic cells in retrovirus-induced myeloid leukemias in mice and several reports documented EVI1 expression in human myelodysplastic syndromes and other hematologic malignancies without 3q26 translocations.
  • EVI1 is abnormally expressed in human myeloid leukemias that are associated with the t(3;3)(q21;q26), t(3;21)(q26;q22), inv(3)(q21q26) and other chromosomal rearrangements.
  • Knockdown of EVI1 function by small interference RNA increases the sensitivity of malignant cells to TGFbeta-mediated or other inducer-mediated apoptosis.
  • [MeSH-major] DNA-Binding Proteins / genetics. Leukemia, Myeloid / genetics. Myelodysplastic Syndromes / genetics. Neoplasms / genetics. Proto-Oncogenes / genetics. Transcription Factors / genetics

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • Genetic Alliance. consumer health - Myelodysplastic syndromes.
  • MedlinePlus Health Information. consumer health - Myelodysplastic Syndromes.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16995417.001).
  • [ISSN] 0008-7335
  • [Journal-full-title] Casopís lékar̆ů c̆eských
  • [ISO-abbreviation] Cas. Lek. Cesk.
  • [Language] cze
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Czech Republic
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / MECOM protein, human; 0 / Neoplasm Proteins; 0 / Transcription Factors
  • [Number-of-references] 40
  •  go-up   go-down


12. Suzuki R, Ohtake S, Takeuchi J, Nagai M, Kodera Y, Hamaguchi M, Miyawaki S, Karasuno T, Shimodaira S, Ohno R, Nakamura S, Naoe T: The clinical characteristics of CD7+ CD56+ acute myeloid leukemias other than M0. Int J Hematol; 2010 Mar;91(2):303-9
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The clinical characteristics of CD7+ CD56+ acute myeloid leukemias other than M0.
  • Immunological phenotyping of acute leukemia have provided enormous and important information for the classification and lineage determination of leukemia.
  • Forty-nine patients with CD7(+) CD56(+) acute myeloid leukemia (AML) were analyzed.
  • There were 17 patients of M0, which corresponded to myeloid/NK cell precursor acute leukemia, and 32 patients of AML other than M0 (9 each for M1 and M2, one for M3, 3 for M4, 4 for M5 and 6 for M7).
  • These findings suggest that extramedullary involvement of myeloid/NK cell precursor acute leukemia is not directly derived from the presence of CD7 and CD56 antigens on leukemic cells.
  • [MeSH-major] Antigens, CD56 / metabolism. Antigens, CD7 / metabolism. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / metabolism. Leukemia, Myeloid, Acute

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20111912.001).
  • [ISSN] 1865-3774
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD56; 0 / Antigens, CD7; 0 / Biomarkers, Tumor; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


13. Sakka V, Tsiodras S, Giamarellos-Bourboulis EJ, Giamarellou H: An update on the etiology and diagnostic evaluation of a leukemoid reaction. Eur J Intern Med; 2006 Oct;17(6):394-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Persistent neutrophilic leukocytosis above 50,000 cells/muL when the cause is other than leukemia defines a leukemoid reaction.
  • The diagnostic work-up consists of the exclusion of chronic myelogenous leukemia (CML) and chronic neutrophilic leukemia (CNL) and the detection of an underlying cause.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16962944.001).
  • [ISSN] 0953-6205
  • [Journal-full-title] European journal of internal medicine
  • [ISO-abbreviation] Eur. J. Intern. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


14. Luong NV, Kantarjian HM, Faderl SH, Thomas DA, Vu KD: Occurence of venothromboembolism (VTE) in patients (pts) with acute lymphocytic leukemia (ALL), Burkitt's leukemia/lymphoma (BL), or lymphoblastic leukemia (LL). J Clin Oncol; 2009 May 20;27(15_suppl):7059

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Occurence of venothromboembolism (VTE) in patients (pts) with acute lymphocytic leukemia (ALL), Burkitt's leukemia/lymphoma (BL), or lymphoblastic leukemia (LL).
  • Although neoplastic diseases are known risk factors for the development of VTE, little is known about the incidence and predisposing factors of VTE among leukemia patients (pts).
  • Further studies should be done in other leukemias to establish guidelines in the prevention and management of VTE in pts with leukemia.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961450.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Quintás-Cardama A, Cortes J: Omacetaxine mepesuccinate--a semisynthetic formulation of the natural antitumoral alkaloid homoharringtonine, for chronic myelocytic leukemia and other myeloid malignancies. IDrugs; 2008 May;11(5):356-72
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Omacetaxine mepesuccinate--a semisynthetic formulation of the natural antitumoral alkaloid homoharringtonine, for chronic myelocytic leukemia and other myeloid malignancies.
  • ChemGenex Pharmaceuticals Ltd, in collaboration with Stragen Group, is developing omacetaxine mepesuccinate, a semisynthetic formulation of HHT, as a potential treatment for chronic myelocytic leukemia (CML), myelodysplastic syndrome (MDS) and acute myelogenous leukemia (AML).
  • In preclinical studies, omacetaxine mepesuccinate induced apoptosis in leukemia cell lines.
  • Phase II and III clinical trials are underway to assess the activity of omacetaxine mepesuccinate, either alone or in combination with TKIs or other cytotoxic drugs, in patients with CML that is resistant to TKI therapy.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / therapeutic use. Harringtonines / therapeutic use. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy. Leukemia, Myeloid, Acute / drug therapy. Leukemia, Promyelocytic, Acute / drug therapy. Myelodysplastic Syndromes / drug therapy


16. Choi JH, Lee WK, Han SH, Ha S, Ahn SM, Kang JS, Choi YJ, Yun CH: Identification and characterization of nonapeptide targeting a human B cell lymphoma, Raji. Int Immunopharmacol; 2008 Jun;8(6):852-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Furthermore, flow-cytometric analysis on the biotinylated synthetic CTLPHLKMC peptide demonstrated the high binding affinity to Raji cells in a dose-dependent manner whereas it has binding activity to neither human peripheral blood mononuclear cells including normal B cell derived from healthy donors nor other leukemia cells including THP-1, HL-60, Jurkat and IM-9.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18442789.001).
  • [ISSN] 1567-5769
  • [Journal-full-title] International immunopharmacology
  • [ISO-abbreviation] Int. Immunopharmacol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Immunoglobulin Heavy Chains; 0 / Ligands; 0 / Oligopeptides; 0 / Peptide Library
  •  go-up   go-down


17. Cunningham SC, Fakhry K, Bass BL, Napolitano LM: Neutropenic enterocolitis in adults: case series and review of the literature. Dig Dis Sci; 2005 Feb;50(2):215-20
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this report, we discuss two cases of neutropenic enterocolitis secondary to the administration of systemic chemotherapy in adult cancer patients: one with lung carcinoma, the other with leukemia.
  • [MeSH-minor] Aged. Carcinoma, Small Cell / drug therapy. Humans. Intestine, Small / pathology. Leukemia, Erythroblastic, Acute / drug therapy. Lung Neoplasms / drug therapy. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15745075.001).
  • [ISSN] 0163-2116
  • [Journal-full-title] Digestive diseases and sciences
  • [ISO-abbreviation] Dig. Dis. Sci.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 36
  •  go-up   go-down


18. Sala A, Rossi E, Antillon F: Nutritional status at diagnosis in children and adolescents with cancer in the Asociacion de Hemato-Oncologia Pediatrica de Centro America (AHOPCA) countries: preliminary results from Guatemala. Pediatr Blood Cancer; 2008 Feb;50(2 Suppl):499-501; discussion 517
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In particular, the proportions of patients with non-lymphoblastic leukemias and myelodysplasia (MDS) with moderate and severe malnutrition were 73% and 9% respectively; higher than that in the population with acute lymphoblastic leukemia (ALL), P = 0.0493.
  • Children with ALL and other leukemias + MDS who had severe malnutrition were significantly younger than such malnourished children with solid tumors (P = 0.0003).

  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 18064663.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 18
  •  go-up   go-down


19. Svojgr K, Burjanivova T, Vaskova M, Kalina T, Stary J, Trka J, Zuna J: Adaptor molecules expression in normal lymphopoiesis and in childhood leukemia. Immunol Lett; 2009 Feb 21;122(2):185-92
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adaptor molecules expression in normal lymphopoiesis and in childhood leukemia.
  • By influencing proliferation and differentiation, these molecules might play a role in ethiopathogenesis of acute lymphoblastic leukemia (ALL).
  • Analysis of childhood ALL samples revealed that in B-cell precursor ALL, the TEL/AML1 subgroup have unique adaptor profile compared to other leukemias.
  • Moreover, NTAL expression separates T lineage leukemias into two subgroups with good and poor response to initial prednisone therapy showing prognostic impact of this molecule in T-ALL.
  • [MeSH-major] Adaptor Proteins, Signal Transducing / metabolism. B-Lymphocytes / metabolism. Lymphopoiesis / immunology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / immunology. T-Lymphocytes / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19183565.001).
  • [ISSN] 1879-0542
  • [Journal-full-title] Immunology letters
  • [ISO-abbreviation] Immunol. Lett.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / Adaptor Proteins, Vesicular Transport; 0 / Biomarkers, Tumor; 0 / LAT protein, human; 0 / LAT2 protein, human; 0 / Lck-interacting protein, human; 0 / Membrane Proteins; 0 / PAG1 protein, human
  •  go-up   go-down


20. Chen SN, Xue YQ, Pan JL, Wu YF, Wang Y, Cen JN: [High tumorigenicity of human acute monocytic leukemic cell Line SHI-1 in nude mice and its mechanism]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Aug;15(4):683-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The results showed that the tumor masses were found in all sixteen mude mice after subcutaneous injection of SHI-1 cells, the tumor mass was mainly composed of leukemia cells, the transcription of MLL-AF6 fusion gene and VEGF gene was proved by RT-PCR analysis, the expressions of MMP-2 and MMP-9 in the serum-free culture supernatant of the SHI-1 cell line were significantly higher than those in U937, K562, and NB4 cell lines.
  • The SHI-1 cell line exhibited significantly higher in vitro invasiveness than other leukemia cell lines, the blocking antibody of MMP-2 could inhibit the migration of the SHI-1 cell line significantly.
  • It is concluded that the SHI-1 cell line presents higher tumorigenicity in nude mice than other leukemia cell line and the mechanism is associated with p53 gene alteration, high transcription level of VEGF gene, high expression level of MMP, and significantly higher invasiveness.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17708782.001).
  • [ISSN] 1009-2137
  • [Journal-full-title] Zhongguo shi yan xue ye xue za zhi
  • [ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi
  • [Language] CHI
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Vascular Endothelial Growth Factor A; EC 3.4.24.24 / Matrix Metalloproteinase 2; EC 3.4.24.35 / Matrix Metalloproteinase 9
  •  go-up   go-down


21. Promsuwicha O, Auewarakul CU: Positive and negative predictive values of HLA-DR and CD34 in the diagnosis of acute promyelocytic leukemia and other types of acute myeloid leukemia with recurrent chromosomal translocations. Asian Pac J Allergy Immunol; 2009 Dec;27(4):209-16
Genetic Alliance. consumer health - Leukemia, Myeloid.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Positive and negative predictive values of HLA-DR and CD34 in the diagnosis of acute promyelocytic leukemia and other types of acute myeloid leukemia with recurrent chromosomal translocations.
  • The predictive value of HLA-DR and CD34 in the diagnosis of four distinct genetic entities of acute myeloid leukemia (AML) is presently not established.
  • The PPV and NPV of other myeloid markers such as CD117, MPO and CD11c to diagnose t(15;17) were much lower than those of HLA-DR and CD34.

  • Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20232575.001).
  • [ISSN] 0125-877X
  • [Journal-full-title] Asian Pacific journal of allergy and immunology
  • [ISO-abbreviation] Asian Pac. J. Allergy Immunol.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Thailand
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / HLA-DR Antigens
  •  go-up   go-down


22. Sasson SC, Smith S, Seddiki N, Zaunders JJ, Bryant A, Koelsch KK, Weatherall C, Munier ML, McGinley C, Yeung J, Mulligan SP, Moore J, Cooper DA, Milliken S, Kelleher AD: IL-7 receptor is expressed on adult pre-B-cell acute lymphoblastic leukemia and other B-cell derived neoplasms and correlates with expression of proliferation and survival markers. Cytokine; 2010 Apr;50(1):58-68
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] IL-7 receptor is expressed on adult pre-B-cell acute lymphoblastic leukemia and other B-cell derived neoplasms and correlates with expression of proliferation and survival markers.
  • CD127 expression was elevated in pre-B-cell acute lymphoblastic leukemia (pre-B-ALL) and in some cases of Non-Hodgkin's Lymphoma (B-NHL).
  • Plasma IL-7 levels were higher in pre-B-ALL, B-cell chronic lymphocytic leukemia (B-CLL) and HIV-1 associated B-NHL (HIV-B-NHL) compared with control groups.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / metabolism. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / pathology. Receptors, Interleukin-7 / immunology

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2009 Elsevier Ltd. All rights reserved.
  • (PMID = 20060740.001).
  • [ISSN] 1096-0023
  • [Journal-full-title] Cytokine
  • [ISO-abbreviation] Cytokine
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cytokines; 0 / IL2RG protein, human; 0 / Interleukin Receptor Common gamma Subunit; 0 / Ki-67 Antigen; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Receptors, Interleukin-7
  •  go-up   go-down


23. Ferrara F: Acute promyelocytic leukemia: what are the treatment options? Expert Opin Pharmacother; 2010 Mar;11(4):587-96
Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute promyelocytic leukemia: what are the treatment options?
  • IMPORTANCE OF THE FIELD: Acute promyelocytic leukemia (APL) represents a paradigm of therapeutic success in clinical hematology.
  • TAKE HOME MESSAGE: To date, the therapy of APL is the most successful example of differentiation therapy and its scientific history can serve as a model for subsequent development of similar treatments in other leukemias and cancers.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Arsenicals / therapeutic use. Leukemia, Promyelocytic, Acute / drug therapy. Oxides / therapeutic use

  • Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. ARSENIC TRIOXIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20163270.001).
  • [ISSN] 1744-7666
  • [Journal-full-title] Expert opinion on pharmacotherapy
  • [ISO-abbreviation] Expert Opin Pharmacother
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Aminoglycosides; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; 0 / Arsenicals; 0 / Oxides; 0 / gemtuzumab; 5688UTC01R / Tretinoin; S7V92P67HO / arsenic trioxide
  • [Number-of-references] 75
  •  go-up   go-down


24. Kong D, Aoki S, Sowa Y, Sakai T, Kobayashi M: Smenospongine, a sesquiterpene aminoquinone from a marine sponge, induces G1 arrest or apoptosis in different leukemia cells. Mar Drugs; 2008;6(3):480-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Smenospongine, a sesquiterpene aminoquinone from a marine sponge, induces G1 arrest or apoptosis in different leukemia cells.
  • Smenospongine, a sesquiterpene aminoquinone isolated from the marine sponge Dactylospongia elegans, was previously reported by us to induce erythroid differentiation and G1 phase arrest of K562 chronic myelogenous leukemia cells.
  • In this study, we investigated the effect of smenospongine on the cell cycles of other leukemia cells, including HL60 human acute promyelocytic leukemia cells and U937 human histiocytic lymphoma cells by flow cytometric analysis.
  • [MeSH-major] Apoptosis / drug effects. G1 Phase / drug effects. Leukemia / drug therapy. Porifera / chemistry. Quinones / chemistry. Quinones / pharmacology. Sesquiterpenes / chemistry. Sesquiterpenes / pharmacology

  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2005 Feb 1;105(3):959-67 [15466934.001]
  • [Cites] Cancer Res. 1999 Sep 1;59(17):4266-70 [10485470.001]
  • [Cites] Cancer Lett. 2007 May 8;249(2):121-32 [16949736.001]
  • [Cites] Stem Cells Dev. 2007 Jun;16(3):503-14 [17610380.001]
  • [Cites] J Manag Care Pharm. 2007 Oct;13(8 Suppl A):8-12 [17970609.001]
  • [Cites] Biochem Biophys Res Commun. 2001 Mar 30;282(2):426-31 [11401476.001]
  • [Cites] Biochem Pharmacol. 2002 Oct 1;64(7):1079-90 [12234611.001]
  • [Cites] Curr Opin Hematol. 2004 Jan;11(1):35-43 [14676625.001]
  • [Cites] Anticancer Drugs. 2004 Apr;15(4):363-9 [15057141.001]
  • [Cites] Chem Pharm Bull (Tokyo). 2004 Aug;52(8):935-7 [15304984.001]
  • [Cites] Anticancer Res. 2004 Jul-Aug;24(4):2325-30 [15330179.001]
  • [Cites] Blood. 1975 Mar;45(3):321-34 [163658.001]
  • [Cites] Nature. 1982 Dec 23;300(5894):765-7 [6960256.001]
  • [Cites] Leukemia. 1992 Aug;6(8):839-42 [1640738.001]
  • [Cites] Biochem Biophys Res Commun. 1997 Dec 8;241(1):142-50 [9405248.001]
  • [Cites] Cell Death Differ. 1998 Aug;5(8):710-5 [10200527.001]
  • [Cites] Biochem Biophys Res Commun. 2006 Mar 31;342(1):101-6 [16480688.001]
  • (PMID = 19005580.001).
  • [ISSN] 1660-3397
  • [Journal-full-title] Marine drugs
  • [ISO-abbreviation] Mar Drugs
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Quinones; 0 / Sesquiterpenes; 0 / smenospongine
  • [Other-IDs] NLM/ PMC2579737
  • [Keywords] NOTNLM ; G1 arrest / Rb / Smenospongine / apoptosis / leukemia cells / p21
  •  go-up   go-down


25. Béné MC, Kaeda JS: How and why minimal residual disease studies are necessary in leukemia: a review from WP10 and WP12 of the European LeukaemiaNet. Haematologica; 2009 Aug;94(8):1135-50
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] How and why minimal residual disease studies are necessary in leukemia: a review from WP10 and WP12 of the European LeukaemiaNet.
  • In leukemia, the resistant cells remaining in the bone marrow and/or peripheral blood constitute minimal residual disease and are detectable by highly sensitive assays when the patient appears to be in complete remission.
  • This notion is supported by a large body of data among chronic myeloid leukemia patients, but minimal residual disease detection and monitoring is increasingly applied to other types of leukemia, and is starting to be a factor in decision-making for some therapeutic trials in childhood acute lymphoblastic leukemia.
  • Here, from the solid ground of minimal residual disease detection in chronic myeloid leukemia, the current state of the art and development of molecular techniques in other leukemias and the growing field of multiparameter flow cytometry are reviewed in two separate parts reporting on the respective advances, advantages and pitfalls of these emerging methods.
  • [MeSH-major] Leukemia / diagnosis. Neoplasm, Residual / diagnosis

  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Leukemia. 2007 May;21(5):956-64 [17361231.001]
  • [Cites] Am J Hematol. 2000 Jun;64(2):101-6 [10814988.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Jun 20;97(13):7521-6 [10861016.001]
  • [Cites] Cytometry. 2000 Aug 15;42(4):247-53 [10934344.001]
  • [Cites] Blood. 2000 Oct 15;96(8):2691-6 [11023499.001]
  • [Cites] Blood. 2000 Dec 1;96(12):3948-52 [11090082.001]
  • [Cites] Blood. 2001 Apr 1;97(7):2115-20 [11264179.001]
  • [Cites] Blood. 2001 Jun 1;97(11):3574-80 [11369653.001]
  • [Cites] Blood. 2001 Jul 1;98(1):29-35 [11418459.001]
  • [Cites] Leukemia. 2001 Jul;15(7):1072-80 [11455976.001]
  • [Cites] Blood. 2001 Nov 1;98(9):2633-9 [11675331.001]
  • [Cites] Lancet. 2001 Oct 13;358(9289):1239-41 [11675066.001]
  • [Cites] Leuk Res. 2001 Dec;25(12):1085-8 [11684280.001]
  • [Cites] Br J Haematol. 2001 Dec;115(3):569-74 [11736937.001]
  • [Cites] Blood. 2002 Jan 15;99(2):443-9 [11781223.001]
  • [Cites] J Clin Oncol. 2002 Feb 15;20(4):1094-104 [11844835.001]
  • [Cites] Blood. 2002 Mar 1;99(5):1873-4 [11871387.001]
  • [Cites] Acta Haematol. 2002;107(2):64-75 [11919387.001]
  • [Cites] Best Pract Res Clin Haematol. 2002 Mar;15(1):105-18 [11987919.001]
  • [Cites] Haematologica. 2003 Nov;88(11):1245-52 [14607753.001]
  • [Cites] J Clin Oncol. 2003 Dec 1;21(23):4413-22 [14645432.001]
  • [Cites] Leukemia. 2003 Dec;17(12):2401-9 [14523461.001]
  • [Cites] Leukemia. 2003 Dec;17(12):2474-86 [14562124.001]
  • [Cites] Leukemia. 2003 Dec;17(12):2318-57 [14562125.001]
  • [Cites] Leukemia. 2003 Dec;17(12):2257-317 [14671650.001]
  • [Cites] Leukemia. 2004 May;18(5):934-8 [15029212.001]
  • [Cites] Br J Haematol. 2004 Jun;125(5):590-600 [15147374.001]
  • [Cites] Cytometry B Clin Cytom. 2004 Jul;60(1):1-13 [15221864.001]
  • [Cites] Leukemia. 2004 Aug;18(8):1380-90 [15201848.001]
  • [Cites] Leukemia. 2004 Aug;18(8):1441-4 [15201851.001]
  • [Cites] N Engl J Med. 2004 Aug 26;351(9):893-901 [15329427.001]
  • [Cites] J Immunol. 2004 Oct 1;173(7):4260-4 [15383553.001]
  • [Cites] Leukemia. 2004 Oct;18(10):1630-6 [15295608.001]
  • [Cites] Haematologica. 2004 Oct;89(10):1271-3 [15477219.001]
  • [Cites] Blood. 2004 Nov 1;104(9):2926-32 [15256429.001]
  • [Cites] Leukemia. 1997 Dec;11(12):2022-31 [9447815.001]
  • [Cites] Lancet. 1998 Feb 21;351(9102):550-4 [9492773.001]
  • [Cites] Am J Clin Pathol. 1998 Jul;110(1):84-94 [9661926.001]
  • [Cites] Blood. 1998 Aug 1;92(3):784-9 [9680345.001]
  • [Cites] Br J Haematol. 1998 Aug;102(3):768-74 [9722305.001]
  • [Cites] Br Med J. 1967 Jan 14;1(5532):84-8 [6015635.001]
  • [Cites] Blood. 1975 Aug;46(2):219-34 [1139039.001]
  • [Cites] Cancer. 1977 Aug;40(2):855-64 [890666.001]
  • [Cites] Leuk Res. 1981;5(4-5):301-9 [7026903.001]
  • [Cites] Ann N Y Acad Sci. 1986;468:268-75 [3089116.001]
  • [Cites] Blood. 1990 Jul 1;76(1):163-71 [1973061.001]
  • [Cites] N Engl J Med. 1990 Sep 13;323(11):720-4 [2201915.001]
  • [Cites] Leukemia. 1990 Sep;4(9):609-14 [1975635.001]
  • [Cites] Br J Haematol. 1991 Jan;77(1):37-42 [1998595.001]
  • [Cites] Proc Natl Acad Sci U S A. 1991 Dec 1;88(23):10431-4 [1720541.001]
  • [Cites] Am J Hematol. 1991 Dec;38(4):332-4 [1836104.001]
  • [Cites] Blood. 1992 Mar 1;79(5):1366-70 [1371420.001]
  • [Cites] Leukemia. 1992;6 Suppl 1:47-59 [1548936.001]
  • [Cites] Cytometry. 1992;13(8):893-901 [1459006.001]
  • [Cites] N Engl J Med. 1993 Jul 15;329(3):177-89 [8515790.001]
  • [Cites] Br J Haematol. 1993 May;84(1):67-74 [8338780.001]
  • [Cites] Cytometry. 1993;14(5):519-26 [8354125.001]
  • [Cites] Blood. 1993 Sep 15;82(6):1929-36 [8400243.001]
  • [Cites] Leukemia. 1993 Oct;7(10):1570-5 [7692192.001]
  • [Cites] Am J Clin Pathol. 1993 Nov;100(5):534-40 [8249893.001]
  • [Cites] Leukemia. 1994 Jan;8(1):186-9 [8289486.001]
  • [Cites] Leukemia. 1994 Sep;8(9):1564-70 [7522295.001]
  • [Cites] N Engl J Med. 1995 Jun 15;332(24):1618-30 [7753142.001]
  • [Cites] Blood. 1995 Jun 15;85(12):3695-703 [7780153.001]
  • [Cites] Blood. 1996 Feb 15;87(4):1549-55 [8608246.001]
  • [Cites] Blood. 1997 Apr 1;89(7):2602-9 [9116308.001]
  • [Cites] Am J Hematol. 2005 Aug;79(4):257-61 [16044453.001]
  • [Cites] Cytometry B Clin Cytom. 2005 Nov;68(1):18-24 [16184615.001]
  • [Cites] Am J Hematol. 2005 Nov;80(3):181-7 [16247752.001]
  • [Cites] Haematologica. 2005 Nov;90(11):1516-23 [16266899.001]
  • [Cites] Crit Rev Oncol Hematol. 2005 Nov;56(2):223-34 [16213152.001]
  • [Cites] Clin Cancer Res. 2005 Nov 1;11(21):7757-63 [16278397.001]
  • [Cites] Blood. 2005 Dec 1;106(12):3733-9 [16076867.001]
  • [Cites] Blood. 2006 Feb 1;107(3):1116-23 [16195338.001]
  • [Cites] Cancer. 2006 Feb 15;106(4):839-47 [16419072.001]
  • [Cites] Leuk Res. 2006 Apr;30(4):389-95 [16243396.001]
  • [Cites] Leukemia. 2006 Apr;20(4):604-9 [16453003.001]
  • [Cites] J Clin Oncol. 2006 Apr 1;24(10):1507-15 [16575000.001]
  • [Cites] Leukemia. 2006 Jan;20(1):87-94 [16281071.001]
  • [Cites] Haematologica. 2006 May;91(5):671-4 [16627255.001]
  • [Cites] Blood. 2006 May 15;107(10):4171-6 [16449534.001]
  • [Cites] Arch Pathol Lab Med. 2006 May;130(5):680-90 [16683886.001]
  • [Cites] Blood. 2006 Jun 1;107(11):4563-9 [16449533.001]
  • [Cites] Leukemia. 2006 Jun;20(6):1103-8 [16541144.001]
  • [Cites] Haematologica. 2006 Jun;91(6):833-6 [16769587.001]
  • [Cites] Haematologica. 2006 Jun;91(6):860-1 [16769593.001]
  • [Cites] Leukemia. 2006 Jul;20(7):1217-20 [16642044.001]
  • [Cites] Blood. 2006 Jul 1;108(1):28-37 [16522812.001]
  • [Cites] Blood. 2006 Jul 1;108(1):97-102 [16537802.001]
  • [Cites] Blood. 2006 Sep 15;108(6):1809-20 [16709930.001]
  • [Cites] Leukemia. 2006 Nov;20(11):1925-30 [16990771.001]
  • [Cites] Clin Adv Hematol Oncol. 2006 Nov;4(11 Suppl 22):1-10; quiz 11-2 [17143256.001]
  • [Cites] Leukemia. 2007 Jan;21(1):1-3 [17167526.001]
  • [Cites] Neoplasma. 2006;53(6):500-6 [17167719.001]
  • [Cites] Leuk Lymphoma. 2006 Dec;47(12):2645-7 [17169810.001]
  • [Cites] Leukemia. 2007 Feb;21(2):222-9 [17170729.001]
  • [Cites] Haematologica. 2007 Mar;92(3):315-22 [17339180.001]
  • [Cites] Leukemia. 2007 Apr;21(4):604-11 [17287850.001]
  • [Cites] Leukemia. 2007 May;21(5):998-1004 [17361227.001]
  • [Cites] Leukemia. 1999 Mar;13(3):419-27 [10086733.001]
  • [Cites] Exp Hematol. 1999 Apr;27(4):673-81 [10210325.001]
  • [Cites] Leukemia. 1999 Apr;13(4):558-67 [10214862.001]
  • [Cites] Cytometry. 1999 Aug 15;38(4):139-52 [10440852.001]
  • [Cites] Blood. 1999 Sep 15;94(6):1840-7 [10477712.001]
  • [Cites] Blood. 1999 Sep 15;94(6):1848-54 [10477713.001]
  • [Cites] Eur J Haematol. 1999 Sep;63(3):192-201 [10485274.001]
  • [Cites] Blood. 2004 Nov 15;104(10):3078-85 [15284114.001]
  • [Cites] Leukemia. 2005 Jan;19(1):49-56 [15538405.001]
  • [Cites] Cytometry B Clin Cytom. 2005 Jan;63(1):1-9 [15624201.001]
  • [Cites] Exp Hematol. 2005 Jan;33(1):120-30 [15661405.001]
  • [Cites] Haematologica. 2005 Mar;90(3):382-90 [15749670.001]
  • [Cites] Br J Haematol. 2005 Mar;128(6):774-82 [15755280.001]
  • [Cites] Blood. 2008 Feb 15;111(4):1774-80 [18055868.001]
  • [Cites] Leukemia. 2008 Mar;22(3):641-4 [17851557.001]
  • [Cites] Blood. 2008 Apr 15;111(8):4329-37 [18272813.001]
  • [Cites] N Engl J Med. 2008 May 1;358(18):1909-18 [18450602.001]
  • [Cites] Br J Haematol. 2008 Jun;141(6):782-91 [18410450.001]
  • [Cites] Haematologica. 2008 Jun;93(6):921-4 [18443273.001]
  • [Cites] Blood. 2008 Jun 15;111(12):5477-85 [18388178.001]
  • [Cites] Blood. 2008 Oct 15;112(8):3330-8 [18684859.001]
  • [Cites] J Clin Oncol. 2008 Oct 10;26(29):4806-13 [18645191.001]
  • [Cites] Cytometry B Clin Cytom. 2008 Nov;74(6):331-40 [18548617.001]
  • [Cites] Haematologica. 2009 Jan;94(1):46-53 [19042917.001]
  • [Cites] N Engl J Med. 2009 Jan 29;360(5):470-80 [19129520.001]
  • [Cites] Br J Haematol. 2009 May;145(3):373-5 [19344397.001]
  • [Cites] Leukemia. 2005 Apr;19(4):507-12 [15703781.001]
  • [Cites] Leukemia. 2005 Apr;19(4):628-35 [15744351.001]
  • [Cites] Clin Cancer Res. 2005 May 1;11(9):3425-32 [15867244.001]
  • [Cites] J Clin Oncol. 2005 Jun 20;23(18):4070-8 [15767647.001]
  • [Cites] Haematologica. 2007 May;92(5):605-11 [17488683.001]
  • [Cites] Leukemia. 2007 Jul;21(7):1481-7 [17476280.001]
  • [Cites] Best Pract Res Clin Haematol. 2007 Sep;20(3):499-512 [17707836.001]
  • [Cites] Haematologica. 2007 Sep;92(9):1268-9 [17768124.001]
  • [Cites] Leukemia. 2002 Jun;16(6):1167-75 [12040449.001]
  • [Cites] Blood. 2002 Jul 1;100(1):59-66 [12070009.001]
  • [Cites] Leukemia. 2002 Jul;16(7):1381-9 [12094264.001]
  • [Cites] Leukemia. 2002 Aug;16(8):1432-6 [12145681.001]
  • [Cites] Blood. 2002 Aug 15;100(4):1177-84 [12149195.001]
  • [Cites] Blood. 2002 Aug 15;100(4):1410-6 [12149225.001]
  • [Cites] Leukemia. 2002 Sep;16(9):1579-83 [12200666.001]
  • [Cites] Blood. 2002 Oct 1;100(7):2387-92 [12239146.001]
  • [Cites] Blood. 2002 Oct 1;100(7):2393-8 [12239147.001]
  • [Cites] Blood. 2002 Oct 1;100(7):2399-402 [12239148.001]
  • [Cites] Haematologica. 2002 Nov;87(11):1126-34 [12414341.001]
  • [Cites] Br J Haematol. 2002 Dec;119(4):970-5 [12472575.001]
  • [Cites] Leukemia. 2003 Jan;17(1):138-48 [12529671.001]
  • [Cites] Best Pract Res Clin Haematol. 2002 Dec;15(4):729-40 [12617873.001]
  • [Cites] Blood. 2003 Apr 1;101(7):2521-8 [12468436.001]
  • [Cites] Br J Haematol. 2003 Mar;120(6):990-9 [12648069.001]
  • [Cites] Biol Blood Marrow Transplant. 2003 Mar;9(3):206-12 [12652472.001]
  • [Cites] Br J Haematol. 2003 Apr;121(2):287-95 [12694251.001]
  • [Cites] Blood. 2003 May 1;101(9):3398-406 [12506020.001]
  • [Cites] Haematologica. 2003 Jun;88(6):646-53 [12801840.001]
  • [Cites] N Engl J Med. 2003 Oct 9;349(15):1423-32 [14534335.001]
  • [Cites] Best Pract Res Clin Haematol. 2003 Dec;16(4):599-612 [14592645.001]
  • [Cites] Clin Chem. 1999 Dec;45(12):2079-85 [10585339.001]
  • [Cites] Blood. 2000 Feb 1;95(3):815-9 [10648391.001]
  • [Cites] Leukemia. 2000 May;14(5):783-5 [10803506.001]
  • [Cites] Blood. 1997 Sep 15;90(6):2465-70 [9310499.001]
  • [Cites] Baillieres Clin Haematol. 1997 Jun;10(2):389-403 [9376671.001]
  • [Cites] Blood. 1997 Oct 15;90(8):2863-92 [9376567.001]
  • [Cites] Leukemia. 1997 Nov;11(11):1878-86 [9369421.001]
  • [CommentIn] Haematologica. 2010 Apr;95(4):691-2 [19951967.001]
  • (PMID = 19586938.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Italy
  • [Number-of-references] 167
  • [Other-IDs] NLM/ PMC2719036
  •  go-up   go-down


26. Wu HJ, Chen Y: [Biological characteristics of hyperleukocytic acute leukemia]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2006 Jun;14(3):450-4
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Biological characteristics of hyperleukocytic acute leukemia].
  • The study was to investigate the biological characteristics of hyperleucocyte acute leukemia (HAL) and its clinical significance.
  • In AML, monocytic leukemia is easier to become into HAL than other leukemias.
  • In ALL, T-lineage antigens of HAL group are more easily expressed than those of NHAL group; the leukemia cells of HAL group are naiver than those of NHAL group, meanwhile the prognosis of HAL is poor.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16800918.001).
  • [ISSN] 1009-2137
  • [Journal-full-title] Zhongguo shi yan xue ye xue za zhi
  • [ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi
  • [Language] CHI
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, CD14; 0 / Antigens, CD79; 0 / Antigens, CD8; 0 / Sialic Acid Binding Ig-like Lectin 2
  •  go-up   go-down


27. Mohi MG, Williams IR, Dearolf CR, Chan G, Kutok JL, Cohen S, Morgan K, Boulton C, Shigematsu H, Keilhack H, Akashi K, Gilliland DG, Neel BG: Prognostic, therapeutic, and mechanistic implications of a mouse model of leukemia evoked by Shp2 (PTPN11) mutations. Cancer Cell; 2005 Feb;7(2):179-91
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic, therapeutic, and mechanistic implications of a mouse model of leukemia evoked by Shp2 (PTPN11) mutations.
  • Germline Shp2 mutations cause Noonan Syndrome (NS), which is associated with increased risk of juvenile myelomonocytic leukemia (JMML).
  • Somatic Shp2 mutations occur in sporadic JMML and other leukemias.
  • We found that Shp2 mutants associated with sporadic leukemias transform murine bone marrow cells, whereas NS mutants are less potent in this assay.
  • [MeSH-major] Leukemia / genetics. Mutation. Protein Tyrosine Phosphatases / genetics

  • MedlinePlus Health Information. consumer health - Leukemia.
  • COS Scholar Universe. author profiles.
  • PhosphoSitePlus. gene/protein/disease-specific - PhosphoSitePlus® - comprehensive post-translational modification resource .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15710330.001).
  • [ISSN] 1535-6108
  • [Journal-full-title] Cancer cell
  • [ISO-abbreviation] Cancer Cell
  • [Language] eng
  • [Grant] United States / NIDDK NIH HHS / DK / DK50654; United States / NCI NIH HHS / CA / P01 CA66996; United States / NIDDK NIH HHS / DK / P01 DK50654; United States / NIDDK NIH HHS / DK / R01 DK50693; United States / NCRR NIH HHS / RR / R24 RR15061
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Complementary; 0 / Interleukin-3; 0 / Intracellular Signaling Peptides and Proteins; 147336-22-9 / Green Fluorescent Proteins; 83869-56-1 / Granulocyte-Macrophage Colony-Stimulating Factor; EC 3.1.3.48 / Protein Tyrosine Phosphatase, Non-Receptor Type 11; EC 3.1.3.48 / Protein Tyrosine Phosphatases; EC 3.1.3.48 / Ptpn11 protein, mouse
  •  go-up   go-down


28. Ravandi F, O'Brien S: Chronic lymphoid leukemias other than chronic lymphocytic leukemia: diagnosis and treatment. Mayo Clin Proc; 2005 Dec;80(12):1660-74
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chronic lymphoid leukemias other than chronic lymphocytic leukemia: diagnosis and treatment.
  • The distinction between lymphoma and leukemia is somewhat arbitrary and is based on variable involvement of the bone marrow, peripheral blood, and lymphatic system.
  • [MeSH-major] Leukemia, Hairy Cell / diagnosis. Leukemia, Hairy Cell / therapy. Leukemia, Lymphocytic, Chronic, B-Cell / diagnosis. Leukemia, Lymphocytic, Chronic, B-Cell / therapy. Leukemia, T-Cell / diagnosis. Leukemia, T-Cell / therapy

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16342661.001).
  • [ISSN] 0025-6196
  • [Journal-full-title] Mayo Clinic proceedings
  • [ISO-abbreviation] Mayo Clin. Proc.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 21
  •  go-up   go-down


29. Suzuki K, Nishimi D, Yagishita T, Takanami M, Hiruta N: Testicular tumor in Down syndrome. Int J Urol; 2005 Oct;12(10):925-7
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • It is currently thought that risk of developing leukemia in patients with Down syndrome is 20- to 30-fold higher than that in normal subjects.
  • Furthermore, the incidence of testicular cancer as a complication other than leukemia is expected to increase because of the increasing postpubertal population with Down syndrome.

  • Genetic Alliance. consumer health - Down Syndrome.
  • MedlinePlus Health Information. consumer health - Down Syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16323991.001).
  • [ISSN] 0919-8172
  • [Journal-full-title] International journal of urology : official journal of the Japanese Urological Association
  • [ISO-abbreviation] Int. J. Urol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


30. Huang ZF, Chen R, Li YZ, Chen GN, Chen XL, Feng SY, Jia PM: [Two-photon excitation fluorescence of 5-ALA induced PpIX in DHL cells]. Guang Pu Xue Yu Guang Pu Fen Xi; 2008 Nov;28(11):2636-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Results indicate that two-photon fluorescence based on laser scanning microscope can be a useful technology for studying the kinetics of 5-ALA induced PpIX production in DHL cells and other leukemia cells.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19271507.001).
  • [ISSN] 1000-0593
  • [Journal-full-title] Guang pu xue yu guang pu fen xi = Guang pu
  • [ISO-abbreviation] Guang Pu Xue Yu Guang Pu Fen Xi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Protoporphyrins; 553-12-8 / protoporphyrin IX; 88755TAZ87 / Aminolevulinic Acid
  •  go-up   go-down


31. Li Z, Godinho FJ, Klusmann JH, Garriga-Canut M, Yu C, Orkin SH: Developmental stage-selective effect of somatically mutated leukemogenic transcription factor GATA1. Nat Genet; 2005 Jun;37(6):613-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Acquired mutations in the hematopoietic transcription factor GATA binding protein-1 (GATA1) are found in megakaryoblasts from nearly all individuals with Down syndrome with transient myeloproliferative disorder (TMD, also called transient leukemia) and the related acute megakaryoblastic leukemia (DS-AMKL, also called DS-AML M7).
  • Our observations raise the possibility that the target cells in other leukemias of infancy and early childhood are distinct from those in adult leukemias and underscore the interplay between specific oncoproteins and potential target cells.
  • [MeSH-minor] Adult. Age Factors. Animals. Cell Differentiation. Cells, Cultured. Down Syndrome / genetics. Embryo, Mammalian. Erythroid-Specific DNA-Binding Factors. GATA1 Transcription Factor. Gene Targeting. Hematopoiesis / genetics. Humans. Infant. Leukemia, Megakaryoblastic, Acute / genetics. Liver / cytology. Liver / embryology. Megakaryocytes. Mice. Transfection


32. Yang J, Chai L, Gao C, Fowles TC, Alipio Z, Dang H, Xu D, Fink LM, Ward DC, Ma Y: SALL4 is a key regulator of survival and apoptosis in human leukemic cells. Blood; 2008 Aug 1;112(3):805-13
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Flow cytometry revealed that reduction of SALL4 expression in NB4 and other leukemia cell lines dramatically increased caspase-3, annexin V, and DNA fragmentation activity.
  • Our studies provide a foundation in the development of leukemia stem cell-specific therapy by targeting SALL4.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mod Pathol. 2006 Dec;19(12):1585-92 [16998462.001]
  • [Cites] Immunity. 2004 Dec;21(6):843-51 [15589172.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Jun 19;104(25):10494-9 [17557835.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Oct 16;104(42):16438-43 [17940043.001]
  • [Cites] Cell. 2007 Nov 30;131(5):861-72 [18035408.001]
  • [Cites] J Invest Dermatol. 2008 Jan;128(1):9-17 [17625597.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Feb 26;105(8):2883-8 [18287077.001]
  • [Cites] Am J Pathol. 2007 Apr;170(4):1370-8 [17392175.001]
  • [Cites] Genes Dev. 1999 Oct 15;13(20):2678-90 [10541554.001]
  • [Cites] Genomics. 1999 Dec 1;62(2):216-22 [10610715.001]
  • [Cites] J Exp Med. 2002 Mar 18;195(6):759-70 [11901201.001]
  • [Cites] Bioinformatics. 2002 Apr;18(4):546-54 [12016052.001]
  • [Cites] Hum Mol Genet. 2002 Nov 1;11(23):2979-87 [12393809.001]
  • [Cites] Am J Hum Genet. 2002 Nov;71(5):1195-9 [12395297.001]
  • [Cites] Nature. 2003 May 15;423(6937):255-60 [12714970.001]
  • [Cites] Nature. 2003 May 15;423(6937):302-5 [12714971.001]
  • [Cites] Nature. 2003 May 15;423(6937):231-3 [12748623.001]
  • [Cites] Trends Immunol. 2003 Oct;24(10):522-4 [14552834.001]
  • [Cites] Nature. 2003 Oct 30;425(6961):962-7 [14574365.001]
  • [Cites] J Biol Chem. 2004 Feb 27;279(9):8169-80 [14660608.001]
  • [Cites] Cell. 2005 Sep 23;122(6):947-56 [16153702.001]
  • [Cites] Blood. 2006 Jan 1;107(1):305-8 [16160010.001]
  • [Cites] Nat Genet. 2006 Apr;38(4):431-40 [16518401.001]
  • [Cites] Genome Res. 2006 May;16(5):595-605 [16606705.001]
  • [Cites] J Biol Chem. 2006 Aug 25;281(34):24090-4 [16840789.001]
  • [Cites] Cell Cycle. 2006 Aug;5(16):1886-901 [16963837.001]
  • [Cites] Stem Cells Dev. 2006 Aug;15(4):532-55 [16978057.001]
  • [Cites] Nat Cell Biol. 2006 Oct;8(10):1114-23 [16980957.001]
  • [Cites] Blood. 2006 Oct 15;108(8):2726-35 [16763212.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Oct 31;103(44):16319-24 [17060609.001]
  • [Cites] J Med Genet. 2004 Aug;41(8):e102 [15286162.001]
  • [Cites] Genes Dev. 1994 Apr 1;8(7):757-69 [7926765.001]
  • [Cites] Development. 1996 Jul;122(7):2215-23 [8681802.001]
  • [Cites] Genomics. 1996 Dec 15;38(3):291-8 [8975705.001]
  • [Cites] Nature. 1999 Jan 14;397(6715):164-8 [9923679.001]
  • [ErratumIn] Blood. 2009 Oct 1; 114(14):3131
  • (PMID = 18487508.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NCRR NIH HHS / RR / P20 RR016464; United States / NHLBI NIH HHS / HL / R01HL087948; United States / NCI NIH HHS / CA / R21 CA131522; United States / NHLBI NIH HHS / HL / R01 HL087948; United States / NCI NIH HHS / CA / K08 CA097185; United States / NIDDK NIH HHS / DK / K08 DK063220; United States / NCI NIH HHS / CA / R21 CA131522-01A1; United States / NCI NIH HHS / CA / CA131522-01A1
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / SALL4 protein, human; 0 / Transcription Factors
  • [Other-IDs] NLM/ PMC2481537
  •  go-up   go-down


33. Matsumoto E, Hatanaka M, Bohgaki M, Maeda S: PKC pathway and ERK/MAPK pathway are required for induction of cyclin D1 and p21Waf1 during 12-o-tetradecanoylphorbol 13-acetate-induced differentiation of myeloleukemia cells. Kobe J Med Sci; 2006;52(6):181-94
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Treatment of human promyelocytic leukemia cell HL60 with 12-o-tetradecanoylphorbol 13-acetate (TPA) induces growth arrest, differentiation towards the monocyte/macrophage lineage, and expression of cell cycle-regulating genes cyclin D1 and p21Waf1.
  • First, we demonstrated that p21Waf1 expression was increased by TPA in other leukemia cell lines also, including THP-1, U937, and KG-1, which differentiate into monocytes/macrophages by TPA.
  • [MeSH-major] Cyclin D1 / biosynthesis. Cyclin-Dependent Kinase Inhibitor p21 / biosynthesis. Extracellular Signal-Regulated MAP Kinases / physiology. Leukemia, Myeloid / pathology. Protein Kinase C / physiology. Signal Transduction / physiology. Tetradecanoylphorbol Acetate / pharmacology

  • National BioResource Project. culture/stock collections - NBRP resources .
  • Hazardous Substances Data Bank. 12-O-TETRADECANOYLPHORBOL-13-ACETATE .
  • Hazardous Substances Data Bank. CYCLOHEXIMIDE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17329956.001).
  • [ISSN] 0023-2513
  • [Journal-full-title] The Kobe journal of medical sciences
  • [ISO-abbreviation] Kobe J Med Sci
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / CDKN1A protein, human; 0 / Cyclin-Dependent Kinase Inhibitor p21; 136601-57-5 / Cyclin D1; 98600C0908 / Cycloheximide; EC 2.7.11.13 / Protein Kinase C; EC 2.7.11.24 / Extracellular Signal-Regulated MAP Kinases; EC 2.7.11.24 / p38 Mitogen-Activated Protein Kinases; NI40JAQ945 / Tetradecanoylphorbol Acetate
  •  go-up   go-down


34. Dai Y, Khanna P, Chen S, Pei XY, Dent P, Grant S: Statins synergistically potentiate 7-hydroxystaurosporine (UCN-01) lethality in human leukemia and myeloma cells by disrupting Ras farnesylation and activation. Blood; 2007 May 15;109(10):4415-23
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Statins synergistically potentiate 7-hydroxystaurosporine (UCN-01) lethality in human leukemia and myeloma cells by disrupting Ras farnesylation and activation.
  • Interactions between UCN-01 and HMG-CoA reductase inhibitors (ie, statins) have been examined in human leukemia and myeloma cells.
  • Comparable effects were observed in other leukemia and myeloma cell lines as well as in primary acute myeloid leukemia (AML) blasts but not in normal hematopoietic cells.

  • MedlinePlus Health Information. consumer health - Leukemia.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • MedlinePlus Health Information. consumer health - Statins.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Leukemia. 2001 Sep;15(9):1398-407 [11516100.001]
  • [Cites] Blood. 2003 May 1;101(9):3628-34 [12506040.001]
  • [Cites] Clin Cancer Res. 2005 Jan 15;11(2 Pt 1):664-71 [15701854.001]
  • [Cites] J Clin Pharmacol. 2005 Apr;45(4):394-403 [15778420.001]
  • [Cites] Clin Cancer Res. 2005 Mar 15;11(6):2398-407 [15788691.001]
  • [Cites] FASEB J. 2005 Apr;19(6):605-7 [15677697.001]
  • [Cites] Cancer Cell. 2005 Apr;7(4):297-300 [15837619.001]
  • [Cites] Clin Cancer Res. 2005 Jun 15;11(12):4589-600 [15958645.001]
  • [Cites] Oncology (Williston Park). 2005 May;19(6):739-50; discussion 753-4 [15971450.001]
  • [Cites] Oncologist. 2005 Sep;10(8):565-78 [16177281.001]
  • [Cites] Int J Oncol. 2005 Nov;27(5):1401-9 [16211237.001]
  • [Cites] Cancer Res. 2005 Oct 15;65(20):9109-12 [16230362.001]
  • [Cites] Curr Top Med Chem. 2005;5(12):1109-17 [16248786.001]
  • [Cites] Nat Clin Pract Oncol. 2005 Feb;2(2):82-9 [16264880.001]
  • [Cites] Cancer Chemother Pharmacol. 2006 Jan;57(2):155-64 [16133537.001]
  • [Cites] Cancer Biol Ther. 2005 Nov;4(11):1275-84 [16319524.001]
  • [Cites] Oncogene. 2006 Feb 9;25(6):877-87 [16170339.001]
  • [Cites] Curr Cancer Drug Targets. 2006 Feb;6(1):15-37 [16475974.001]
  • [Cites] Blood. 2003 Sep 1;102(5):1824-32 [12738674.001]
  • [Cites] Cancer Biol Ther. 2003 Jul-Aug;2(4 Suppl 1):S96-104 [14508086.001]
  • [Cites] Blood. 2003 Nov 1;102(9):3354-62 [12855556.001]
  • [Cites] Curr Oncol Rep. 2004 Mar;6(2):123-30 [14751090.001]
  • [Cites] Blood. 2004 Apr 1;103(7):2761-70 [14645003.001]
  • [Cites] Clin Cancer Res. 2004 Jun 15;10(12 Pt 1):4029-37 [15217935.001]
  • [Cites] Clin Cancer Res. 2004 Aug 1;10(15):5242-52 [15297428.001]
  • [Cites] Blood. 2004 Sep 15;104(6):1825-32 [15161667.001]
  • [Cites] Cancer Res. 2004 Sep 15;64(18):6461-8 [15374955.001]
  • [Cites] Cancer Res. 2004 Oct 15;64(20):7570-8 [15492284.001]
  • [Cites] Adv Enzyme Regul. 1984;22:27-55 [6382953.001]
  • [Cites] Science. 1988 Apr 22;240(4851):518-21 [2833817.001]
  • [Cites] Blood. 1992 Jan 1;79(1):213-22 [1728309.001]
  • [Cites] Nature. 1994 Jun 2;369(6479):411-4 [8196769.001]
  • [Cites] Oncogene. 1995 Aug 3;11(3):447-54 [7630628.001]
  • [Cites] Science. 1995 Nov 24;270(5240):1326-31 [7481820.001]
  • [Cites] J Immunol. 1997 Sep 1;159(5):2212-21 [9278309.001]
  • [Cites] Blood. 1999 Feb 15;93(4):1308-18 [9949174.001]
  • [Cites] Cancer Treat Rev. 2004 Nov;30(7):609-41 [15531395.001]
  • [Cites] Blood. 2005 Feb 15;105(4):1706-16 [15494423.001]
  • [Cites] Clin Cancer Res. 2006 Apr 1;12(7 Pt 2):2371s-2375s [16609061.001]
  • [Cites] Cancer Invest. 2006 Jun-Jul;24(4):413-24 [16777695.001]
  • [Cites] J Biol Chem. 2006 Nov 10;281(45):33939-48 [16954213.001]
  • [Cites] Mol Pharmacol. 2006 Dec;70(6):1965-73 [16940414.001]
  • [Cites] Nat Rev Drug Discov. 2003 Jul;2(7):517-26 [12815379.001]
  • [Cites] Mol Cell Biol. 1999 Dec;19(12):8469-78 [10567572.001]
  • [Cites] J Biol Chem. 2000 Feb 25;275(8):5600-5 [10681541.001]
  • [Cites] Science. 2000 May 5;288(5467):870-4 [10797012.001]
  • [Cites] Blood. 2000 Sep 1;96(5):1655-69 [10961860.001]
  • [Cites] Biochem Pharmacol. 2000 Nov 15;60(10):1445-56 [11020446.001]
  • [Cites] Blood. 2000 Dec 1;96(12):3907-14 [11090077.001]
  • [Cites] EMBO J. 2001 Feb 15;20(4):743-54 [11179219.001]
  • [Cites] Leuk Res. 2001 Aug;25(8):651-60 [11397469.001]
  • [Cites] Cancer Res. 2001 Jul 1;61(13):5106-15 [11431348.001]
  • [Cites] Oncogene. 2002 Mar 7;21(11):1727-38 [11896604.001]
  • [Cites] J Biol Chem. 2002 Mar 22;277(12):10678-82 [11788600.001]
  • [Cites] Leukemia. 2002 Apr;16(4):508-19 [11960327.001]
  • [Cites] Blood. 2002 Nov 1;100(9):3333-43 [12384435.001]
  • [Cites] Biochemistry. 2002 Nov 19;41(46):13698-704 [12427032.001]
  • [Cites] Cell Cycle. 2002 Jan;1(1):82-9 [12429913.001]
  • [Cites] J Cell Biochem. 2003 Jan 1;88(1):191-204 [12461788.001]
  • [Cites] Oncogene. 2002 Dec 12;21(57):8769-75 [12483530.001]
  • [Cites] Nat Rev Cancer. 2003 Jan;3(1):11-22 [12509763.001]
  • [Cites] Leuk Res. 2003 Feb;27(2):133-45 [12526919.001]
  • [Cites] Cancer Res. 2001 Dec 15;61(24):8758-68 [11751396.001]
  • (PMID = 17264303.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA088906; United States / NCI NIH HHS / CA / P01 CA072955; United States / NCI NIH HHS / CA / CA72955; United States / NCI NIH HHS / CA / CA63753; United States / NCI NIH HHS / CA / R01 CA100866; United States / NCI NIH HHS / CA / R01 CA063753; United States / NCI NIH HHS / CA / R01 CA093738; United States / NCI NIH HHS / CA / CA88906; United States / NCI NIH HHS / CA / CA100866; United States / NCI NIH HHS / CA / CA93738
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Hydroxymethylglutaryl-CoA Reductase Inhibitors; 7BU5H4V94A / 7-hydroxystaurosporine; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; EC 2.7.12.2 / Mitogen-Activated Protein Kinase Kinases; EC 3.6.5.2 / Proto-Oncogene Proteins p21(ras); H88EPA0A3N / Staurosporine
  • [Other-IDs] NLM/ PMC1885487
  •  go-up   go-down


35. Dai Y, Rahmani M, Pei XY, Khanna P, Han SI, Mitchell C, Dent P, Grant S: Farnesyltransferase inhibitors interact synergistically with the Chk1 inhibitor UCN-01 to induce apoptosis in human leukemia cells through interruption of both Akt and MEK/ERK pathways and activation of SEK1/JNK. Blood; 2005 Feb 15;105(4):1706-16
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Farnesyltransferase inhibitors interact synergistically with the Chk1 inhibitor UCN-01 to induce apoptosis in human leukemia cells through interruption of both Akt and MEK/ERK pathways and activation of SEK1/JNK.
  • Interactions between the Chk1 inhibitor UCN-01 and the farnesyltransferase inhibitor L744832 were examined in human leukemia cells.
  • Similar interactions were noted in other leukemia cells (HL-60, Raji, Jurkat) and primary acute myeloid leukemia (AML) blasts.
  • Together, these findings suggest that farnesyltransferase inhibitors interrupt the cytoprotective Akt and MAPK pathways while reciprocally activating SAPK/JNK in leukemia cells exposed to UCN-01 and, in so doing, dramatically increase mitochondria-dependent apoptosis.
  • [MeSH-major] Alkyl and Aryl Transferases / antagonists & inhibitors. Apoptosis / drug effects. Extracellular Signal-Regulated MAP Kinases / antagonists & inhibitors. JNK Mitogen-Activated Protein Kinases / metabolism. Leukemia, Myeloid / drug therapy. MAP Kinase Kinase 4 / metabolism. MAP Kinase Signaling System / drug effects. Methionine / analogs & derivatives. Protein Kinases / metabolism. Protein-Serine-Threonine Kinases / antagonists & inhibitors. Proto-Oncogene Proteins / antagonists & inhibitors. Staurosporine / analogs & derivatives. Staurosporine / metabolism

  • Hazardous Substances Data Bank. (L)-Methionine .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15494423.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA100866; United States / NCI NIH HHS / CA / CA63753; United States / NCI NIH HHS / CA / CA93738
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Enzyme Inhibitors; 0 / L 744832; 0 / Protein Kinase Inhibitors; 0 / Proto-Oncogene Proteins; 7BU5H4V94A / 7-hydroxystaurosporine; AE28F7PNPL / Methionine; EC 2.5.- / Alkyl and Aryl Transferases; EC 2.5.1.29 / Farnesyltranstransferase; EC 2.7.- / Protein Kinases; EC 2.7.11.1 / AKT1 protein, human; EC 2.7.11.1 / Checkpoint kinase 1; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; EC 2.7.11.24 / Extracellular Signal-Regulated MAP Kinases; EC 2.7.11.24 / JNK Mitogen-Activated Protein Kinases; EC 2.7.12.2 / MAP Kinase Kinase 4; EC 3.4.22.- / Caspases; H88EPA0A3N / Staurosporine
  •  go-up   go-down


36. Qazi HA, Manikandan R, Foster CS, Fordham MV: Testicular metastasis from gastric carcinoma. Urology; 2006 Oct;68(4):890.e7-8
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Other than leukemias and lymphomas, the most common sites from which metastases occur are the lung and prostate gland.

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17070383.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


37. Salemi S, Yousefi S, Simon D, Schmid I, Moretti L, Scapozza L, Simon HU: A novel FIP1L1-PDGFRA mutant destabilizing the inactive conformation of the kinase domain in chronic eosinophilic leukemia/hypereosinophilic syndrome. Allergy; 2009 Jun;64(6):913-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A novel FIP1L1-PDGFRA mutant destabilizing the inactive conformation of the kinase domain in chronic eosinophilic leukemia/hypereosinophilic syndrome.
  • BACKGROUND: The Fip1-like-1-platelet-derived growth factor receptor alpha (FIP1L1-PDGFRA) gene fusion is a common cause of chronic eosinophilic leukemia (CEL)/hypereosinophilic syndrome (HES), and patients suffering from this particular subgroup of CEL/HES respond to low-dose imatinib therapy.
  • The identification of novel drug-resistant FIP1L1-PDGFRA variants may help to develop the next generation of target-directed compounds for CEL/HES and other leukemias.

  • Genetic Alliance. consumer health - Hypereosinophilic syndromes.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • Hazardous Substances Data Bank. NICOTINAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19210352.001).
  • [ISSN] 1398-9995
  • [Journal-full-title] Allergy
  • [ISO-abbreviation] Allergy
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Benzamides; 0 / Benzenesulfonates; 0 / FIP1L1-PDGFRA fusion protein, human; 0 / Oncogene Proteins, Fusion; 0 / Phenylurea Compounds; 0 / Piperazines; 0 / Protein Kinase Inhibitors; 0 / Pyridines; 0 / Pyrimidines; 0 / mRNA Cleavage and Polyadenylation Factors; 25X51I8RD4 / Niacinamide; 8A1O1M485B / Imatinib Mesylate; 9ZOQ3TZI87 / sorafenib; EC 2.7.10.1 / Receptor, Platelet-Derived Growth Factor alpha
  •  go-up   go-down


38. Foss B, Bruserud O: Platelet functions and clinical effects in acute myelogenous leukemia. Thromb Haemost; 2008 Jan;99(1):27-37
MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Platelet functions and clinical effects in acute myelogenous leukemia.
  • Interactions may also be involved between platelets and circulating malignant cells, which is suggested by the effects platelets seem to have on metastasis and the various platelet abnormalities observed in various malignant disorders, including acute myelogenous leukemia (AML) and other leukemias.
  • i) platelets and AML blasts can affect functional characteristic of each other, ii) chemotherapeutic drugs frequently used in AML therapy can alter several platelet functions, iii) the systemic levels of various cytokines are enhanced during AML chemotherapy, including cytokines known to affect both leukemic blasts and platelet activation, and iv) platelet secretion of growth factors are clearly detected in peripheral blood stem cells autografts.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Blood Platelets / metabolism. Leukemia, Myeloid, Acute / blood. Leukemia, Myeloid, Acute / therapy. Leukocytes / metabolism. Platelet Activation. Platelet Transfusion. Stem Cell Transplantation
  • [MeSH-minor] Animals. Apoptosis. Cell Communication. Cell Proliferation. Cytokines / blood. Hematopoietic Stem Cells / metabolism. Hemorrhage / blood. Hemorrhage / etiology. Hemorrhage / prevention & control. Humans. Intercellular Signaling Peptides and Proteins / blood. Leukemia, Megakaryoblastic, Acute / blood. Leukemia, Megakaryoblastic, Acute / therapy. Leukemia, Promyelocytic, Acute / blood. Leukemia, Promyelocytic, Acute / therapy

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18217131.001).
  • [ISSN] 0340-6245
  • [Journal-full-title] Thrombosis and haemostasis
  • [ISO-abbreviation] Thromb. Haemost.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Cytokines; 0 / Intercellular Signaling Peptides and Proteins
  • [Number-of-references] 164
  •  go-up   go-down


39. Wang J, Li L, Cang H, Shi G, Yi J: NADPH oxidase-derived reactive oxygen species are responsible for the high susceptibility to arsenic cytotoxicity in acute promyelocytic leukemia cells. Leuk Res; 2008 Mar;32(3):429-36
Hazardous Substances Data Bank. ARSENIC TRIOXIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] NADPH oxidase-derived reactive oxygen species are responsible for the high susceptibility to arsenic cytotoxicity in acute promyelocytic leukemia cells.
  • We have previously demonstrated that an acute promyelocytic leukemia (APL)-derived cell line NB4 exhibited a relatively higher basal level of reactive oxygen species (ROS) than other leukemia cell lines, which is one of the mechanisms determining a higher apoptotic susceptibility of NB4 cells to arsenic trioxide (ATO)-induced apoptosis.
  • [MeSH-major] Arsenicals / pharmacology. Leukemia, Promyelocytic, Acute / metabolism. NADPH Oxidase / metabolism. Oxides / pharmacology. Reactive Oxygen Species / metabolism

  • Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17804067.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Arsenicals; 0 / Oxides; 0 / Reactive Oxygen Species; EC 1.6.3.1 / NADPH Oxidase; S7V92P67HO / arsenic trioxide
  •  go-up   go-down


40. Prindull G: Hemangioblasts representing a functional endothelio-hematopoietic entity in ontogeny, postnatal life, and CML neovasculogenesis. Stem Cell Rev; 2005;1(3):277-84
MedlinePlus Health Information. consumer health - Stem Cells.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The relation of the other leukemias to hemangioblasts is not known.
  • [MeSH-major] Endothelial Cells / metabolism. Hematopoiesis. Hematopoietic Stem Cells / metabolism. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / metabolism. Neoplastic Stem Cells / metabolism. Neovascularization, Pathologic / metabolism

  • MedlinePlus Health Information. consumer health - Chronic Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17142866.001).
  • [ISSN] 1550-8943
  • [Journal-full-title] Stem cell reviews
  • [ISO-abbreviation] Stem Cell Rev
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.10.2 / Fusion Proteins, bcr-abl
  • [Number-of-references] 193
  •  go-up   go-down


41. Chen G, Zhang W, Cao X, Li F, Liu X, Yao L: Serological identification of immunogenic antigens in acute monocytic leukemia. Leuk Res; 2005 May;29(5):503-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serological identification of immunogenic antigens in acute monocytic leukemia.
  • In order to improve disease-free survival and potentially a cure, it is necessary to identify more potent leukemia antigen.
  • Here, we defined the acute monocytic leukemia-associated antigen (LAA) recognized by the humoral immune system for the first time.
  • We have applied the method of serologic analysis of recombinant cDNA expression library (SEREX) on acute monocytic leukemia (FAB M5), followed by DNA sequencing and analyzing of positive clones.
  • Then, the reactivity of normal and other leukemia sera with positive clones were performed.
  • Thirty-five distinct novel antigens reactive with autologous IgG were identified by SEREX analysis on an acute monocytic leukemia patient and were characterized according to cDNA sequence and the reactivity with allogeneic sera.
  • Twenty of the 35 antigens identified in this study were recognized by IgG antibodies in normal sera, and the remaining 15 were recognized exclusively by sera from allogeneic leukemia patients but not by normal donor sera, suggested that the immune response to these 15 antigens are leukemia related.
  • The 15 immunogenic antigens detected by immune responses in the autologous host facilitate the identification of epitopes recognized by antigen-specific cytotoxic T lymphocytes (CTL) and are potential candidates for diagnosis and immunotherapy in acute myeloid leukemia (AML).
  • [MeSH-major] Antibodies, Neoplasm / immunology. Antigens, Neoplasm / immunology. Immunoglobulin G / immunology. Leukemia, Monocytic, Acute / immunology. T-Lymphocytes, Cytotoxic / immunology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15755502.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Neoplasm; 0 / Antigens, Neoplasm; 0 / Immunoglobulin G
  •  go-up   go-down


42. Noga SJ, Choksi JK, Ding B, Dreiling L, Ozer H: Low incidence of neutropenic events in patients with lymphoma receiving first-cycle pegfilgrastim with chemotherapy: results from a prospective community-based study. Clin Lymphoma Myeloma; 2007 May;7(6):413-20
Hazardous Substances Data Bank. Filgrastim .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PATIENTS AND METHODS: Patients aged > or = 18 years with cancer other than leukemia or myelodysplastic syndromes were eligible, including patients with major comorbidities who were generally not eligible for most clinical trials.

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17621407.001).
  • [ISSN] 1557-9190
  • [Journal-full-title] Clinical lymphoma & myeloma
  • [ISO-abbreviation] Clin Lymphoma Myeloma
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase IV; Comparative Study; Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Recombinant Proteins; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 3A58010674 / pegfilgrastim; PVI5M0M1GW / Filgrastim
  •  go-up   go-down


43. Hasegawa H, Yamada Y, Komiyama K, Hayashi M, Ishibashi M, Sunazuka T, Izuhara T, Sugahara K, Tsuruda K, Masuda M, Takasu N, Tsukasaki K, Tomonaga M, Kamihira S: A novel natural compound, a cycloanthranilylproline derivative (Fuligocandin B), sensitizes leukemia cells to apoptosis induced by tumor necrosis factor related apoptosis-inducing ligand (TRAIL) through 15-deoxy-Delta 12, 14 prostaglandin J2 production. Blood; 2007 Sep 1;110(5):1664-74
antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A novel natural compound, a cycloanthranilylproline derivative (Fuligocandin B), sensitizes leukemia cells to apoptosis induced by tumor necrosis factor related apoptosis-inducing ligand (TRAIL) through 15-deoxy-Delta 12, 14 prostaglandin J2 production.
  • More importantly, similar effects were observed in other leukemia cell lines irrespective of their origin.
  • [MeSH-major] Apoptosis / drug effects. Leukemia / drug therapy. Proline / analogs & derivatives. Prostaglandin D2 / analogs & derivatives. TNF-Related Apoptosis-Inducing Ligand / pharmacology

  • MedlinePlus Health Information. consumer health - Leukemia.
  • Hazardous Substances Data Bank. (L)-PROLINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17551094.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / 15-deoxy-delta(12,14)-prostaglandin J2; 0 / Inhibitor of Apoptosis Proteins; 0 / Neoplasm Proteins; 0 / PPAR gamma; 0 / TNF-Related Apoptosis-Inducing Ligand; 0 / TNFSF10 protein, human; 0 / cycloanthranilylproline; 0 / fuligocandin B; 9DLQ4CIU6V / Proline; EC 1.14.99.1 / Cyclooxygenase 2; RXY07S6CZ2 / Prostaglandin D2
  •  go-up   go-down


44. Wang YY, Zhou GB, Yin T, Chen B, Shi JY, Liang WX, Jin XL, You JH, Yang G, Shen ZX, Chen J, Xiong SM, Chen GQ, Xu F, Liu YW, Chen Z, Chen SJ: AML1-ETO and C-KIT mutation/overexpression in t(8;21) leukemia: implication in stepwise leukemogenesis and response to Gleevec. Proc Natl Acad Sci U S A; 2005 Jan 25;102(4):1104-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] AML1-ETO and C-KIT mutation/overexpression in t(8;21) leukemia: implication in stepwise leukemogenesis and response to Gleevec.
  • To explore the genetic abnormalities that cooperate with AML1-ETO (AE) fusion gene to cause acute myeloid leukemia (AML) with t(8;21), we screened a number of candidate genes and identified 11 types of mutations in C-KIT gene (mC-KIT), including 6 previously undescribed ones among 26 of 54 (48.1%) cases with t(8;21).
  • This may lead to an alternative way of C-KIT activation and may explain the significantly higher C-KIT expression in 81.3% of patients with t(8;21) than in patients with other leukemias.
  • These data strongly suggest that t(8;21) AML follows a stepwise model in leukemogenesis, i.e., AE represents the first, fundamental genetic hit to initiate the disease, whereas activation of the C-KIT pathway may be a second but also crucial hit for the development of a full-blown leukemia.
  • Gleevec also exerted a synergic effect in apoptosis induction with cytarabine, thus providing a potential therapeutic for t(8;21) leukemia.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Chromosomes, Human, Pair 21. Chromosomes, Human, Pair 8. Leukemia, Myeloid, Acute / genetics. Mutation. Oncogene Proteins, Fusion / genetics. Piperazines / pharmacology. Proto-Oncogene Proteins c-kit / genetics. Pyrimidines / pharmacology. Transcription Factors / genetics. Translocation, Genetic

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Genome Res. 2003 Feb;13(2):287-93 [12566407.001]
  • [Cites] Leukemia. 2001 Sep;15(9):1359-68 [11516096.001]
  • [Cites] Br J Haematol. 2003 Jun;121(5):775-7 [12780793.001]
  • [Cites] J Clin Microbiol. 2003 Jul;41(7):3306-11 [12843079.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Aug 5;100(16):9506-11 [12881486.001]
  • [Cites] Oncogene. 2003 Aug 28;22(36):5646-57 [12944913.001]
  • [Cites] Blood. 2003 Dec 15;102(13):4369-76 [12946995.001]
  • [Cites] Blood. 2004 May 15;103(10):3644-54 [14726395.001]
  • [Cites] Oncogene. 2004 May 24;23(24):4255-62 [15156181.001]
  • [Cites] Haematologica. 2004 Aug;89(8):920-5 [15339674.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Oct 19;101(42):15184-9 [15477599.001]
  • [Cites] Blood. 1993 Aug 1;82(3):712-5 [8338940.001]
  • [Cites] Cancer Res. 1993 Aug 1;53(15):3638-42 [7687925.001]
  • [Cites] Leukemia. 1994 Feb;8(2):258-63 [7508533.001]
  • [Cites] Blood. 1995 Apr 1;85(7):1769-80 [7535588.001]
  • [Cites] Leukemia. 1996 Feb;10(2):288-96 [8637238.001]
  • [Cites] Blood. 1996 Jun 1;87(11):4789-96 [8639850.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Oct 15;93(21):11895-900 [8876234.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Nov 26;93(24):14059-64 [8943060.001]
  • [Cites] Science. 1997 Nov 7;278(5340):1059-64 [9353180.001]
  • [Cites] Oncogene. 1999 Mar 4;18(9):1701-10 [10208431.001]
  • [Cites] Mol Cell Biol. 1999 May;19(5):3635-44 [10207087.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Dec 21;96(26):14882-7 [10611307.001]
  • [Cites] Blood. 2000 Jan 15;95(2):726-7 [10660321.001]
  • [Cites] Blood. 2000 Jul 15;96(2):655-63 [10887131.001]
  • [Cites] Blood. 2000 Jul 1;96(1):288-96 [10891464.001]
  • [Cites] Blood. 2000 Sep 15;96(6):2108-15 [10979955.001]
  • [Cites] J Pharmacol Exp Ther. 2000 Oct;295(1):139-45 [10991971.001]
  • [Cites] J Biol Chem. 2000 Dec 22;275(51):40282-7 [11032826.001]
  • [Cites] Biochem J. 2001 Mar 15;354(Pt 3):481-4 [11237851.001]
  • [Cites] EMBO Rep. 2000 Aug;1(2):133-9 [11265752.001]
  • [Cites] Nat Med. 2001 Apr;7(4):444-51 [11283671.001]
  • [Cites] Nature. 2001 May 17;411(6835):355-65 [11357143.001]
  • [Cites] Mol Cell Biol. 2001 Aug;21(16):5577-90 [11463839.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Aug 28;98(18):10398-403 [11526243.001]
  • [Cites] Mol Cell Biol. 2001 Oct;21(19):6470-83 [11533236.001]
  • [Cites] Blood. 2002 Jan 1;99(1):15-23 [11756147.001]
  • [Cites] Br J Haematol. 2002 Mar;116(4):744-57 [11886377.001]
  • [Cites] Hematol J. 2001;2(5):330-40 [11920269.001]
  • [Cites] Cancer Cell. 2002 Feb;1(1):63-74 [12086889.001]
  • [Cites] Mol Cell Biol. 2002 Aug;22(15):5506-17 [12101243.001]
  • [Cites] Hematol J. 2002;3(3):157-63 [12111653.001]
  • [Cites] Annu Rev Genomics Hum Genet. 2002;3:179-98 [12194988.001]
  • [Cites] Mol Cancer Ther. 2002 Oct;1(12):1115-24 [12481435.001]
  • [Cites] Blood. 2003 Jan 1;101(1):270-7 [12393465.001]
  • [Cites] Blood. 2003 Jan 15;101(2):624-32 [12393523.001]
  • [Cites] Leukemia. 2003 Feb;17(2):471-2 [12592353.001]
  • (PMID = 15650049.001).
  • [ISSN] 0027-8424
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / AML1-ETO fusion protein, human; 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Core Binding Factor Alpha 2 Subunit; 0 / Oncogene Proteins, Fusion; 0 / Piperazines; 0 / Pyrimidines; 0 / Transcription Factors; 8A1O1M485B / Imatinib Mesylate; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  • [Other-IDs] NLM/ PMC545849
  •  go-up   go-down


45. Salerni BL, Bates DJ, Albershardt TC, Lowrey CH, Eastman A: Vinblastine induces acute, cell cycle phase-independent apoptosis in some leukemias and lymphomas and can induce acute apoptosis in others when Mcl-1 is suppressed. Mol Cancer Ther; 2010 Apr;9(4):791-802
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Vinblastine induces acute, cell cycle phase-independent apoptosis in some leukemias and lymphomas and can induce acute apoptosis in others when Mcl-1 is suppressed.
  • Inhibition of the extracellular signal-regulated kinase by PD98059 dramatically accelerates vinblastine-mediated apoptosis in ML-1 leukemia with cells dying in 4 hours from all phases of the cell cycle.
  • We also investigated the response of 13 other leukemia and lymphoma cell lines and cells from seven chronic lymphocytic leukemia patients.
  • Four cell lines and all chronic lymphocytic leukemia cells were killed in 6 hours by vinblastine alone.
  • PD98059 did not suppress Mcl-1 in other cell lines whereas sorafenib did, but this did not sensitize the cells to vinblastine, suggesting that the acute apoptosis varies depending on which Bcl-2 protein mediates protection.

  • MedlinePlus Health Information. consumer health - Leukemia.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYCLOHEXIMIDE .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2001 Jun 1;61(11):4450-8 [11389075.001]
  • [Cites] Nature. 2005 Jun 2;435(7042):677-81 [15902208.001]
  • [Cites] Nat Rev Cancer. 2002 Sep;2(9):647-56 [12209154.001]
  • [Cites] J Biol Chem. 2002 Nov 15;277(46):43730-4 [12223490.001]
  • [Cites] Mol Cancer Ther. 2002 Jul;1(9):707-17 [12479367.001]
  • [Cites] Leukemia. 2003 Jan;17(1):120-4 [12529668.001]
  • [Cites] Curr Med Chem Anticancer Agents. 2002 Jan;2(1):1-17 [12678749.001]
  • [Cites] Neuron. 2003 Jun 19;38(6):899-914 [12818176.001]
  • [Cites] Cell. 2005 Jul 1;121(7):1085-95 [15989957.001]
  • [Cites] J Cell Biol. 2005 Jul 18;170(2):295-304 [16009721.001]
  • [Cites] Breast Cancer Res Treat. 2005 Sep;93(2):177-88 [16187238.001]
  • [Cites] Oncogene. 2005 Oct 20;24(46):6861-9 [16007148.001]
  • [Cites] Mol Cell. 2006 Mar 17;21(6):749-60 [16543145.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Apr 10;104(15):6217-22 [17389404.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Dec 4;104(49):19512-7 [18040043.001]
  • [Cites] Toxicol Appl Pharmacol. 2008 Apr 1;228(1):93-104 [18201741.001]
  • [Cites] Clin Cancer Res. 2008 Jun 15;14(12):3651-6 [18559577.001]
  • [Cites] Mol Cell Biol. 1999 Dec;19(12):8469-78 [10567572.001]
  • [Cites] J Biol Chem. 2000 Jan 7;275(1):322-7 [10617621.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Jun 20;97(13):7124-9 [10860979.001]
  • [Cites] J Biol Chem. 2000 Sep 29;275(39):29980-5 [10913135.001]
  • [Cites] Nat Cell Biol. 2001 Feb;3(2):183-91 [11175751.001]
  • [Cites] Cancer Res. 2001 Feb 15;61(4):1533-40 [11245462.001]
  • [Cites] Blood. 2009 Jan 1;113(1):149-53 [18836097.001]
  • [Cites] Gene Ther. 2003 Aug;10(17):1446-57 [12900759.001]
  • [Cites] J Med Chem. 2003 Sep 25;46(20):4259-64 [13678404.001]
  • [Cites] EMBO J. 2004 Apr 21;23(8):1889-99 [15071501.001]
  • [Cites] Oncogene. 2004 Jul 8;23(31):5301-15 [15241487.001]
  • [Cites] Cancer Res. 1977 Aug;37(8 Pt 1):2597-602 [889590.001]
  • [Cites] Leukemia. 1993 Apr;7(4):563-8 [8096557.001]
  • [Cites] J Cell Biol. 1995 Mar;128(6):1173-84 [7896880.001]
  • [Cites] Mol Biol Cell. 1995 Sep;6(9):1215-29 [8534917.001]
  • [Cites] J Cell Physiol. 1996 Mar;166(3):523-36 [8600156.001]
  • [Cites] Blood. 1998 May 1;91(9):3379-89 [9558396.001]
  • [Cites] Oncogene. 1998 Sep 10;17(10):1223-34 [9771965.001]
  • [Cites] J Biol Chem. 1999 Jan 15;274(3):1801-13 [9880563.001]
  • [Cites] Oncogene. 2005 Feb 17;24(8):1348-58 [15608680.001]
  • [Cites] Mol Cell Biol. 2005 Apr;25(8):3117-26 [15798198.001]
  • [Cites] J Clin Invest. 2002 Jul;110(1):91-9 [12093892.001]
  • (PMID = 20371726.001).
  • [ISSN] 1538-8514
  • [Journal-full-title] Molecular cancer therapeutics
  • [ISO-abbreviation] Mol. Cancer Ther.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / T32 CA009658-17; United States / NCI NIH HHS / CA / CA23108; United States / NCI NIH HHS / CA / CA009658-17; United States / NCI NIH HHS / CA / T32 CA009658; United States / NCI NIH HHS / CA / R01 CA050224; United States / NCI NIH HHS / CA / P30 CA023108-315657; United States / NCI NIH HHS / CA / P30 CA023108; United States / NCI NIH HHS / CA / CA023108-315657; United States / NCI NIH HHS / CA / CA050224-14; United States / NCI NIH HHS / CA / R01 CA050224-14; United States / NCI NIH HHS / CA / CA50224
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one; 0 / Flavonoids; 0 / Myeloid Cell Leukemia Sequence 1 Protein; 0 / Proto-Oncogene Proteins c-bcl-2; 5V9KLZ54CY / Vinblastine; 98600C0908 / Cycloheximide; EC 2.7.11.24 / JNK Mitogen-Activated Protein Kinases
  • [Other-IDs] NLM/ NIHMS184304; NLM/ PMC2852489
  •  go-up   go-down


46. Wang C, Chen Z, Li Z, Cen J: The essential roles of matrix metalloproteinase-2, membrane type 1 metalloproteinase and tissue inhibitor of metalloproteinase-2 in the invasive capacity of acute monocytic leukemia SHI-1 cells. Leuk Res; 2010 Aug;34(8):1083-90
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The essential roles of matrix metalloproteinase-2, membrane type 1 metalloproteinase and tissue inhibitor of metalloproteinase-2 in the invasive capacity of acute monocytic leukemia SHI-1 cells.
  • The frequency of extramedullary infiltration (EMI) in acute myeloblastic leukemia (AML) is reported up to 40% and most prevalent in myelo-monoblastic and monoblastic subtypes of AML (M4 and M5 according to FAB classification).
  • To explore mechanism underlying EMI, we analyzed SHI-1 cells, a highly invasive human acute monocytic leukemia cell line, and found their strong expression of matrix metalloproteinase 2 (MMP-2), membrane type 1 MMP (MT1-MMP) and tissue inhibitor of metalloproteinase 2 (TIMP-2).
  • SHI-1 cells showed higher invasive ability to traverse reconstituted basement membranes (Matrigel) and stronger activation of proMMP-2 than other leukemia cell line such as NB4, K562, U937 and THP-1 cells.
  • [MeSH-major] Leukemia, Monocytic, Acute / metabolism. Leukemia, Monocytic, Acute / pathology. Matrix Metalloproteinase 14 / metabolism. Matrix Metalloproteinase 2 / metabolism. Tissue Inhibitor of Metalloproteinase-2 / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20138666.001).
  • [ISSN] 1873-5835
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Drug Combinations; 0 / Laminin; 0 / Matrix Metalloproteinase Inhibitors; 0 / Proteoglycans; 0 / RNA, Messenger; 0 / RNA, Small Interfering; 119978-18-6 / matrigel; 127497-59-0 / Tissue Inhibitor of Metalloproteinase-2; 9007-34-5 / Collagen; EC 3.4.24.24 / Matrix Metalloproteinase 2; EC 3.4.24.80 / MMP14 protein, human; EC 3.4.24.80 / Matrix Metalloproteinase 14
  •  go-up   go-down


47. Rosato RR, Kolla SS, Hock SK, Almenara JA, Patel A, Amin S, Atadja P, Fisher PB, Dent P, Grant S: Histone deacetylase inhibitors activate NF-kappaB in human leukemia cells through an ATM/NEMO-related pathway. J Biol Chem; 2010 Mar 26;285(13):10064-77
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histone deacetylase inhibitors activate NF-kappaB in human leukemia cells through an ATM/NEMO-related pathway.
  • Mechanisms underlying histone deacetylase inhibitor (HDACI)-mediated NF-kappaB activation were investigated in human leukemia cells.
  • Exposure of U937 and other leukemia cells to LBH-589 induced reactive oxygen species (ROS) followed by single strand (XRCC1) and double strand (gamma-H2AX) DNA breaks.
  • Together, these findings indicate that in human leukemia cells, HDACIs activate the cytoprotective NF-kappaB pathway through an ATM/NEMO/SUMOylation-dependent process involving the induction of ROS and DNA damage and suggest that blocking NF-kappaB activation via the atypical ATM/NEMO nuclear pathway can enhance HDACI antileukemic activity.

  • MedlinePlus Health Information. consumer health - Leukemia.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Cell Biol. 2000 Apr;20(8):2687-95 [10733571.001]
  • [Cites] Science. 2001 Aug 31;293(5535):1653-7 [11533489.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10833-8 [11535817.001]
  • [Cites] Mol Cell Biol. 2001 Oct;21(20):7065-77 [11564889.001]
  • [Cites] Oncogene. 2002 May 30;21(24):3917-24 [12032830.001]
  • [Cites] J Virol. 2002 Nov;76(21):11091-103 [12368351.001]
  • [Cites] EMBO J. 2002 Dec 2;21(23):6539-48 [12456660.001]
  • [Cites] Nat Rev Cancer. 2003 Mar;3(3):155-68 [12612651.001]
  • [Cites] Biochem J. 2003 Mar 15;370(Pt 3):737-49 [12429021.001]
  • [Cites] Genes Dev. 2003 Apr 1;17(7):873-82 [12654725.001]
  • [Cites] J Biol Chem. 2003 May 23;278(21):18980-9 [12649266.001]
  • [Cites] Nat Cell Biol. 2003 Jun;5(6):489-90 [12776118.001]
  • [Cites] Cancer Res. 2003 Jul 1;63(13):3637-45 [12839953.001]
  • [Cites] EMBO J. 2003 Jul 1;22(13):3356-66 [12839997.001]
  • [Cites] Mol Cell Biol. 2003 Sep;23(17):6200-9 [12917341.001]
  • [Cites] Cell Cycle. 2003 Sep-Oct;2(5):467-72 [12963846.001]
  • [Cites] J Mol Med (Berl). 2003 Sep;81(9):549-57 [12920522.001]
  • [Cites] Cell. 2003 Sep 19;114(6):673-88 [14505568.001]
  • [Cites] Mol Cell. 2003 Oct;12(4):829-39 [14580335.001]
  • [Cites] Cell. 2003 Nov 26;115(5):565-76 [14651848.001]
  • [Cites] Nat Rev Drug Discov. 2004 Jan;3(1):17-26 [14708018.001]
  • [Cites] Novartis Found Symp. 2004;259:208-17; discussion 218-25 [15171256.001]
  • [Cites] J Biol Chem. 2004 Jul 2;279(27):28209-19 [15087454.001]
  • [Cites] Biochem J. 1996 Jan 1;313 ( Pt 1):17-29 [8546679.001]
  • [Cites] Eur Cytokine Netw. 1996 Apr-Jun;7(2):93-124 [8688493.001]
  • [Cites] J Exp Med. 1998 Jul 6;188(1):211-6 [9653098.001]
  • [Cites] Oncogene. 1999 Jan 7;18(1):93-102 [9926924.001]
  • [Cites] Nat Struct Mol Biol. 2004 Nov;11(11):1037-43 [15523479.001]
  • [Cites] Biochem J. 2004 Dec 15;384(Pt 3):543-9 [15330761.001]
  • [Cites] FEBS Lett. 2004 Dec 3;578(1-2):111-5 [15581626.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jan 18;102(3):673-8 [15637150.001]
  • [Cites] Cell. 2005 Mar 11;120(5):649-61 [15766528.001]
  • [Cites] Nature. 2005 Mar 31;434(7033):605-11 [15758953.001]
  • [Cites] EMBO Rep. 2005 Apr;6(4):321-6 [15809659.001]
  • [Cites] J Clin Oncol. 2005 Jun 10;23(17):3971-93 [15897549.001]
  • [Cites] Mol Cell Biol. 2005 Jul;25(13):5429-44 [15964800.001]
  • [Cites] J Biol Chem. 2005 Jul 22;280(29):26729-34 [15937340.001]
  • [Cites] Nat Cell Biol. 2005 Aug;7(8):758-65 [16056267.001]
  • [Cites] Cell Death Differ. 2006 May;13(5):773-84 [16410802.001]
  • [Cites] Cell Death Differ. 2006 May;13(5):687-92 [16485032.001]
  • [Cites] Nature. 2006 May 25;441(7092):431-6 [16724054.001]
  • [Cites] J Biol Chem. 2006 Aug 4;281(31):21698-709 [16740634.001]
  • [Cites] Mol Cancer Res. 2006 Aug;4(8):563-73 [16877702.001]
  • [Cites] Nat Cell Biol. 2006 Sep;8(9):986-93 [16906147.001]
  • [Cites] Nat Rev Drug Discov. 2006 Sep;5(9):769-84 [16955068.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Oct 17;103(42):15540-5 [17030815.001]
  • [Cites] Sci STKE. 2006 Oct 17;2006(357):re13 [17047224.001]
  • [Cites] J Biol Chem. 2005 Oct 21;280(42):35217-27 [16109713.001]
  • [Cites] Biotechniques. 2005 Nov;39(5):715-25 [16315372.001]
  • [Cites] Gene. 2005 Dec 19;363:15-23 [16289629.001]
  • [Cites] Cell. 2005 Dec 16;123(6):1079-92 [16360037.001]
  • [Cites] Science. 2006 Feb 24;311(5764):1110-1 [16497923.001]
  • [Cites] Science. 2006 Feb 24;311(5764):1141-6 [16497931.001]
  • [Cites] Biochem Pharmacol. 2006 Nov 30;72(11):1493-505 [16723122.001]
  • [Cites] Cell Death Differ. 2006 Dec;13(12):2033-41 [16628233.001]
  • [Cites] Cancer Res. 2006 Dec 1;66(23):11298-304 [17145876.001]
  • [Cites] Nat Rev Drug Discov. 2007 Jan;6(1):21-2 [17269160.001]
  • [Cites] Oncogene. 2007 Feb 1;26(5):641-51 [16862178.001]
  • [Cites] Oncogene. 2007 Apr 5;26(16):2299-307 [17043643.001]
  • [Cites] Cancer Res. 2007 Jun 1;67(11):5318-27 [17545612.001]
  • [Cites] Mol Cell Biol. 2007 Aug;27(15):5499-513 [17548474.001]
  • [Cites] Oncogene. 2007 Aug 13;26(37):5541-52 [17694093.001]
  • [Cites] FASEB J. 2007 Sep;21(11):2642-54 [17431096.001]
  • [Cites] Cell Cycle. 2007 Sep 15;6(18):2284-92 [17890907.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Dec 4;104(49):19482-7 [18042714.001]
  • [Cites] Cell. 2008 Feb 8;132(3):344-62 [18267068.001]
  • [Cites] Mol Cell. 2008 Apr 11;30(1):61-72 [18406327.001]
  • [Cites] Curr Opin Genet Dev. 2008 Feb;18(1):19-26 [18440219.001]
  • [Cites] Mol Immunol. 2008 Sep;45(15):3984-9 [18657320.001]
  • [Cites] Mol Cancer Ther. 2008 Oct;7(10):3285-97 [18852132.001]
  • [Cites] Nat Rev Immunol. 2008 Nov;8(11):837-48 [18927578.001]
  • [Cites] Nat Rev Drug Discov. 2009 Jan;8(1):33-40 [19116625.001]
  • [Cites] Carcinogenesis. 2009 Jan;30(1):2-10 [18978338.001]
  • [Cites] Oncogene. 2009 Feb 26;28(8):1099-109 [19079347.001]
  • [Cites] Annu Rev Immunol. 2009;27:693-733 [19302050.001]
  • [Cites] J Mol Biol. 2009 Jun 12;389(3):495-510 [19409903.001]
  • [Cites] Oncogene. 2009 Jun 4;28(22):2205-18 [19398952.001]
  • [Cites] Mol Cancer Res. 2006 Feb;4(2):125-33 [16513843.001]
  • [Cites] Oncogene. 1999 Nov 22;18(49):6867-74 [10602462.001]
  • [RetractionIn] Rosato RR, Kolla SS, Hock SK, Almenara JA, Patel A, Amin S, Atadja P, Fisher PB, Dent P, Grant S. J Biol Chem. 2016 Aug 19;291(34):17535 [27543593.001]
  • (PMID = 20065354.001).
  • [ISSN] 1083-351X
  • [Journal-full-title] The Journal of biological chemistry
  • [ISO-abbreviation] J. Biol. Chem.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / 1P50 CA130805; United States / NCI NIH HHS / CA / CA63753; United States / NCI NIH HHS / CA / R01 CA100866; United States / NCI NIH HHS / CA / R01 CA063753; United States / NCI NIH HHS / CA / R01 CA093738; United States / NCI NIH HHS / CA / CA100866; United States / NCI NIH HHS / CA / P50 CA130805; United States / NCI NIH HHS / CA / R01 CA141703; United States / NCI NIH HHS / CA / P30 CA016059; United States / NCI NIH HHS / CA / CA93738; United States / NIDDK NIH HHS / DK / R01 DK052825; United States / NCI NIH HHS / CA / R01 CA150214
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Retracted Publication
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cell Cycle Proteins; 0 / DNA-Binding Proteins; 0 / Histone Deacetylase Inhibitors; 0 / IKBKG protein, human; 0 / NF-kappa B; 0 / Reactive Oxygen Species; 0 / SUMO-1 Protein; 0 / SUMO1 protein, human; 0 / Tumor Suppressor Proteins; EC 2.7.11.1 / ATM protein, human; EC 2.7.11.1 / Ataxia Telangiectasia Mutated Proteins; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 2.7.11.10 / I-kappa B Kinase
  • [Other-IDs] NLM/ PMC2843169
  •  go-up   go-down


48. Chiorazzi N: Cell proliferation and death: forgotten features of chronic lymphocytic leukemia B cells. Best Pract Res Clin Haematol; 2007 Sep;20(3):399-413
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cell proliferation and death: forgotten features of chronic lymphocytic leukemia B cells.
  • Chronic lymphocytic leukemia (CLL) results from an accumulation of abnormal B cells due to an imbalance between birth and death rates such that the former exceeds the latter.
  • Thus the dynamic interplay between birth and death that characterizes other leukemias and lymphomas applies to CLL.
  • [MeSH-major] B-Lymphocytes / pathology. Cell Death / physiology. Cell Proliferation. Leukemia, Lymphocytic, Chronic, B-Cell / pathology

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17707829.001).
  • [ISSN] 1521-6926
  • [Journal-full-title] Best practice & research. Clinical haematology
  • [ISO-abbreviation] Best Pract Res Clin Haematol
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / M01 RR018535; United States / NCI NIH HHS / CA / R01 CA81554; United States / NCI NIH HHS / CA / R01 CA87956
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD
  • [Number-of-references] 83
  •  go-up   go-down


49. Wang J, Hasui K, Utsunomiya A, Jia X, Matsuyama T, Murata F: Association of high proliferation in adult T-cell leukemia cells with apoptosis, and expression of p53 protein in acute type ATL. J Clin Exp Hematop; 2008 Apr;48(1):1-10
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association of high proliferation in adult T-cell leukemia cells with apoptosis, and expression of p53 protein in acute type ATL.
  • Proliferation, apoptosis and p53 protein expression in adult T-cell leukemia (ATL) cells were investigated.
  • Twenty peripheral blood tissue specimens (PBTS) comprising 7 cases of acute type ATL, 7 cases of chronic type ATL and 6 other leukemias were examined by means of antigen retrieval and the polymer method employing anti-Ki67 antigen (MIB-1), anti-cleaved caspase-3, anti-single stranded DNA and three kinds of anti-p53 protein antibodies including DO7.
  • Most acute and chronic cases of ATL included more than 10% MIB-1-positive proliferating leukemia cells and more than 1% cleaved caspase-3-positive apoptotic cells.
  • [MeSH-major] Apoptosis / physiology. Cell Proliferation. Leukemia, Prolymphocytic, T-Cell / pathology. Leukemia-Lymphoma, Adult T-Cell / pathology. Tumor Suppressor Protein p53 / biosynthesis

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18434687.001).
  • [ISSN] 1346-4280
  • [Journal-full-title] Journal of clinical and experimental hematopathology : JCEH
  • [ISO-abbreviation] J Clin Exp Hematop
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Ki-67 Antigen; 0 / Tumor Suppressor Protein p53; EC 3.4.22.- / Caspase 3
  •  go-up   go-down


50. Randolph TR: Chronic myelocytic leukemia--Part II: Approaches to and molecular monitoring of therapy. Clin Lab Sci; 2005;18(1):49-56
Hazardous Substances Data Bank. IMATINIB MESYLATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chronic myelocytic leukemia--Part II: Approaches to and molecular monitoring of therapy.
  • DATA SYNTHESIS: Chronic myelocytic leukemia (CML) was initially described in 1845 and is considered one of the first leukemias discovered.
  • As in CML, an understanding of the leukemogenic mechanisms involved in other leukemias will provide the groundwork for the development of therapeutic interventions tailored to the specific molecular defects identified, eventually rendering obsolete the shotgun approaches to massive cell killing produced by chemotherapy.
  • [MeSH-major] Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy

  • MedlinePlus Health Information. consumer health - Chronic Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15747786.001).
  • [ISSN] 0894-959X
  • [Journal-full-title] Clinical laboratory science : journal of the American Society for Medical Technology
  • [ISO-abbreviation] Clin Lab Sci
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Interferon Type I; 0 / Piperazines; 0 / Protein Kinase Inhibitors; 0 / Pyrimidines; 0 / Recombinant Proteins; 8A1O1M485B / Imatinib Mesylate; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.2 / Fusion Proteins, bcr-abl
  • [Number-of-references] 55
  •  go-up   go-down


51. Gao N, Kramer L, Rahmani M, Dent P, Grant S: The three-substituted indolinone cyclin-dependent kinase 2 inhibitor 3-[1-(3H-imidazol-4-yl)-meth-(Z)-ylidene]-5-methoxy-1,3-dihydro-indol-2-one (SU9516) kills human leukemia cells via down-regulation of Mcl-1 through a transcriptional mechanism. Mol Pharmacol; 2006 Aug;70(2):645-55
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The three-substituted indolinone cyclin-dependent kinase 2 inhibitor 3-[1-(3H-imidazol-4-yl)-meth-(Z)-ylidene]-5-methoxy-1,3-dihydro-indol-2-one (SU9516) kills human leukemia cells via down-regulation of Mcl-1 through a transcriptional mechanism.
  • Mechanisms of lethality of the three-substituted indolinone and putatively selective cyclin-dependent kinase (CDK)2 inhibitor 3-[1-(3H-imidazol-4-yl)-meth-(Z)-ylidene]-5-methoxy-1,3-dihydro-indol-2-one (SU9516) were examined in human leukemia cells.
  • Exposure of U937 and other leukemia cells to SU9516 concentrations > or =5 microM rapidly (i.e., within 4 h) induced cytochrome c release, Bax mitochondrial translocation, and apoptosis in association with pronounced down-regulation of the antiapoptotic protein Mcl-1.
  • Similar results were obtained in Jurkat and HL-60 leukemia cells.
  • [MeSH-minor] Apoptosis / drug effects. Caspases / physiology. Down-Regulation. Humans. Mitochondria / drug effects. Myeloid Cell Leukemia Sequence 1 Protein. Phosphorylation. Protein Processing, Post-Translational. RNA Polymerase II / metabolism. Reactive Oxygen Species / metabolism. Transcription, Genetic / drug effects. U937 Cells

  • PhosphoSitePlus. gene/protein/disease-specific - PhosphoSitePlus® - comprehensive post-translational modification resource .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16672643.001).
  • [ISSN] 0026-895X
  • [Journal-full-title] Molecular pharmacology
  • [ISO-abbreviation] Mol. Pharmacol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA100866; United States / NCI NIH HHS / CA / CA63753, CA93738
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Imidazoles; 0 / Indoles; 0 / Myeloid Cell Leukemia Sequence 1 Protein; 0 / Neoplasm Proteins; 0 / Protein Kinase Inhibitors; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Reactive Oxygen Species; 0 / SU 9516; EC 2.7.11.22 / Cyclin-Dependent Kinase 2; EC 2.7.7.- / RNA Polymerase II; EC 3.4.22.- / Caspases
  •  go-up   go-down


52. Tsubata C, Higuchi M, Takahashi M, Oie M, Tanaka Y, Gejyo F, Fujii M: PDZ domain-binding motif of human T-cell leukemia virus type 1 Tax oncoprotein is essential for the interleukin 2 independent growth induction of a T-cell line. Retrovirology; 2005;2:46
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] PDZ domain-binding motif of human T-cell leukemia virus type 1 Tax oncoprotein is essential for the interleukin 2 independent growth induction of a T-cell line.
  • BACKGROUND: Human T-cell leukemia virus type 1 (HTLV-1) is the etiologic agent of adult T-cell leukemia (ATL), whereas HTLV type 2 (HTLV-2), is not associated with ATL or any other leukemia.
  • [MeSH-minor] Binding Sites. Cell Line. Cell Proliferation. Humans. Leukemia-Lymphoma, Adult T-Cell / etiology. NF-kappa B / physiology

  • Genetic Alliance. consumer health - Human T-cell leukemia virus type 1.
  • Genetic Alliance. consumer health - Human T-cell leukemia virus type 2.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Virol. 1997 Mar;71(3):1956-62 [9032327.001]
  • [Cites] J Virol. 1996 Aug;70(8):5194-202 [8764028.001]
  • [Cites] Oncogene. 1998 Feb 5;16(5):643-54 [9482110.001]
  • [Cites] J Virol. 1999 Feb;73(2):1271-7 [9882331.001]
  • [Cites] J Virol. 1999 Jun;73(6):4856-65 [10233947.001]
  • [Cites] J Virol. 1999 Oct;73(10):7981-7 [10482545.001]
  • [Cites] Retrovirology. 2004;1:20 [15310405.001]
  • [Cites] J Virol. 2005 Sep;79(18):11925-34 [16140768.001]
  • [Cites] Oncogene. 1999 Oct 28;18(44):5967-72 [10557085.001]
  • [Cites] J Biol Chem. 2000 Apr 14;275(15):11154-63 [10753922.001]
  • [Cites] Virology. 2000 May 25;271(1):142-54 [10814579.001]
  • [Cites] Oncogene. 2001 Apr 19;20(17):2055-67 [11360190.001]
  • [Cites] J Virol. 2002 Mar;76(6):2648-53 [11861831.001]
  • [Cites] Int J Cancer. 2002 May 20;99(3):378-85 [11992406.001]
  • [Cites] Blood. 2002 Sep 1;100(5):1828-34 [12176906.001]
  • [Cites] J Virol. 2003 Jun;77(12):6957-64 [12768014.001]
  • [Cites] Oncogene. 2003 Aug 11;22(33):5131-40 [12910250.001]
  • [Cites] Virology. 2004 Jan 5;318(1):327-36 [14972558.001]
  • [Cites] Virology. 2004 Mar 1;320(1):52-62 [15003862.001]
  • [Cites] Blood. 1977 Sep;50(3):481-92 [301762.001]
  • [Cites] Proc Natl Acad Sci U S A. 1980 Dec;77(12):7415-9 [6261256.001]
  • [Cites] Proc Natl Acad Sci U S A. 1981 Oct;78(10):6476-80 [7031654.001]
  • [Cites] Nature. 1981 Dec 24;294(5843):770-1 [6275274.001]
  • [Cites] Science. 1982 Aug 20;217(4561):737-9 [6980467.001]
  • [Cites] Proc Natl Acad Sci U S A. 1983 Jun;80(12):3618-22 [6304725.001]
  • [Cites] Nature. 1983 Oct 6-12;305(5934):502-5 [6312323.001]
  • [Cites] Proc Natl Acad Sci U S A. 1983 Nov;80(22):7006-9 [6316341.001]
  • [Cites] Science. 1985 Jul 5;229(4708):54-8 [2990037.001]
  • [Cites] EMBO J. 1986 Mar;5(3):561-5 [3011413.001]
  • [Cites] EMBO J. 1986 Nov;5(11):2883-8 [3024966.001]
  • [Cites] Cell. 1987 Jan 30;48(2):343-50 [3026643.001]
  • [Cites] Cell. 1987 Apr 10;49(1):47-56 [3030566.001]
  • [Cites] Science. 1987 Sep 11;237(4820):1324-9 [2888190.001]
  • [Cites] Science. 1988 Sep 23;241(4873):1652-5 [2843985.001]
  • [Cites] Int J Cancer. 1991 Jun 19;48(4):623-30 [1710610.001]
  • [Cites] Oncogene. 1991 Jun;6(6):1023-9 [1906155.001]
  • [Cites] J Virol. 1992 Jul;66(7):4570-5 [1351105.001]
  • [Cites] J Virol. 1993 Mar;67(3):1211-7 [8437212.001]
  • [Cites] AIDS Res Hum Retroviruses. 1994 Oct;10(10):1259-68 [7531462.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Feb 14;92(4):1057-61 [7862633.001]
  • [Cites] Oncogene. 1996 Apr 18;12(8):1645-52 [8622884.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Oct 14;94(21):11612-6 [9326658.001]
  • (PMID = 16042787.001).
  • [ISSN] 1742-4690
  • [Journal-full-title] Retrovirology
  • [ISO-abbreviation] Retrovirology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Gene Products, tax; 0 / Interleukin-2; 0 / NF-kappa B
  • [Other-IDs] NLM/ PMC1199618
  •  go-up   go-down


53. Ozer H, Mirtsching B, Rader M, Luedke S, Noga SJ, Ding B, Dreiling L: Neutropenic events in community practices reduced by first and subsequent cycle pegfilgrastim use. Oncologist; 2007 Apr;12(4):484-94
Hazardous Substances Data Bank. Filgrastim .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Patients > or = 18 years old with cancers other than leukemia or myelodysplastic syndrome, including those with major comorbidities, were eligible.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Oncologist. 2007 Dec;12(12):1464; author reply 1465-6 [18240458.001]
  • (PMID = 17470691.001).
  • [ISSN] 1083-7159
  • [Journal-full-title] The oncologist
  • [ISO-abbreviation] Oncologist
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Recombinant Proteins; 143011-72-7 / Granulocyte Colony-Stimulating Factor; PVI5M0M1GW / Filgrastim
  •  go-up   go-down


54. Brink DS: Transient leukemia (transient myeloproliferative disorder, transient abnormal myelopoiesis) of Down syndrome. Adv Anat Pathol; 2006 Sep;13(5):256-62
MedlinePlus Health Information. consumer health - Down Syndrome.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transient leukemia (transient myeloproliferative disorder, transient abnormal myelopoiesis) of Down syndrome.
  • Transient leukemia of Down syndrome (DS-TL), also known as transient myeloproliferative disorder of Down syndrome (DS) and transient abnormal myelopoiesis of DS, occurs in approximately 10% of DS neonates and in phenotypically normal neonates with trisomy 21 mosaicism.
  • In DS-TL, peripheral blood analysis shows variable numbers of blasts and, usually, thrombocytopenia; other cytopenias are uncommon.
  • Bone marrow characteristics of DS-TL are, likewise, variable, though (in contrast to other leukemias) the bone marrow blast differential can be lower than the peripheral blood blast differential.
  • Despite its typical transient nature, 20% to 30% of DS-TL patients develop overt (nontransient) acute leukemia, usually within 3 years and typically of the M7 phenotype (acute megakaryoblastic leukemia).
  • The pathogenesis of DS-TL (and of subsequent acute leukemia) involves mutation of GATA1 (on chromosome X), which normally encodes a transcription factor integral to normal development of erythroid, megakaryocytic, and basophilic/mast cell lines.
  • [MeSH-minor] GATA1 Transcription Factor / genetics. Humans. Hydrops Fetalis / etiology. Infant, Newborn. Leukemia / etiology. Liver Diseases / etiology. Mutation

  • Genetic Alliance. consumer health - Down Syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16998319.001).
  • [ISSN] 1072-4109
  • [Journal-full-title] Advances in anatomic pathology
  • [ISO-abbreviation] Adv Anat Pathol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / GATA1 Transcription Factor; 0 / GATA1 protein, human
  • [Number-of-references] 81
  •  go-up   go-down


55. Mohr A, Zwacka RM, Jarmy G, Büneker C, Schrezenmeier H, Döhner K, Beltinger C, Wiesneth M, Debatin KM, Stahnke K: Caspase-8L expression protects CD34+ hematopoietic progenitor cells and leukemic cells from CD95-mediated apoptosis. Oncogene; 2005 Mar 31;24(14):2421-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Dysfunctional or deregulated apoptosis can potentially contribute to the development of immune deficiencies, autoimmune diseases, and leukemia.
  • Thus, caspase-8L expression might explain constitutive resistance to CD95-mediated apoptosis in CD34+ progenitor cells and might participate in the development of stem cell-derived and other leukemias by providing protection from regulatory apoptosis.
  • [MeSH-major] Antigens, CD / physiology. Antigens, CD34 / immunology. Apoptosis / physiology. Caspases / metabolism. Hematopoietic Stem Cells / cytology. Lectins, C-Type / physiology. Leukemia / pathology

  • MedlinePlus Health Information. consumer health - Leukemia.
  • MedlinePlus Health Information. consumer health - Stem Cells.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15735742.001).
  • [ISSN] 0950-9232
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD34; 0 / Lectins, C-Type; 0 / NK Cell Lectin-Like Receptor Subfamily D; EC 3.4.22.- / CASP8 protein, human; EC 3.4.22.- / Caspase 8; EC 3.4.22.- / Caspases
  •  go-up   go-down


56. Iglesias-Serret D, Piqué M, Barragán M, Cosialls AM, Santidrián AF, González-Gironès DM, Coll-Mulet L, de Frias M, Pons G, Gil J: Aspirin induces apoptosis in human leukemia cells independently of NF-kappaB and MAPKs through alteration of the Mcl-1/Noxa balance. Apoptosis; 2010 Feb;15(2):219-29
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aspirin induces apoptosis in human leukemia cells independently of NF-kappaB and MAPKs through alteration of the Mcl-1/Noxa balance.
  • Aspirin and other non-steroidal anti-inflammatory drugs induce apoptosis in most cell types.
  • In this study we examined the mechanism of aspirin-induced apoptosis in human leukemia cells.
  • Our results show that aspirin induced apoptosis in leukemia Jurkat T cells independently of NF-kappaB.
  • This alteration of the Mcl-1/Noxa balance was also found in other leukemia cell lines and primary chronic lymphocytic leukemia cells (CLL).
  • [MeSH-major] Apoptosis / drug effects. Aspirin / pharmacology. Leukemia, Lymphocytic, Chronic, B-Cell / enzymology. Mitogen-Activated Protein Kinases / metabolism. NF-kappa B / metabolism. Proto-Oncogene Proteins c-bcl-2 / metabolism
  • [MeSH-minor] Apoptosis Regulatory Proteins / metabolism. Cell Line, Tumor. Cell Survival / drug effects. Cycloheximide / pharmacology. Cytochromes c / secretion. Drug Screening Assays, Antitumor. Enzyme Activation / drug effects. Humans. JNK Mitogen-Activated Protein Kinases / metabolism. MAP Kinase Kinase Kinases / metabolism. Mitochondria / drug effects. Mitochondria / secretion. Myeloid Cell Leukemia Sequence 1 Protein. Proto-Oncogene Proteins / metabolism

  • Hazardous Substances Data Bank. ACETYLSALICYLIC ACID .
  • Hazardous Substances Data Bank. CYCLOHEXIMIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19936928.001).
  • [ISSN] 1573-675X
  • [Journal-full-title] Apoptosis : an international journal on programmed cell death
  • [ISO-abbreviation] Apoptosis
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Apoptosis Regulatory Proteins; 0 / BBC3 protein, human; 0 / Myeloid Cell Leukemia Sequence 1 Protein; 0 / NF-kappa B; 0 / PMAIP1 protein, human; 0 / Proto-Oncogene Proteins; 0 / Proto-Oncogene Proteins c-bcl-2; 9007-43-6 / Cytochromes c; 98600C0908 / Cycloheximide; EC 2.7.11.24 / JNK Mitogen-Activated Protein Kinases; EC 2.7.11.24 / Mitogen-Activated Protein Kinases; EC 2.7.11.25 / MAP Kinase Kinase Kinases; EC 2.7.11.25 / MAP3K8 protein, human; R16CO5Y76E / Aspirin
  •  go-up   go-down


57. Khalid S, Adil SN, Vaziri IA: Granulocytic sarcoma in the absence of acute myeloid leukemia: a case report. Indian J Pathol Microbiol; 2007 Jan;50(1):88-90
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Granulocytic sarcoma in the absence of acute myeloid leukemia: a case report.
  • The tumor may develop during the course of acute myeloid leukemia, chronic myeloid leukemia or other myelodysplastic disorders.
  • It can occur without blood or bone marrow manifestations of leukemia and in this case, the diagnosis is difficult.
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Biopsy. Bone Marrow / pathology. Cyclophosphamide / administration & dosage. Diagnosis, Differential. Doxorubicin / administration & dosage. Histocytochemistry. Humans. Leukemia, Myeloid, Acute / complications. Lymphoma, Non-Hodgkin / diagnosis. Lymphoma, Non-Hodgkin / drug therapy. Male. Neoplasms. Prednisolone / administration & dosage. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • Genetic Alliance. consumer health - Myeloid sarcoma.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17474271.001).
  • [ISSN] 0377-4929
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; VAP-cyclo protocol
  •  go-up   go-down


58. Liu B, Lin Y, Darwanto A, Song X, Xu G, Zhang K: Identification and characterization of propionylation at histone H3 lysine 23 in mammalian cells. J Biol Chem; 2009 Nov 20;284(47):32288-95
antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • However, other proteins subject to this modification remain to be identified, and the modifying enzymes involved need to be characterized.
  • Propionylation at H3 lysine Lys(23) was detected in the leukemia cell line U937 by mass spectrometry and Western analysis using a specific antibody.
  • In this cell line, the propionylated form of Lys(23) accounted for 7%, a level at least 6-fold higher than in other leukemia cell lines (HL-60 and THP-1) or non-leukemia cell lines (HeLa and IMR-90).

  • Hazardous Substances Data Bank. L-Lysine .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cell Metab. 2008 Feb;7(2):104-12 [18249170.001]
  • [Cites] Oncogene. 2007 Oct 15;26(47):6697-714 [17934479.001]
  • [Cites] Annu Rev Med. 2008;59:267-80 [17937590.001]
  • [Cites] Nature. 2008 Apr 17;452(7189):877-81 [18354397.001]
  • [Cites] J Proteome Res. 2009 Feb;8(2):900-6 [19113941.001]
  • [Cites] Blood. 2009 Jul 16;114(3):651-8 [19443658.001]
  • [Cites] Nature. 2000 Jan 6;403(6765):41-5 [10638745.001]
  • [Cites] Anal Biochem. 2002 Jul 15;306(2):259-69 [12123664.001]
  • [Cites] Anal Biochem. 2003 May 1;316(1):23-33 [12694723.001]
  • [Cites] Anal Biochem. 1985 Apr;146(1):173-9 [3993929.001]
  • [Cites] Immunol Cell Biol. 1992 Apr;70 ( Pt 2):97-105 [1356919.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 May 14;93(10):4804-9 [8643484.001]
  • [Cites] Mol Cell Biol. 1998 Mar;18(3):1236-47 [9488438.001]
  • [Cites] J Immunol. 1998 Aug 1;161(3):1390-8 [9686602.001]
  • [Cites] Cold Spring Harb Symp Quant Biol. 1998;63:501-7 [10384314.001]
  • [Cites] Cell. 2005 Apr 22;121(2):167-78 [15851025.001]
  • [Cites] Nature. 2005 Jun 30;435(7046):1262-6 [15988529.001]
  • [Cites] Nat Cell Biol. 2006 Sep;8(9):1017-24 [16921363.001]
  • [Cites] Mol Cell Proteomics. 2007 May;6(5):812-9 [17267393.001]
  • [Cites] Nature. 2007 May 24;447(7143):425-32 [17522676.001]
  • [Cites] J Biol Chem. 2007 Oct 12;282(41):30239-45 [17684016.001]
  • [Cites] Chembiochem. 2008 Mar 3;9(4):499-503 [18247445.001]
  • (PMID = 19801601.001).
  • [ISSN] 1083-351X
  • [Journal-full-title] The Journal of biological chemistry
  • [ISO-abbreviation] J. Biol. Chem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Histones; EC 6.2.1.- / Coenzyme A Ligases; EC 6.2.1.17 / propionate - CoA ligase; K3Z4F929H6 / Lysine
  • [Other-IDs] NLM/ PMC2781642
  •  go-up   go-down


59. Zhang J, Wang JC, Han YH, Wang LF, Ji SP, Liu SX, Liu XP, Yao LB: High expression of bcl-x(L) in K562 cells and its role in the low sensitivity of K562 to realgar-induced apoptosis. Acta Haematol; 2005;113(4):247-54
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Arsenic compounds (As(2)O(3 )or()As(4)S(4)) have been used successfully for the treatment of acute promyelocytic leukemia (APL) for quite a long time.
  • It has been noticed that the sensitivity to apoptosis induced by As(2)O(3 )varies among various leukemia cells.
  • It was reported by several groups that As(2)O(3) could induce apoptosis in APL-derived NB4 cells at concentrations of 0.5-1 mumol/l, whereas in other leukemia cells like K562, As(2)O(3) has no effects at the same concentration.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2005 S. Karger AG, Basel
  • (PMID = 15983431.001).
  • [ISSN] 0001-5792
  • [Journal-full-title] Acta haematologica
  • [ISO-abbreviation] Acta Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Arsenicals; 0 / BCL2L1 protein, human; 0 / DNA Primers; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Sulfides; 0 / bcl-X Protein; 56320-22-0 / arsenic disulfide
  •  go-up   go-down


60. Lin TH, Lu FJ, Yin YF, Tseng TH: Enhancement of esculetin on arsenic trioxide-provoked apoptosis in human leukemia U937 cells. Chem Biol Interact; 2009 Jun 15;180(1):61-8
Hazardous Substances Data Bank. ARSENIC TRIOXIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Enhancement of esculetin on arsenic trioxide-provoked apoptosis in human leukemia U937 cells.
  • Arsenic trioxide (As(2)O(3)) is widely used in treating human acute polymyelocytic leukemia (APL).
  • However, solid tumors and other leukemia cells such as U937 promonocytic leukemia cells are insensitive to As(2)O(3).
  • In this study, esculetin inhibited proliferation and mitogen activated protein kinases (MAPKs) activation in human leukemia U937 cells.
  • Since inhibitors of MAPKs have modulated the GSH-redox state and enhanced the sensitivity of leukemia cells to As(2)O(3)-provoked apoptosis, we monitored the effect of combining esculetin and As(2)O(3) (2.5 microM) on the GSH level.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Antineoplastic Combined Chemotherapy Protocols / pharmacology. Apoptosis / drug effects. Arsenicals / pharmacology. Leukemia. Oxides / pharmacology. Umbelliferones / pharmacology

  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19428345.001).
  • [ISSN] 1872-7786
  • [Journal-full-title] Chemico-biological interactions
  • [ISO-abbreviation] Chem. Biol. Interact.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antioxidants; 0 / Arsenicals; 0 / Oxides; 0 / Umbelliferones; S7V92P67HO / arsenic trioxide; SM2XD6V944 / esculetin
  •  go-up   go-down


61. Tsimberidou AM, Tirado-Gomez M, Andreeff M, O'Brien S, Kantarjian H, Keating M, Lopez-Berestein G, Estey E: Single-agent liposomal all-trans retinoic acid can cure some patients with untreated acute promyelocytic leukemia: an update of The University of Texas M. D. Anderson Cancer Center Series. Leuk Lymphoma; 2006 Jun;47(6):1062-8
Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Single-agent liposomal all-trans retinoic acid can cure some patients with untreated acute promyelocytic leukemia: an update of The University of Texas M. D. Anderson Cancer Center Series.
  • The present study aimed to investigate single-agent liposomal all-trans retinoic acid (Lipo-ATRA) in untreated acute promyelocytic leukemia (APL).
  • Induction therapy consisted of Lipo-ATRA 90 mg/m2 i.v. every other day.
  • Idarubicin was added only if a polymerase chain reaction test for promyelocytic leukemia-retinoic acid receptor alpha (sensitivity level, 10(-4)), performed every 3 months from CR, was positive.
  • The observation that patients can be cured of APL without the use of chemotherapy should encourage further study of 'targeted' therapy in APL and in other leukemias.
  • [MeSH-major] Leukemia, Promyelocytic, Acute / drug therapy. Leukemia, Promyelocytic, Acute / metabolism. Liposomes / therapeutic use. Tretinoin / therapeutic use

  • Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16840198.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Liposomes; 0 / Receptors, Retinoic Acid; 0 / retinoic acid receptor alpha; 5688UTC01R / Tretinoin; ZRP63D75JW / Idarubicin
  •  go-up   go-down


62. Romanenko AE, Gudzenko NA, Bebeshko VG, Bazyka DA, Ledoshchuk BA, Trotsiuk NK, Babkina NG, Bomko EI, Beliaev IuN, Diagil' IS, Fedorenko ZP, Gulak LO, Gorokh EL, Kortushin GI: [Informative value of the specialized registers in research of leukemia in Chernobyl accident liquidators in Ukraine]. Lik Sprava; 2006 Jun;(4):15-20
MedlinePlus Health Information. consumer health - Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Informative value of the specialized registers in research of leukemia in Chernobyl accident liquidators in Ukraine].
  • The article considers the possibility of the use of current infrastructure of specialized population registers of Ukraine to study leukemia and other systemic blood diseases revealed in Chernobyl accident liquidators.
  • To solve issues on leukemia and other oncological diseases is recommended to use in complex data of specialized registers of Ukraine.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17100233.001).
  • [ISSN] 1019-5297
  • [Journal-full-title] Likars'ka sprava
  • [ISO-abbreviation] Lik. Sprava
  • [Language] RUS
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Ukraine
  •  go-up   go-down


63. Bate J, Yung CF, Hoschler K, Sheasby L, Morden J, Taj M, Heath PT, Miller E: Immunogenicity of pandemic (H1N1) 2009 vaccine in children with cancer in the United Kingdom. Clin Infect Dis; 2010 Dec 15;51(12):e95-104
Hazardous Substances Data Bank. VITAMIN E .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Seroconversion rates were 33.3% (9 of 27) among children with acute lymphoblastic leukemia, 36.4% (4 of 11) among those with lymphoma or other leukemias, 66.7% (6 of 9) among those with brain tumors, and 71.4% (5 of 7) among those with other solid tumors.
  • Seroconversion occurred in 4 (28.6%) of 14 children receiving acute lymphoblastic leukemia maintenance therapy.

  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • MedlinePlus Health Information. consumer health - Flu Shot.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21067352.001).
  • [ISSN] 1537-6591
  • [Journal-full-title] Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • [ISO-abbreviation] Clin. Infect. Dis.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / ASO3B adjuvant; 0 / Adjuvants, Immunologic; 0 / Antibodies, Viral; 0 / Drug Combinations; 0 / Influenza Vaccines; 0 / Polysorbates; 7QWM220FJH / Squalene; H4N855PNZ1 / alpha-Tocopherol
  •  go-up   go-down


64. Gutierrez-Aguirre CH, Gomez-Almaguer D, Cantu-Rodríguez OG, Gonzalez-Llano O, Jaime-Perez JC, Herena-Perez S, Manzano CA, Estrada-Gomez R, Gonzalez-Carrillo ML, Ruiz-Argüelles GJ: Non-myeloablative stem cell transplantation in patients with relapsed acute lymphoblastic leukemia: results of a multicenter study. Bone Marrow Transplant; 2007 Sep;40(6):535-9
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-myeloablative stem cell transplantation in patients with relapsed acute lymphoblastic leukemia: results of a multicenter study.
  • These results are inferior to those obtained using the same allografting method in other leukemias, probably as a consequence of poor susceptibility to the graft-versus-leukemia effect of the ALL cells beyond first remission as compared with other hematological malignancies.
  • [MeSH-major] Graft vs Leukemia Effect. Hematopoietic Stem Cell Transplantation. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Transplantation Conditioning / methods


65. Gharagozloo M, Amirghofran Z: Effects of silymarin on the spontaneous proliferation and cell cycle of human peripheral blood leukemia T cells. J Cancer Res Clin Oncol; 2007 Aug;133(8):525-32
MedlinePlus Health Information. consumer health - Antioxidants.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of silymarin on the spontaneous proliferation and cell cycle of human peripheral blood leukemia T cells.
  • The purpose of this study was to analyze the effects of the silymarin on the proliferation and cell cycle progression of Jurkat cells, a human peripheral blood leukemia T cell line.
  • In conclusion, this study demonstrated an in vitro growth stimulatory effect of silymarin on leukemia cells with monocyte, T and B cell origin that has not been previously reported for either solid tumors or other leukemia cells, suggesting a possible specific stimulatory effect of silymarin on the key cells of the immune system.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17436018.001).
  • [ISSN] 0171-5216
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Anticarcinogenic Agents; 0 / Antioxidants; 0 / Protective Agents; 0 / Silymarin
  •  go-up   go-down


66. Hasegawa H, Yamada Y, Komiyama K, Hayashi M, Ishibashi M, Yoshida T, Sakai T, Koyano T, Kam TS, Murata K, Sugahara K, Tsuruda K, Akamatsu N, Tsukasaki K, Masuda M, Takasu N, Kamihira S: Dihydroflavonol BB-1, an extract of natural plant Blumea balsamifera, abrogates TRAIL resistance in leukemia cells. Blood; 2006 Jan 15;107(2):679-88
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dihydroflavonol BB-1, an extract of natural plant Blumea balsamifera, abrogates TRAIL resistance in leukemia cells.
  • Previously, we showed that although most adult T-cell leukemia/lymphoma (ATLL) cells express the TRAIL death receptor DR4 (TRAIL-R1) or DR5 (TRAIL-R2), they are resistant to TRAIL.
  • More interestingly, similar effects were observed in other leukemia cell lines by exactly the same mechanisms.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Apoptosis / drug effects. Apoptosis Regulatory Proteins / therapeutic use. Asteraceae / chemistry. Drug Resistance, Neoplasm. Flavonols / therapeutic use. Leukemia / drug therapy. Membrane Glycoproteins / therapeutic use. Tumor Necrosis Factor-alpha / therapeutic use
  • [MeSH-minor] Drug Synergism. Drug Therapy, Combination. Humans. Leukemia-Lymphoma, Adult T-Cell. Plant Extracts / therapeutic use. Promoter Regions, Genetic / genetics. RNA, Small Interfering / pharmacology. Receptors, TNF-Related Apoptosis-Inducing Ligand. Receptors, Tumor Necrosis Factor / antagonists & inhibitors. Receptors, Tumor Necrosis Factor / genetics. Receptors, Tumor Necrosis Factor / metabolism. Signal Transduction / drug effects. TNF-Related Apoptosis-Inducing Ligand. Tumor Cells, Cultured. Tumor Suppressor Protein p53 / metabolism

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16195335.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Apoptosis Regulatory Proteins; 0 / Flavonols; 0 / Membrane Glycoproteins; 0 / Plant Extracts; 0 / RNA, Small Interfering; 0 / Receptors, TNF-Related Apoptosis-Inducing Ligand; 0 / Receptors, Tumor Necrosis Factor; 0 / TNF-Related Apoptosis-Inducing Ligand; 0 / TNFRSF10B protein, human; 0 / TNFSF10 protein, human; 0 / Tumor Necrosis Factor-alpha; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


67. Nobuhisa T, Naomoto Y, Okawa T, Takaoka M, Gunduz M, Motoki T, Nagatsuka H, Tsujigiwa H, Shirakawa Y, Yamatsuji T, Haisa M, Matsuoka J, Kurebayashi J, Nakajima M, Taniguchi S, Sagara J, Dong J, Tanaka N: Translocation of heparanase into nucleus results in cell differentiation. Cancer Sci; 2007 Apr;98(4):535-40
Hazardous Substances Data Bank. 12-O-TETRADECANOYLPHORBOL-13-ACETATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Our results suggest that a novel function of heparanase upon cell differentiation would raise a potential new strategy for cancer therapy of promyeloid leukemia and other types of cancer.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17284253.001).
  • [ISSN] 1347-9032
  • [Journal-full-title] Cancer science
  • [ISO-abbreviation] Cancer Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Benzoquinones; 0 / HSP90 Heat-Shock Proteins; 0 / Lactams, Macrocyclic; EC 3.2.1.- / heparanase; EC 3.2.1.31 / Glucuronidase; NI40JAQ945 / Tetradecanoylphorbol Acetate; Z3K3VJ16KU / geldanamycin
  •  go-up   go-down


68. Amiel A, Goldzak G, Gaber E, Fejgin MD: Molecular cytogenetic characteristics of Down syndrome newborns. J Hum Genet; 2006;51(6):541-7
Nature Publishing Group. Nature Publishing Group (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Down syndrome (DS) is a multifactorial disorder with a high predisposition to leukemia and other malignancies.

  • Genetic Alliance. consumer health - Down Syndrome.
  • MedlinePlus Health Information. consumer health - Down Syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16683054.001).
  • [ISSN] 1434-5161
  • [Journal-full-title] Journal of human genetics
  • [ISO-abbreviation] J. Hum. Genet.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


69. Wei Y, Kadia T, Tong W, Zhang M, Jia Y, Yang H, Hu Y, Viallet J, O'Brien S, Garcia-Manero G: The combination of a histone deacetylase inhibitor with the BH3-mimetic GX15-070 has synergistic antileukemia activity by activating both apoptosis and autophagy. Autophagy; 2010 Oct;6(7):976-8
Hazardous Substances Data Bank. Vorinostat .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We analyzed the cellular and molecular effects of two different histone deacetylase inhibitors (HDACi), MGCD0103 and vorinostat, in combination with GX15-070, a BH3-mimetic, in acute myeloid leukemia (AML) cell lines and primary AML cells, and demonstrated that the combination has a synergistic antileukemia effect.
  • These findings reveal that for this specific combination, autophagy plays a positive role in inducing cytotoxicity, and that the involved ER signaling networks, as well as their clinical relevance, should be further studied in both preclinical and clinical trials of leukemia and other malignancies.
  • [MeSH-major] Apoptosis / drug effects. Autophagy / drug effects. Histone Deacetylase Inhibitors. Leukemia, Myeloid, Acute / drug therapy. Pyrroles

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20729640.001).
  • [ISSN] 1554-8635
  • [Journal-full-title] Autophagy
  • [ISO-abbreviation] Autophagy
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016672
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BH3 Interacting Domain Death Agonist Protein; 0 / Benzamides; 0 / Histone Deacetylase Inhibitors; 0 / Hydroxamic Acids; 0 / Pyrimidines; 0 / Pyrroles; 0 / obatoclax; 58IFB293JI / vorinostat; A6GWB8T96J / mocetinostat
  •  go-up   go-down


70. Wood KL, Voss OH, Huang Q, Parihar A, Mehta N, Batra S, Doseff AI: The small heat shock protein 27 is a key regulator of CD8+ CD57+ lymphocyte survival. J Immunol; 2010 May 15;184(10):5582-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • However, CD8(+)CD57(+) are expanded in certain disease states including T cell large granular leukemia and other hematologic malignancies.
  • Unlike other antiapoptotic Bcl-2-like molecules, the expression of Hsp27 tightly correlates with CD8(+)CD57(+) and CD8(+)CD57(-) lifespan.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Breast Cancer Res Treat. 1999 Jul;56(2):187-96 [10573111.001]
  • [Cites] Clin Immunol. 2005 Dec;117(3):294-301 [16290071.001]
  • [Cites] Oncogene. 2000 Apr 13;19(16):1975-81 [10803458.001]
  • [Cites] Br J Haematol. 2000 Jul;110(1):203-9 [10930999.001]
  • [Cites] Nat Cell Biol. 2000 Sep;2(9):645-52 [10980706.001]
  • [Cites] Mol Cell Biol. 2000 Oct;20(20):7602-12 [11003656.001]
  • [Cites] Ann N Y Acad Sci. 2000;926:126-31 [11193028.001]
  • [Cites] J Clin Invest. 2001 Feb;107(3):351-62 [11160159.001]
  • [Cites] Immunology. 2001 Jul;103(3):281-90 [11454057.001]
  • [Cites] Blood. 2001 Nov 1;98(9):2817-27 [11675356.001]
  • [Cites] Science. 2002 Mar 8;295(5561):1852-8 [11884745.001]
  • [Cites] Apoptosis. 2003 Jan;8(1):61-70 [12510153.001]
  • [Cites] Blood. 2003 Apr 1;101(7):2711-20 [12433688.001]
  • [Cites] Hematol J. 2003;4(1):18-25 [12692516.001]
  • [Cites] Am J Respir Cell Mol Biol. 2003 Sep;29(3 Pt 1):367-74 [12663328.001]
  • [Cites] J Immunol. 1981 Sep;127(3):1024-9 [6790607.001]
  • [Cites] J Clin Immunol. 1986 Nov;6(6):502-9 [3097061.001]
  • [Cites] Blood. 1991 May 15;77(10):2237-41 [1709378.001]
  • [Cites] Arthritis Rheum. 1993 May;36(5):608-12 [7683880.001]
  • [Cites] Clin Exp Immunol. 1993 Nov;94(2):297-305 [7693383.001]
  • [Cites] Am J Respir Crit Care Med. 1994 Apr;149(4 Pt 1):972-80 [7511468.001]
  • [Cites] J Immunol. 1995 Jun 1;154(11):6182-90 [7538544.001]
  • [Cites] J Immunol. 1995 Nov 15;155(10):5046-56 [7594513.001]
  • [Cites] Blood. 1997 Jan 1;89(1):256-60 [8978299.001]
  • [Cites] Arthritis Rheum. 1997 Feb;40(2):237-48 [9041935.001]
  • [Cites] Br J Haematol. 1998 Mar;100(3):469-77 [9504628.001]
  • [Cites] Leukemia. 1998 Oct;12(10):1573-82 [9766502.001]
  • [Cites] Blood. 1998 Dec 15;92(12):4771-7 [9845544.001]
  • [Cites] Blood. 2006 Jun 15;107(12):4834-40 [16484592.001]
  • [Cites] Eur J Immunol. 2006 Jul;36(7):1654-8 [16791883.001]
  • [Cites] J Biol Chem. 2007 Aug 24;282(34):25088-99 [17597071.001]
  • [Cites] Am J Hematol. 2007 Dec;82(12):1103-5 [17626255.001]
  • [Cites] J Cell Mol Med. 2008 Jun;12(3):743-61 [18266962.001]
  • [Cites] Clin Cancer Res. 2008 Dec 15;14(24):8279-87 [19088045.001]
  • [Cites] Front Biosci (Landmark Ed). 2009;14:2413-31 [19273209.001]
  • [Cites] Front Biosci (Landmark Ed). 2009;14:3771-81 [19273309.001]
  • [Cites] Clin Exp Immunol. 2005 Feb;139(2):268-78 [15654825.001]
  • [Cites] Blood Rev. 1999 Dec;13(4):230-40 [10741898.001]
  • (PMID = 20385876.001).
  • [ISSN] 1550-6606
  • [Journal-full-title] Journal of immunology (Baltimore, Md. : 1950)
  • [ISO-abbreviation] J. Immunol.
  • [Language] ENG
  • [Grant] United States / NHLBI NIH HHS / HL / K08 HL080701-05; United States / NHLBI NIH HHS / HL / R01 HL075040-01; United States / NHLBI NIH HHS / HL / R01 HL075040-05; United States / NHLBI NIH HHS / HL / K08 HL080701; United States / NHLBI NIH HHS / HL / R01 HL075040
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD57; 0 / Genetic Markers; 0 / HSP27 Heat-Shock Proteins
  • [Other-IDs] NLM/ NIHMS346129; NLM/ PMC3253717
  •  go-up   go-down


71. Zhou Y, Du W, Koretsky T, Bagby GC, Pang Q: TAT-mediated intracellular delivery of NPM-derived peptide induces apoptosis in leukemic cells and suppresses leukemogenesis in mice. Blood; 2008 Sep 15;112(6):2474-83
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Nucleophosmin (NPM) is frequently overexpressed in leukemias and other tumors.
  • Using an inflammation-associated leukemia model, we demonstrate that TAT-NPMDeltaC induced proliferative suppression and apoptosis of preleukemic stem cells and significantly delayed leukemic development in mice.
  • [MeSH-major] Apoptosis / drug effects. Gene Products, tat / therapeutic use. Leukemia / drug therapy. Nuclear Proteins / administration & dosage. Peptide Fragments / administration & dosage

  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 2006 Jun 16;281(24):16536-45 [16608843.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Nov 29;102(48):17448-53 [16287968.001]
  • [Cites] Carcinogenesis. 2007 Jun;28(6):1163-70 [17277230.001]
  • [Cites] J Clin Invest. 2007 Nov;117(11):3283-95 [17960249.001]
  • [Cites] J Biol Chem. 2000 Aug 11;275(32):24451-7 [10829026.001]
  • [Cites] Nature. 2000 Nov 16;408(6810):307-10 [11099028.001]
  • [Cites] J Neurosci. 2002 Jul 1;22(13):5423-31 [12097494.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Dec 24;99(26):17107-12 [12475933.001]
  • [Cites] Cancer Treat Rev. 2003 May;29 Suppl 1:41-8 [12738242.001]
  • [Cites] Trends Pharmacol Sci. 2003 May;24(5):216-8 [12767717.001]
  • [Cites] Oncogene. 2003 Nov 20;22(52):8432-40 [14627984.001]
  • [Cites] Mol Cell Biol. 2004 Feb;24(3):985-96 [14729947.001]
  • [Cites] Cancer Lett. 2004 Apr 8;206(2):193-9 [15013524.001]
  • [Cites] Mol Cell Biol. 2004 May;24(9):3703-11 [15082766.001]
  • [Cites] J Biol Chem. 2004 Jul 2;279(27):28209-19 [15087454.001]
  • [Cites] J Exp Med. 2004 Jul 5;200(1):107-13 [15226358.001]
  • [Cites] Nature. 2004 Sep 23;431(7007):405-6 [15385993.001]
  • [Cites] J Biol Chem. 2004 Oct 1;279(40):41275-9 [15310764.001]
  • [Cites] J Biol Chem. 1988 Aug 5;263(22):10608-12 [3392030.001]
  • [Cites] Biochemistry. 1989 Feb 7;28(3):1033-9 [2713355.001]
  • [Cites] Cancer Res. 1992 Jun 15;52(12):3372-7 [1596895.001]
  • [Cites] J Pathol. 1996 Jan;178(1):48-52 [8778315.001]
  • [Cites] Cancer Res. 1997 Apr 15;57(8):1442-6 [9108443.001]
  • [Cites] Nat Med. 1997 Jun;3(6):632-8 [9176489.001]
  • [Cites] Cell. 1997 Oct 31;91(3):325-34 [9363941.001]
  • [Cites] Oncogene. 1998 Feb 5;16(5):587-96 [9482104.001]
  • [Cites] Mol Cell Biol. 1999 May;19(5):3485-95 [10207072.001]
  • [Cites] Prostate. 1999 Jun 1;39(4):298-304 [10344220.001]
  • [Cites] Science. 1999 Sep 3;285(5433):1569-72 [10477521.001]
  • [Cites] Mol Cell Biol. 2005 Feb;25(4):1258-71 [15684379.001]
  • [Cites] Nature. 2005 Sep 1;437(7055):147-53 [16007073.001]
  • [Cites] Nat Rev Immunol. 2005 Oct;5(10):749-59 [16175180.001]
  • [Cites] Leuk Res. 2005 Dec;29(12):1415-23 [15964625.001]
  • [Cites] Nat Rev Cancer. 2006 Jul;6(7):493-505 [16794633.001]
  • (PMID = 18574026.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Grant] United States / NHLBI NIH HHS / HL / P01 HL048546; United States / NCI NIH HHS / CA / R01 CA109641; United States / NHLBI NIH HHS / HL / R01 HL072321; United States / NHLBI NIH HHS / HL / R01 HL076712
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Gene Products, tat; 0 / NF-kappa B; 0 / Nuclear Proteins; 0 / Peptide Fragments; 0 / Recombinant Fusion Proteins; 117896-08-9 / nucleophosmin
  • [Other-IDs] NLM/ PMC2532814
  •  go-up   go-down


72. Zhang Z, Meier KE: New assignments for multitasking signal transduction inhibitors. Mol Pharmacol; 2006 May;69(5):1510-2
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this article, the action of dasatinib (BMS-354825) is contrasted with that of imatinib, a kinase inhibitor that is currently being used to treat chronic myelogenous leukemia and other disorders.

  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Mol Pharmacol. 2006 May;69(5):1527-33 [16436588.001]
  • (PMID = 16497876.001).
  • [ISSN] 0026-895X
  • [Journal-full-title] Molecular pharmacology
  • [ISO-abbreviation] Mol. Pharmacol.
  • [Language] eng
  • [Publication-type] Comment; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Benzamides; 0 / Piperazines; 0 / Protein Kinase Inhibitors; 0 / Pyrimidines; 0 / Thiazoles; 8A1O1M485B / Imatinib Mesylate; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptors, Platelet-Derived Growth Factor; RBZ1571X5H / Dasatinib
  •  go-up   go-down


73. Hadi E, Sharony R, Goldberg-Bittman L, Biron-Shental T, Fejgin M, Amiel A: Telomere aggregates in trisomy 21 amniocytes. Cancer Genet Cytogenet; 2009 Nov;195(1):23-6
MedlinePlus Health Information. consumer health - Down Syndrome.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Down syndrome carries an increased risk of developing acute leukemia and other malignancies.
  • The TAs found in trisomy 21 amniocytes apparently represent an additional parameter that reflects the high genetic instability of this syndrome and its recognized predisposition to develop leukemia and other malignancies.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19837264.001).
  • [ISSN] 1873-4456
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


74. Sarvis JA, Auge BK: Myeloid (granulocytic) sarcoma of epididymis as rare manifestation of recurrent acute myelogenous leukemia. Urology; 2009 May;73(5):1163.e1-3
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Myeloid (granulocytic) sarcoma of epididymis as rare manifestation of recurrent acute myelogenous leukemia.
  • Myeloid sarcoma involving the genitourinary system is a rare complication associated with acute myelogenous leukemia or other myeloproliferative disorders.
  • We report the second known case of myeloid sarcoma involving the epididymis in a patient with a history of acute myelogenous leukemia.
  • [MeSH-major] Epididymis / pathology. Leukemia, Myeloid, Acute / diagnosis. Sarcoma, Myeloid / diagnosis. Testicular Neoplasms / diagnosis


75. Higa F, Fujita J, Koide M, Haranaga S, Tateyama M: Clinical features of two cases of Legionnaires' disease with persistence of Legionella urinary antigen excretion. Intern Med; 2008;47(3):173-8
MedlinePlus Health Information. consumer health - Legionnaires' Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • One patient had an underlying disease, adult T-cell leukemia, and the other patient had ulcerative colitis and was receiving oral corticosteroids.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18239328.001).
  • [ISSN] 1349-7235
  • [Journal-full-title] Internal medicine (Tokyo, Japan)
  • [ISO-abbreviation] Intern. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antigens, Bacterial
  •  go-up   go-down


76. Baker SJ, Rane SG, Reddy EP: Hematopoietic cytokine receptor signaling. Oncogene; 2007 Oct 15;26(47):6724-37
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Aberration in these pathways, such as that caused by the recently identified JAK2V617F mutation, is an underlying cause for diseases such as leukemias and other myeloproliferative disorders.

  • MedlinePlus Health Information. consumer health - Stem Cells.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17934481.001).
  • [ISSN] 0950-9232
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] eng
  • [Grant] United States / NHLBI NIH HHS / HL / 5R01HL080666-02
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cytokines; 0 / Receptors, Cytokine
  • [Number-of-references] 130
  •  go-up   go-down


77. Chen SJ, Chen LJ, Zhou GB: [Basic and clinical studies of the gene product-targeting therapy based on leukemogenesis--editorial]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2005 Feb;13(1):1-8
Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In the last twenty years, using all-trans retinoic acid (ATRA) as a differentiation inducer, Shanghai Institute of Hematology has achieved an important breakthrough in the treatment of acute promyelocytic leukemia (APL), which realized the theory of reversing phenotype of cells and provided a successful model of differentiation therapy in cancers.
  • This is the best clinical effect achieved in treating adult acute leukemia to this day, possibly making APL the first adult curable leukemia.
  • Based on the great success of the pathogenetic gene target therapy in APL, this strategy may extend to other leukemias.
  • Combination of Gleevec and arsenic agents in treating chronic myeloid leukemia has already make a figure both in clinical and laboratory research, aiming at counteracting the abnormal tyrosine kinase activity of ABL and the degradating BCR-ABL fusion protein.
  • In acute myeloid leukemia M(2b), using new target therapy degradating AML1-ETO fusion protein and reducing the abnormal tyrosine kinase activity of c-kit will also lead to new therapeutic management in acute leukemias.

  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15748426.001).
  • [ISSN] 1009-2137
  • [Journal-full-title] Zhongguo shi yan xue ye xue za zhi
  • [ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi
  • [Language] CHI
  • [Publication-type] Editorial; English Abstract
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Oncogene Proteins, Fusion; 0 / Piperazines; 0 / Pyrimidines; 0 / Receptors, Retinoic Acid; 0 / promyelocytic leukemia-retinoic acid receptor alpha fusion oncoprotein; 5688UTC01R / Tretinoin; 8A1O1M485B / Imatinib Mesylate; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.2 / Fusion Proteins, bcr-abl
  •  go-up   go-down


78. Ozato K, Tailor P, Kubota T: The interferon regulatory factor family in host defense: mechanism of action. J Biol Chem; 2007 Jul 13;282(28):20065-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • IRFs also regulate growth and differentiation of many cell types, thus playing a role in leukemia and other cancers.
  • [MeSH-major] Immunity, Innate. Interferon Regulatory Factors / immunology. Interferon Type I / immunology. Leukemia / immunology. Transcription, Genetic / immunology. Virus Diseases / immunology

  • MedlinePlus Health Information. consumer health - Leukemia.
  • MedlinePlus Health Information. consumer health - Viral Infections.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17502370.001).
  • [ISSN] 0021-9258
  • [Journal-full-title] The Journal of biological chemistry
  • [ISO-abbreviation] J. Biol. Chem.
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Interferon Regulatory Factors; 0 / Interferon Type I
  • [Number-of-references] 55
  •  go-up   go-down


79. Tabassum H, Parvez S, Pasha ST, Banerjee BD, Raisuddin S: Protective effect of lipoic acid against methotrexate-induced oxidative stress in liver mitochondria. Food Chem Toxicol; 2010 Jul;48(7):1973-9
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Methotrexate (MTX) is a folic acid antagonist widely used as a cytotoxic chemotherapeutic agent for leukemia and other malignancies.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20451574.001).
  • [ISSN] 1873-6351
  • [Journal-full-title] Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association
  • [ISO-abbreviation] Food Chem. Toxicol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Folic Acid Antagonists; 0 / Free Radicals; 0 / Sulfhydryl Compounds; 0 / Thiobarbituric Acid Reactive Substances; 11062-77-4 / Superoxides; 73Y7P0K73Y / Thioctic Acid; 9007-49-2 / DNA; EC 1.11.1.9 / Glutathione Peroxidase; EC 1.15.1.1 / Superoxide Dismutase; GAN16C9B8O / Glutathione; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


80. Mitiushova EV, Aksenov ND, Marakhova II: [Specific function of STAT5 in regulation of proliferation of chronic leukemia K562 cells: inhibitory effect of WHI-P131]. Tsitologiia; 2010;52(2):184-90

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Specific function of STAT5 in regulation of proliferation of chronic leukemia K562 cells: inhibitory effect of WHI-P131].
  • In this study, we examined the possible role of JAK/STAT signaling pathway in regulation of proliferation of chronic leukemia cells K562.
  • Thus, our findings indicate a preferential role for STAT5 (not constitutively active STAT3) in proliferation of leukemia to other JAK drugs which stimulate apoptosis and decrease proliferation, WHI-P131 prevents K562 cells growth by arresting in G2/M phases of cell cycle.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20352702.001).
  • [ISSN] 0041-3771
  • [Journal-full-title] Tsitologiia
  • [ISO-abbreviation] Tsitologiia
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Quinazolines; 0 / STAT5 Transcription Factor; 0 / WHI P131
  •  go-up   go-down


81. Jerse M, Mlakar U, Popovic M, Vranic A, Zidar N: Granulocytic sarcoma in a patient with essential thrombocythemia presented as acute spinal cord compression--case report and review of the literature. Clin Neuropathol; 2008 Jul-Aug;27(4):241-7
Hazardous Substances Data Bank. ACETYLSALICYLIC ACID .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Granulocytic sarcoma (GS) is a rare solid tumor of myeloid origin, which usually precedes or occurs concurrently with myeloid leukemia, or with other types of myeloproliferative and myelodysplastic disorders.
  • We present a case of a 75-year-old woman with a long history of essential thrombocythemia who developed 2 tumors: 1 in the bodies of T3 - 6 vertebras extending epidurally, and the other in the right frontal lobe, adherent to dura, thus, mimicking meningioma.

  • Genetic Alliance. consumer health - Essential Thrombocythemia.
  • Hazardous Substances Data Bank. MELPHALAN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18666440.001).
  • [ISSN] 0722-5091
  • [Journal-full-title] Clinical neuropathology
  • [ISO-abbreviation] Clin. Neuropathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Anticoagulants; 0 / Antigens, CD; 0 / Antineoplastic Agents, Alkylating; Q41OR9510P / Melphalan; R16CO5Y76E / Aspirin
  •  go-up   go-down


82. Chorny A, Gonzalez-Rey E, Fernandez-Martin A, Ganea D, Delgado M: Vasoactive intestinal peptide induces regulatory dendritic cells that prevent acute graft-versus-host disease while maintaining the graft-versus-tumor response. Blood; 2006 May 1;107(9):3787-94
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Acute graft-versus-host disease (GVHD) is a major cause of morbidity and mortality in patients undergoing allogeneic bone marrow transplantation (BMT) for the treatment of leukemia and other immunogenetic disorders.
  • VIP-induced tolerogenic DCs did not abrogate the graft-versus-leukemia response presumably by not affecting the cytotoxicity of transplanted T cells against the leukemic cells.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Immunity. 2003 Mar;18(3):367-79 [12648454.001]
  • [Cites] Annu Rev Immunol. 2003;21:685-711 [12615891.001]
  • [Cites] Biol Blood Marrow Transplant. 2003 Apr;9(4):243-56 [12720217.001]
  • [Cites] Immunity. 2003 May;18(5):605-17 [12753738.001]
  • [Cites] Nat Med. 2003 Sep;9(9):1144-50 [12925844.001]
  • [Cites] Immunol Rev. 2003 Dec;196:125-46 [14617202.001]
  • [Cites] J Clin Invest. 2003 Dec;112(11):1688-96 [14660744.001]
  • [Cites] Nat Rev Immunol. 2004 Jan;4(1):24-34 [14704765.001]
  • [Cites] Blood. 2004 May 15;103(10):3970-8 [14764532.001]
  • [Cites] Pharmacol Rev. 2004 Jun;56(2):249-90 [15169929.001]
  • [Cites] Immunol Lett. 2004 Jun 15;94(1-2):11-26 [15234530.001]
  • [Cites] FASEB J. 2004 Sep;18(12):1325-34 [15333575.001]
  • [Cites] Blood. 1988 Oct;72(4):1168-76 [3048436.001]
  • [Cites] Blood. 1996 Jun 15;87(12):5355-69 [8652851.001]
  • [Cites] J Exp Med. 1998 Jul 20;188(2):287-96 [9670041.001]
  • [Cites] Blood. 1998 Oct 1;92(7):2571-80 [9746799.001]
  • [Cites] Bone Marrow Transplant. 1999 Mar;23(5):443-50 [10100557.001]
  • [Cites] J Immunol. 2004 Dec 15;173(12):7308-16 [15585854.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Sep 20;102(38):13562-7 [16150720.001]
  • [Cites] J Immunol. 2005 Dec 1;175(11):7311-24 [16301637.001]
  • [Cites] Blood. 2006 May 1;107(9):3632-8 [16397128.001]
  • [Cites] Annu Rev Immunol. 2000;18:767-811 [10837075.001]
  • [Cites] J Exp Med. 2000 Jul 17;192(2):295-302 [10899916.001]
  • [Cites] J Exp Med. 2000 Jul 17;192(2):303-10 [10899917.001]
  • [Cites] J Exp Med. 2001 Jan 15;193(2):F5-9 [11208869.001]
  • [Cites] J Exp Med. 2001 Sep 17;194(6):769-79 [11560993.001]
  • [Cites] Blood. 2002 Sep 15;100(6):2020-5 [12200361.001]
  • [Cites] Immunity. 2003 Jan;18(1):155-67 [12530984.001]
  • [Cites] Blood. 2003 May 1;101(9):3581-9 [12511411.001]
  • (PMID = 16418327.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / PHS HHS / / 2R01A047325
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 37221-79-7 / Vasoactive Intestinal Peptide
  • [Other-IDs] NLM/ PMC1895782
  •  go-up   go-down


83. Carvalho FP, Oliveira JM: Uranium isotopes in the Balkan's environment and foods following the use of depleted uranium in the war. Environ Int; 2010 May;36(4):352-60
Hazardous Substances Data Bank. Water .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Exposure of military staff and local populations to uranium metal and to its ionizing radiation were feared as potential causes for leukemia and other diseases in that region.
  • Concentrations of uranium in most of the environmental and food samples were comparable to concentrations of uranium measured in other European regions, such as Portugal and United Kingdom, and uranium isotopic ratios were in general compatible with isotopic ratios typical of natural uranium.

  • Hazardous Substances Data Bank. URANIUM, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20303178.001).
  • [ISSN] 1873-6750
  • [Journal-full-title] Environment international
  • [ISO-abbreviation] Environ Int
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Radioactive Pollutants; 0 / Radioisotopes; 0 / Soil; 059QF0KO0R / Water; 4OC371KSTK / Uranium
  •  go-up   go-down


84. Ong HL, Cheng KT, Liu X, Bandyopadhyay BC, Paria BC, Soboloff J, Pani B, Gwack Y, Srikanth S, Singh BB, Gill DL, Ambudkar IS: Dynamic assembly of TRPC1-STIM1-Orai1 ternary complex is involved in store-operated calcium influx. Evidence for similarities in store-operated and calcium release-activated calcium channel components. J Biol Chem; 2007 Mar 23;282(12):9105-16
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Store-operated calcium entry (SOCE) is a ubiquitous mechanism that is mediated by distinct SOC channels, ranging from the highly selective calcium release-activated Ca2+ (CRAC) channel in rat basophilic leukemia and other hematopoietic cells to relatively Ca2+-selective or non-selective SOC channels in other cells.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 1999 Dec 24;274(52):37370-8 [10601307.001]
  • [Cites] Biochim Biophys Acta. 2006 Nov;1763(11):1147-60 [17034882.001]
  • [Cites] J Biol Chem. 2000 Feb 4;275(5):3403-11 [10652333.001]
  • [Cites] J Biol Chem. 2000 Apr 21;275(16):11934-42 [10766822.001]
  • [Cites] Circ Res. 2001 Jan 19;88(1):84-7 [11139478.001]
  • [Cites] Annu Rev Immunol. 2001;19:497-521 [11244045.001]
  • [Cites] FASEB J. 2001 Jul;15(9):1652-4 [11427516.001]
  • [Cites] J Exp Med. 2002 Mar 18;195(6):673-81 [11901194.001]
  • [Cites] Biochim Biophys Acta. 2002 Apr 1;1596(1):131-7 [11983428.001]
  • [Cites] Nat Cell Biol. 2002 Nov;4(11):E263-72 [12415286.001]
  • [Cites] J Biol Chem. 2003 Mar 28;278(13):11337-43 [12536150.001]
  • [Cites] Nat Rev Mol Cell Biol. 2003 Jul;4(7):517-29 [12838335.001]
  • [Cites] J Biol Chem. 2003 Jul 18;278(29):27208-15 [12732636.001]
  • [Cites] J Biol Chem. 2003 Jul 18;278(29):26629-38 [12736256.001]
  • [Cites] J Biol Chem. 2003 Aug 29;278(35):33492-500 [12766172.001]
  • [Cites] Cell. 2003 Sep 19;114(6):777-89 [14505576.001]
  • [Cites] Sci STKE. 2004 Jul 27;2004(243):pe34 [15280576.001]
  • [Cites] Physiol Rev. 1997 Oct;77(4):901-30 [9354808.001]
  • [Cites] J Biol Chem. 1998 Dec 11;273(50):33295-304 [9837902.001]
  • [Cites] Am J Physiol. 1999 Apr;276(4 Pt 1):C969-79 [10199829.001]
  • [Cites] J Membr Biol. 2004 Jul 15;200(2):93-104 [15520907.001]
  • [Cites] Sci STKE. 2005 Feb 22;2005(272):re3 [15728426.001]
  • [Cites] Physiol Rev. 2005 Apr;85(2):757-810 [15788710.001]
  • [Cites] J Cell Biol. 2005 May 9;169(3):435-45 [15866891.001]
  • [Cites] J Biol Chem. 2005 Jun 3;280(22):21600-6 [15834157.001]
  • [Cites] Curr Biol. 2005 Jul 12;15(13):1235-41 [16005298.001]
  • [Cites] J Biol Chem. 2005 Aug 19;280(33):29559-69 [15972814.001]
  • [Cites] Pflugers Arch. 2005 Oct;451(1):53-60 [15965706.001]
  • [Cites] Pflugers Arch. 2005 Oct;451(1):116-24 [16044307.001]
  • [Cites] Thromb Haemost. 2005 Oct;94(4):839-45 [16270640.001]
  • [Cites] Sci STKE. 2005 Dec 6;2005(313):pe53 [16333017.001]
  • [Cites] Trends Pharmacol Sci. 2006 Jan;27(1):25-32 [16337693.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Mar 14;103(11):4040-5 [16537481.001]
  • [Cites] J Pharmacol Exp Ther. 2006 May;317(2):488-99 [16415091.001]
  • [Cites] Nature. 2006 May 11;441(7090):179-85 [16582901.001]
  • [Cites] Science. 2006 May 26;312(5777):1220-3 [16645049.001]
  • [Cites] Nat Cell Biol. 2006 Jul;8(7):771-3 [16733527.001]
  • [Cites] J Biol Chem. 2006 Jul 28;281(30):20661-5 [16766533.001]
  • [Cites] J Biol Chem. 2006 Aug 25;281(34):24979-90 [16807233.001]
  • [Cites] Nat Cell Biol. 2006 Sep;8(9):1003-10 [16906149.001]
  • [Cites] J Cell Biol. 2006 Sep 11;174(6):803-13 [16966422.001]
  • [Cites] J Cell Biol. 2006 Sep 11;174(6):815-25 [16966423.001]
  • [Cites] Nature. 2006 Sep 14;443(7108):230-3 [16921383.001]
  • [Cites] Nature. 2006 Sep 14;443(7108):226-9 [16921385.001]
  • [Cites] J Biol Chem. 2006 Sep 22;281(38):28254-64 [16870612.001]
  • [Cites] Curr Biol. 2006 Oct 24;16(20):2073-9 [16978865.001]
  • [ErratumIn] J Biol Chem. 2007 Sep 14;282(37):27556. Gill, Donald [corrected to Gill, Donald L]
  • (PMID = 17224452.001).
  • [ISSN] 0021-9258
  • [Journal-full-title] The Journal of biological chemistry
  • [ISO-abbreviation] J. Biol. Chem.
  • [Language] ENG
  • [Grant] United States / NIDCR NIH HHS / DE / R01 DE017102-06A1; United States / NIDCR NIH HHS / DE / R01 DE017102; United States / NIDCR NIH HHS / DE / R01 DE017102-03; United States / NCRR NIH HHS / RR / RR017699-077011; United States / NIDCR NIH HHS / DE / R01 DE017102-01A1; United States / NIDCR NIH HHS / DE / R01 DE017102-02; United States / NIDCR NIH HHS / DE / DE017102; United States / NCRR NIH HHS / RR / P20 RR017699; United States / NIGMS NIH HHS / GM / GM07525; United States / NCRR NIH HHS / RR / P20 RR017699-077011; United States / NIDCR NIH HHS / DE / R01 DE017102-05
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Calcium Channels; 0 / Membrane Glycoproteins; 0 / Membrane Proteins; 0 / Neoplasm Proteins; 0 / ORAI1 protein, human; 0 / STIM1 protein, human; 0 / Stim1 protein, mouse; 67526-95-8 / Thapsigargin; SY7Q814VUP / Calcium
  • [Other-IDs] NLM/ NIHMS112595; NLM/ PMC3309402
  •  go-up   go-down


85. Hossain A, Nixon M, Kuo MT, Saunders GF: N-terminally truncated WT1 protein with oncogenic properties overexpressed in leukemia. J Biol Chem; 2006 Sep 22;281(38):28122-30
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] N-terminally truncated WT1 protein with oncogenic properties overexpressed in leukemia.
  • The sWT1 transcript, but not the full-length transcript, was over-expressed in the leukemia samples tested. sWT1-specific small interfering RNA retarded the proliferation of leukemia cell line K562 in vitro.
  • Further studies are needed to clarify the oncogenic behavior of this isoform and to determine the mechanism underlying its up-regulation in leukemia and other forms of cancer.
  • [MeSH-major] Leukemia / etiology. Oncogenes. WT1 Proteins / genetics

  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16698800.001).
  • [ISSN] 0021-9258
  • [Journal-full-title] The Journal of biological chemistry
  • [ISO-abbreviation] J. Biol. Chem.
  • [Language] eng
  • [Databank-accession-numbers] GENBANK/ DQ537939
  • [Grant] United States / NCI NIH HHS / CA / CA16672; United States / NCI NIH HHS / CA / CA34936
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / RNA, Small Interfering; 0 / WT1 Proteins; 9007-49-2 / DNA
  •  go-up   go-down


86. Middelhof CA, Loudon WG, Muhonen MD, Xavier C, Greene CS Jr: Improved survival in central nervous system aspergillosis: a series of immunocompromised children with leukemia undergoing stereotactic resection of aspergillomas. Report of four cases. J Neurosurg; 2005 Oct;103(4 Suppl):374-8
MedlinePlus Health Information. consumer health - Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Improved survival in central nervous system aspergillosis: a series of immunocompromised children with leukemia undergoing stereotactic resection of aspergillomas. Report of four cases.
  • From their literature review, the authors concluded that children contracting CNS aspergillosis while undergoing systemic chemotherapy for leukemias represent a particularly unfortunate prognostic group.
  • The authors present a series of four immunosuppressed patients whose course of treatment for leukemia was complicated by CNS Aspergillus sp. abscesses.
  • At 2- to 4-year follow ups, one patient has died of leukemia and the other three continue to thrive without evidence of recurrent aspergillosis.
  • [MeSH-major] Brain Diseases / mortality. Brain Diseases / surgery. Immunocompromised Host. Leukemia / drug therapy. Neuroaspergillosis / mortality. Neuroaspergillosis / surgery. Stereotaxic Techniques

  • Genetic Alliance. consumer health - Aspergillosis.
  • MedlinePlus Health Information. consumer health - Brain Diseases.
  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16270691.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


87. Qian XF, Shen YF, Zhang SJ, Li JY: [Mutation of tet2 gene and malignant blood disease]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Aug;18(4):1096-100
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this review, the relation of tet2 mutation with myeloproliferative neoplasm, systemic mastocytosis, myelodysplastic syndrome, acute myeloid leukemia and other malignant blood diseases are summarized.

  • MedlinePlus Health Information. consumer health - Blood Disorders.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20723337.001).
  • [ISSN] 1009-2137
  • [Journal-full-title] Zhongguo shi yan xue ye xue za zhi
  • [ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi
  • [Language] CHI
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] China
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / Proto-Oncogene Proteins; 0 / TET2 protein, human
  •  go-up   go-down


88. Elghissassi I, Inrhaoun H, Mrabti H, Errihani H: Nonleukemic granulocytic sarcoma of knee: a case report. Case Rep Med; 2010;2010:235295
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • It is usually associated with leukemia or other myeloproliferative disorders.
  • There was no systemic manifestation of leukemia, and bone marrow biopsiy was negative for neoplastic infiltration.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1986 Dec 15;58(12):2697-709 [3465429.001]
  • [Cites] Cleve Clin J Med. 1991 Nov-Dec;58(6):471-4 [1752028.001]
  • [Cites] Pediatr Int. 2001 Oct;43(5):505-7 [11737714.001]
  • [Cites] Cancer. 2002 Mar 15;94(6):1739-46 [11920536.001]
  • [Cites] Ann Hematol. 2003 Jul;82(7):431-4 [12768322.001]
  • [Cites] Leuk Lymphoma. 2006 Dec;47(12):2527-41 [17169797.001]
  • [Cites] Cancer. 2008 Sep 15;113(6):1370-8 [18623376.001]
  • [Cites] Acta Haematol. 2009;122(4):238-46 [19887783.001]
  • [Cites] Cancer. 1981 Sep 15;48(6):1426-37 [7023656.001]
  • [Cites] Am J Surg Pathol. 1993 Oct;17(10):1011-9 [8372941.001]
  • [Cites] Zhonghua Xue Ye Xue Za Zhi. 2003 Nov;24(11):568-71 [14720440.001]
  • [Cites] J Korean Med Sci. 2006 Aug;21(4):745-8 [16891824.001]
  • [Cites] Intern Med. 2007;46(9):633-5 [17473505.001]
  • [Cites] Clin Transl Oncol. 2008 Nov;10(11):758-60 [19015073.001]
  • [Cites] Int J Hematol. 2009 Jan;89(1):95-7 [19109732.001]
  • [Cites] Histopathology. 1999 May;34(5):391-8 [10231412.001]
  • (PMID = 21209806.001).
  • [ISSN] 1687-9635
  • [Journal-full-title] Case reports in medicine
  • [ISO-abbreviation] Case Rep Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC3014795
  •  go-up   go-down


89. Sudo K, Yasuda J, Nakamura Y: Gene expression profiles of cryopreserved CD34(+) human umbilical cord blood cells are related to their bone marrow reconstitution abilities in mouse xenografts. Biochem Biophys Res Commun; 2010 Jul 9;397(4):697-705
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Human umbilical cord blood (UCB) cells are an alternative source of hematopoietic stem cells for treatment of leukemia and other diseases.
  • UCB cells from three donors failed to establish an engraftment in the host mice, while the other nine succeeded to various extents.

  • MedlinePlus Health Information. consumer health - Stem Cells.
  • SciCrunch. ArrayExpress: Data: Microarray .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20570655.001).
  • [ISSN] 1090-2104
  • [Journal-full-title] Biochemical and biophysical research communications
  • [ISO-abbreviation] Biochem. Biophys. Res. Commun.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / Genetic Markers; 0 / HOXB4 protein, human; 0 / Homeodomain Proteins; 0 / Transcription Factors
  •  go-up   go-down


90. Zhu W, Huang L, Xu X, Qian H, Xu W: Anti-proliferation effect of BMI-1 in U937 cells with siRNA. Int J Mol Med; 2010 Jun;25(6):889-95

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Polycomb protein BMI-1 is often overexpressed in various types of leukemia, and its depletion in those leukemic cells leads to cell proliferation arrest, differentiation, and apoptosis.
  • These findings have led us to believe that Bmi-1 has potential as a therapeutic target for leukemia.
  • Our proof-of-principle findings confirm that Bmi-1 siRNA can be used as a therapeutic target of any Bmi-1 expressing leukemia and other cancer cells.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Epigenomics. 2010 Oct;2(5):611 [22232789.001]
  • (PMID = 20428793.001).
  • [ISSN] 1791-244X
  • [Journal-full-title] International journal of molecular medicine
  • [ISO-abbreviation] Int. J. Mol. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / BMI1 protein, human; 0 / Nuclear Proteins; 0 / Proto-Oncogene Proteins; 0 / RNA, Messenger; 0 / RNA, Small Interfering; 0 / Repressor Proteins; EC 6.3.2.19 / Polycomb Repressive Complex 1
  •  go-up   go-down


91. Chan FH, Carl D, Lyckholm LJ: Severe lactic acidosis in a patient with B-cell lymphoma: a case report and review of the literature. Case Rep Med; 2009;2009:534561

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Lymphoma and leukemia are among other clinical situations where lactic acidosis has been reported.
  • Prompt diagnosis and treatment of underlying lymphoma or leukemia remains the only way to achieve complete resolution of lactic acidosis in these patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Adv Ther. 2007 May-Jun;24(3):505-9 [17660158.001]
  • [Cites] Chest. 2000 Jan;117(1):260-7 [10631227.001]
  • [Cites] Mayo Clin Proc. 2006 Nov;81(11):1505-6; author reply 1506 [17120408.001]
  • [Cites] Adv Ther. 2005 Sep-Oct;22(5):443-6 [16418152.001]
  • [Cites] J Intensive Care Med. 2005 Sep-Oct;20(5):255-71 [16145217.001]
  • [Cites] Leuk Lymphoma. 2005 Feb;46(2):281-3 [15621814.001]
  • [Cites] Int J Hematol. 2004 Dec;80(5):428-31 [15646654.001]
  • [Cites] N Engl J Med. 1964 Feb 6;270:274-8 [14074652.001]
  • [Cites] Lung Cancer. 1998 Dec;22(3):251-4 [10048478.001]
  • [Cites] J Bioenerg Biomembr. 1997 Aug;29(4):315-30 [9387092.001]
  • [Cites] Am Surg. 1997 Nov;63(11):951-3 [9358778.001]
  • [Cites] Ann Hematol. 1996 Feb;72(2):97-9 [8597616.001]
  • [Cites] Nephron. 1994;66(3):258-61 [8190176.001]
  • [Cites] Leukemia. 1994 Jun;8(6):1065-6 [8207979.001]
  • [Cites] Chest. 1993 Sep;104(3):913-8 [8396003.001]
  • [Cites] Am J Med. 1991 Aug;91(2):197-8 [1651052.001]
  • [Cites] Crit Care Med. 1991 Nov;19(11):1352-6 [1935152.001]
  • [Cites] J Natl Cancer Inst. 1988 Sep 7;80(13):1077-8 [3411621.001]
  • [Cites] South Med J. 1988 Apr;81(4):533-6 [3282319.001]
  • [Cites] Minn Med. 1986 Sep;69(9):511-4 [3020387.001]
  • [Cites] Am J Physiol. 1985 Nov;249(5 Pt 2):F630-5 [2998202.001]
  • [Cites] Am J Med. 1989 Jul;87(1):7-14 [2741982.001]
  • [Cites] Mil Med. 1985 Apr;150(4):206-8 [3925375.001]
  • [Cites] Aust N Z J Med. 1983 Apr;13(2):179-80 [6577838.001]
  • [Cites] N Engl J Med. 1980 Jul 3;303(1):15-7 [7374729.001]
  • [Cites] Cancer. 1981 Apr 15;47(8):2026-9 [6261933.001]
  • [Cites] Am J Hematol. 1978;4(4):359-65 [362908.001]
  • [Cites] Am J Med. 1974 Feb;56(2):162-8 [4812073.001]
  • [Cites] Gut. 1975 Feb;16(2):144-9 [1126664.001]
  • [Cites] J Clin Invest. 1971 Mar;50(3):700-6 [5545127.001]
  • [Cites] Leuk Lymphoma. 2002 Jun;43(6):1341-2 [12153006.001]
  • [Cites] Cancer. 2001 Nov 1;92(9):2237-46 [11745277.001]
  • [Cites] Nephron. 2001 Jul;88(3):276-7 [11423762.001]
  • [Cites] Chest. 2000 Sep;118(3):882-4 [10988226.001]
  • [Cites] Medicine (Baltimore). 2007 Jul;86(4):225-32 [17632264.001]
  • (PMID = 20069124.001).
  • [ISSN] 1687-9635
  • [Journal-full-title] Case reports in medicine
  • [ISO-abbreviation] Case Rep Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2804112
  •  go-up   go-down


92. Bao F, Munker R, Lowery C, Martin S, Shi R, Veillon DM, Cotelingam JD, Nordberg ML: Comparison of FISH and quantitative RT-PCR for the diagnosis and follow-up of BCR-ABL-positive leukemias. Mol Diagn Ther; 2007;11(4):239-45
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of FISH and quantitative RT-PCR for the diagnosis and follow-up of BCR-ABL-positive leukemias.
  • BACKGROUND: For Philadelphia chromosome positive (Ph+) leukemias (chronic myelogenous leukemia [CML], acute lymphoblastic leukemia [ALL], and rare other leukemias), both allogeneic transplantation and treatment with tyrosine kinase inhibitors offer chances of molecular remission (the molecular marker being consistently undetectable).
  • QRT-PCR, due to its superior sensitivity, is considered the gold standard for the follow-up of Ph+ leukemias treated with imatinib.
  • AIM: The objective of our study was to compare the diagnostic and clinical usefulness of FISH and QRT-PCR at different timepoints for Ph+ leukemias.
  • [MeSH-major] Fusion Proteins, bcr-abl / metabolism. In Situ Hybridization, Fluorescence / methods. Leukemia / diagnosis. Leukemia / metabolism. Reverse Transcriptase Polymerase Chain Reaction / methods

  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17705578.001).
  • [ISSN] 1177-1062
  • [Journal-full-title] Molecular diagnosis & therapy
  • [ISO-abbreviation] Mol Diagn Ther
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] New Zealand
  • [Chemical-registry-number] EC 2.7.10.2 / Fusion Proteins, bcr-abl
  •  go-up   go-down


93. Yan Z, Hua H, Gao Y: Paraneoplastic pemphigus characterized by polymorphic oral mucosal manifestations--report of two cases. Quintessence Int; 2010 Sep;41(8):689-94
Hazardous Substances Data Bank. PREDNISOLONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report two Chinese patients, one with chronic lymphocytic leukemia and the other with thymoma.
  • [MeSH-major] Leukemia, Lymphocytic, Chronic, B-Cell / complications. Lichen Planus, Oral / etiology. Oral Ulcer / etiology. Paraneoplastic Syndromes / etiology. Pemphigus / etiology. Thymoma / complications. Thymus Neoplasms / complications

  • Genetic Alliance. consumer health - Pemphigus.
  • MedlinePlus Health Information. consumer health - Pemphigus.
  • MedlinePlus Health Information. consumer health - Thymus Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20657859.001).
  • [ISSN] 1936-7163
  • [Journal-full-title] Quintessence international (Berlin, Germany : 1985)
  • [ISO-abbreviation] Quintessence Int
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Glucocorticoids; 9PHQ9Y1OLM / Prednisolone
  •  go-up   go-down


94. Pantanowitz L, Schlecht HP, Dezube BJ: The growing problem of non-AIDS-defining malignancies in HIV. Curr Opin Oncol; 2006 Sep;18(5):469-78
HIV InSite. treatment guidelines - Coinfection with Hepatitis Viruses and HIV .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RECENT FINDINGS: Recent epidemiological studies have identified higher rates of carcinoma of the anus, lung, breast, skin, conjunctiva, liver and prostate; hematopoietic malignancies such as Hodgkin's lymphoma, plasma-cell neoplasia and leukemia; and other neoplasms like melanoma and leiomyosarcoma in HIV-positive patients.

  • Genetic Alliance. consumer health - AIDS-HIV.
  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16894295.001).
  • [ISSN] 1040-8746
  • [Journal-full-title] Current opinion in oncology
  • [ISO-abbreviation] Curr Opin Oncol
  • [Language] eng
  • [Grant] United States / NIAID NIH HHS / AI / P30 AI 060354
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Retroviral Agents
  • [Number-of-references] 95
  •  go-up   go-down


95. Zhang Y, Secrist JA 3rd, Ealick SE: The structure of human deoxycytidine kinase in complex with clofarabine reveals key interactions for prodrug activation. Acta Crystallogr D Biol Crystallogr; 2006 Feb;62(Pt 2):133-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • It is the precursor of an effective chemotherapeutic agent for leukemias and other hematological malignancies and received accelerated approval by the FDA for the treatment of pediatric patients with relapsed or refractory acute lymphoblastic leukemia.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16421443.001).
  • [ISSN] 0907-4449
  • [Journal-full-title] Acta crystallographica. Section D, Biological crystallography
  • [ISO-abbreviation] Acta Crystallogr. D Biol. Crystallogr.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 1P01CA34200; United States / NCRR NIH HHS / RR / RR15301
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Adenine Nucleotides; 0 / Arabinonucleosides; 61D2G4IYVH / Adenosine Diphosphate; 762RDY0Y2H / clofarabine; 8L70Q75FXE / Adenosine Triphosphate; EC 2.7.1.74 / Deoxycytidine Kinase
  •  go-up   go-down


96. Liebich HM, Müller-Hagedorn S, Klaus F, Meziane K, Kim KR, Frickenschmidt A, Kammerer B: Chromatographic, capillary electrophoretic and matrix-assisted laser desorption ionization time-of-flight mass spectrometry analysis of urinary modified nucleosides as tumor markers. J Chromatogr A; 2005 Apr 15;1071(1-2):271-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In two clinical studies the diagnostic value of urinary modified nucleosides is investigated, in a study on children with leukemia and other malignant diseases and a study on women with breast cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15865203.001).
  • [ISSN] 0021-9673
  • [Journal-full-title] Journal of chromatography. A
  • [ISO-abbreviation] J Chromatogr A
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Nucleosides
  •  go-up   go-down


97. Schilsky RL, McIntyre OR, Holland JF, Frei E 3rd: A concise history of the cancer and leukemia group B. Clin Cancer Res; 2006 Jun 1;12(11 Pt 2):3553s-5s
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A concise history of the cancer and leukemia group B.
  • The founders of the Cancer and Leukemia Group B, James Holland and Emil (Tom) Frei, III, envisioned that successful chemotherapy for leukemia and other hematologic malignancies could be expeditiously realized through carefully designed clinical trials executed uniformly as a cooperative effort among several institutions.
  • In 1956, the group was designated the Acute Leukemia Group B by the Chemotherapy National Service Center Clinical Studies Panel, and Frei was elected chairman.
  • In the ensuing 50 years, the Cancer and Leukemia Group B has expanded to national and even international membership, and its research programs have expanded to include all of the common adult solid tumors and hematologic malignancies in a multidisciplinary effort to improve the outcomes for patients with cancer and to better understand the biology of malignant disease.
  • [MeSH-major] Leukemia / therapy. Medical Oncology / history. Neoplasms / therapy. Societies, Medical / history

  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16740784.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Historical Article; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 1
  •  go-up   go-down


98. Kurkjian C, Patel S, Kamble R, Dunn ST, Kern W, Kharfan-Dabaja MA: Acute promyelocytic leukemia and constitutional trisomy 21. Cancer Genet Cytogenet; 2006 Mar;165(2):176-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute promyelocytic leukemia and constitutional trisomy 21.
  • The incidence of acute myelogenous leukemia (AML) in patients with constitutional trisomy 21 is estimated to be 1 in 300; it is usually seen before age four.
  • Clinical and epidemiological data confirm the improved life expectancy of patients with Down syndrome and their increased susceptibility to the development of leukemia, among other cancers.
  • The most frequent subtype of AML associated with Down syndrome is acute megakaryoblastic leukemia (FAB: M7).
  • The description of acute promyelocytic leukemia (APL) in adult patients with Down syndrome is exceedingly rare.
  • [MeSH-major] Down Syndrome. Leukemia, Promyelocytic, Acute / genetics

  • Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.
  • MedlinePlus Health Information. consumer health - Down Syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16527614.001).
  • [ISSN] 0165-4608
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


99. Valmary S, Danjoux M, Delsol G, Brousset P: [Diagnostic value of anti-terminal deoxynucleotidyl transferase antibody (TdT) in hematologic pathology]. Ann Pathol; 2005 Feb;25(1):25-32

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • MATERIALS AND METHODS: 13 lesions were examined by immunohistochemistry: 4 B and T lymphoblastic lymphomas, 2 Burkitt's lymphomas, 5 B and T acute lymphoblastic leukemias and 2 acute monoblastic leukemias.
  • Significant numbers of cases of acute myeloblastic leukemias are TdT positive but could be easily distinguished from lymphoblastic proliferations.
  • CONCLUSION: Anti-TdT antibody represents a useful marker for differentiating lymphoma/acute lymphoblastic leukemia from other lymphomas.
  • [MeSH-minor] Adolescent. Adult. Aged. Burkitt Lymphoma / diagnosis. Child. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Immunophenotyping. Leukemia, Monocytic, Acute / diagnosis. Leukemia-Lymphoma, Adult T-Cell / diagnosis. Lymphoma, B-Cell / diagnosis. Lymphoma, T-Cell / diagnosis. Male. Middle Aged. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15981929.001).
  • [ISSN] 0242-6498
  • [Journal-full-title] Annales de pathologie
  • [ISO-abbreviation] Ann Pathol
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antibodies; EC 2.7.7.31 / DNA Nucleotidylexotransferase
  •  go-up   go-down


100. Sholl LM, Longtine J: Molecular analysis of gene rearrangements and mutations in acute leukemias and myeloproliferative neoplasms. Curr Protoc Hum Genet; 2010 Oct;Chapter 10:Unit 10.4
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular analysis of gene rearrangements and mutations in acute leukemias and myeloproliferative neoplasms.
  • A large subset of acute leukemias and other myeloproliferative neoplasms contain specific genetic alterations, many of which are associated with unique clinical and pathologic features.
  • Molecular analysis is central to diagnosis and clinical management of leukemias, permitting genetic confirmation of a clinical and histologic impression, providing prognostic and predictive information, and facilitating detection of minimal residual disease.
  • This unit will outline approaches to the molecular diagnosis of the most frequent and clinically relevant genetic alterations in acute leukemias and myeloproliferative neoplasms.

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20891029.001).
  • [ISSN] 1934-8258
  • [Journal-full-title] Current protocols in human genetics
  • [ISO-abbreviation] Curr Protoc Hum Genet
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down






Advertisement